Found 208 hits of ic50 for UniProtKB: P55899 Target/Host
(Institution) | Ligand | Target/Host
Links | Ligand
Links | Trg + Lig
Links | Ki
nM | ΔG°
kcal/mole | IC50
nM | Kd
nM | EC50/IC50
nM | koff
s-1 | kon
M-1s-1 | pH | Temp
°C |
|---|
IgG receptor FcRn large subunit p51
(Homo sapiens (Human)) | BDBM50314095
(CHEMBL1090633)Show SMILES CC(C)C[C@@H]1N(C)C(=O)CN(C)C(=O)CNC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](Cc2cnc[nH]2)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](CCCNC(N)=N)NCCNC(=O)CCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](Cc2ccccc2)C(=O)N[C@@H]2C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](Cc3cnc[nH]3)C(=O)N[C@@H](Cc3ccccc3)C(=O)NCC(=O)N(C)CC(=O)N(C)[C@@H](CC(C)C)C(=O)N[C@@H](Cc3ccc(O)cc3)C(=O)C(=O)N3CCC[C@H]3C(=O)N[C@@H](CSSC2(C)C)C(N)=O)C(C)(C)SSC[C@H](NC(=O)[C@@H]2CCCN2C(=O)C(=O)[C@H](Cc2ccc(O)cc2)NC1=O)C(N)=O)[C@@H](C)O |r| Show InChI InChI=1S/C148H205N39O34S4/c1-81(2)59-109-137(214)170-97(61-89-43-47-93(190)48-44-89)121(200)143(220)186-57-29-41-107(186)135(212)176-105(125(149)202)77-222-224-147(7,8)123(141(218)178-119(83(5)188)139(216)161-71-113(194)168-103(67-91-69-155-79-165-91)131(208)172-99(63-85-31-19-15-20-32-85)127(204)163-73-115(196)182(11)75-117(198)184(109)13)180-133(210)101(65-87-35-23-17-24-36-87)174-129(206)95(39-27-53-159-145(151)152)157-55-56-158-111(192)51-52-112(193)167-96(40-28-54-160-146(153)154)130(207)175-102(66-88-37-25-18-26-38-88)134(211)181-124-142(219)179-120(84(6)189)140(217)162-72-114(195)169-104(68-92-70-156-80-166-92)132(209)173-100(64-86-33-21-16-22-34-86)128(205)164-74-116(197)183(12)76-118(199)185(14)110(60-82(3)4)138(215)171-98(62-90-45-49-94(191)50-46-90)122(201)144(221)187-58-30-42-108(187)136(213)177-106(126(150)203)78-223-225-148(124,9)10/h15-26,31-38,43-50,69-70,79-84,95-110,119-120,123-124,157,188-191H,27-30,39-42,51-68,71-78H2,1-14H3,(H2,149,202)(H2,150,203)(H,155,165)(H,156,166)(H,158,192)(H,161,216)(H,162,217)(H,163,204)(H,164,205)(H,167,193)(H,168,194)(H,169,195)(H,170,214)(H,171,215)(H,172,208)(H,173,209)(H,174,206)(H,175,207)(H,176,212)(H,177,213)(H,178,218)(H,179,219)(H,180,210)(H,181,211)(H4,151,152,159)(H4,153,154,160)/t83-,84-,95+,96+,97+,98+,99+,100+,101+,102+,103+,104+,105+,106+,107+,108+,109+,110+,119+,120+,123-,124-/m1/s1 | PDB
MMDB
KEGG
UniProtKB/SwissProt
B.MOAD
antibodypedia
GoogleScholar
AffyNet 
| CHEMBL
PC cid
PC sid
UniChem
Similars
| Article
PubMed
| n/a | n/a | 1.60 | n/a | n/a | n/a | n/a | n/a | n/a |
Syntonix Pharmaceuticals, Inc.
Curated by ChEMBL
| Assay Description
Inhibition of IgG binding to soluble human FcRn after 5 hrs by competition ELISA |
J Med Chem 53: 1587-96 (2010)
Article DOI: 10.1021/jm901128z
BindingDB Entry DOI: 10.7270/Q23R0T1H |
More data for this
Ligand-Target Pair | |
IgG receptor FcRn large subunit p51
(Homo sapiens (Human)) | BDBM50314105
(CHEMBL1090970 | N1,N4-bis((S)-1-((S)-1-((3R,8R,11S...)Show SMILES CC(C)C[C@@H]1N(C)C(=O)CN(C)C(=O)CNC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](Cc2cnc[nH]2)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](CCCNC(N)=N)NC(=O)CCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](Cc2ccccc2)C(=O)N[C@@H]2C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](Cc3cnc[nH]3)C(=O)N[C@@H](Cc3ccccc3)C(=O)NCC(=O)N(C)CC(=O)N(C)[C@@H](CC(C)C)C(=O)N[C@@H](Cc3ccc(O)cc3)C(=O)C(=O)N3CCC[C@H]3C(=O)N[C@@H](CSSC2(C)C)C(N)=O)C(C)(C)SSC[C@H](NC(=O)[C@@H]2CCCN2C(=O)C(=O)[C@H](Cc2ccc(O)cc2)NC1=O)C(N)=O)[C@@H](C)O |r| Show InChI InChI=1S/C146H200N38O34S4/c1-79(2)57-107-135(211)167-95(59-87-43-47-91(187)48-44-87)119(197)141(217)183-55-29-41-105(183)133(209)173-103(123(147)199)75-219-221-145(7,8)121(139(215)175-117(81(5)185)137(213)157-69-111(191)165-101(65-89-67-153-77-161-89)129(205)169-97(61-83-31-19-15-20-32-83)125(201)159-71-113(193)179(11)73-115(195)181(107)13)177-131(207)99(63-85-35-23-17-24-36-85)171-127(203)93(39-27-53-155-143(149)150)163-109(189)51-52-110(190)164-94(40-28-54-156-144(151)152)128(204)172-100(64-86-37-25-18-26-38-86)132(208)178-122-140(216)176-118(82(6)186)138(214)158-70-112(192)166-102(66-90-68-154-78-162-90)130(206)170-98(62-84-33-21-16-22-34-84)126(202)160-72-114(194)180(12)74-116(196)182(14)108(58-80(3)4)136(212)168-96(60-88-45-49-92(188)50-46-88)120(198)142(218)184-56-30-42-106(184)134(210)174-104(124(148)200)76-220-222-146(122,9)10/h15-26,31-38,43-50,67-68,77-82,93-108,117-118,121-122,185-188H,27-30,39-42,51-66,69-76H2,1-14H3,(H2,147,199)(H2,148,200)(H,153,161)(H,154,162)(H,157,213)(H,158,214)(H,159,201)(H,160,202)(H,163,189)(H,164,190)(H,165,191)(H,166,192)(H,167,211)(H,168,212)(H,169,205)(H,170,206)(H,171,203)(H,172,204)(H,173,209)(H,174,210)(H,175,215)(H,176,216)(H,177,207)(H,178,208)(H4,149,150,155)(H4,151,152,156)/t81-,82-,93+,94+,95+,96+,97+,98+,99+,100+,101+,102+,103+,104+,105+,106+,107+,108+,117+,118+,121-,122-/m1/s1 | PDB
MMDB
KEGG
UniProtKB/SwissProt
B.MOAD
antibodypedia
GoogleScholar
AffyNet
| CHEMBL
PC cid
PC sid
UniChem
Similars
| Article
PubMed
| n/a | n/a | 2.40 | n/a | n/a | n/a | n/a | n/a | n/a |
Syntonix Pharmaceuticals, Inc.
Curated by ChEMBL
| Assay Description
Inhibition of IgG binding to soluble human FcRn after 5 hrs by competition ELISA |
J Med Chem 53: 1587-96 (2010)
Article DOI: 10.1021/jm901128z
BindingDB Entry DOI: 10.7270/Q23R0T1H |
More data for this
Ligand-Target Pair | |
IgG receptor FcRn large subunit p51
(Homo sapiens (Human)) | BDBM50314094
(CHEMBL1090632)Show SMILES CC(C)C[C@@H]1N(C)C(=O)CN(C)C(=O)CNC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](Cc2cnc[nH]2)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](CCCNC(N)=N)NC(=O)CCNC(=O)CCNC(=O)CCNC(=O)CN(C)CCNC(=O)CCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](Cc2ccccc2)C(=O)N[C@@H]2C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](Cc3cnc[nH]3)C(=O)N[C@@H](Cc3ccccc3)C(=O)NCC(=O)N(C)CC(=O)N(C)[C@@H](CC(C)C)C(=O)N[C@@H](Cc3ccc(O)cc3)C(=O)C(=O)N3CCC[C@H]3C(=O)N[C@@H](CSSC2(C)C)C(N)=O)C(C)(C)SSC[C@H](NC(=O)[C@@H]2CCCN2C(=O)C(=O)[C@H](Cc2ccc(O)cc2)NC1=O)C(N)=O)[C@@H](C)O |r| Show InChI InChI=1S/C160H225N43O38S4/c1-89(2)66-117-149(234)185-105(68-97-44-48-101(206)49-45-97)133(220)155(240)202-63-30-42-115(202)147(232)191-113(137(161)222)85-242-244-159(7,8)135(153(238)193-131(91(5)204)151(236)175-78-124(213)183-111(74-99-76-167-87-179-99)143(228)187-107(70-93-32-20-16-21-33-93)139(224)177-80-127(216)198(12)83-129(218)200(117)14)195-145(230)109(72-95-36-24-18-25-37-95)189-141(226)103(40-28-57-173-157(163)164)181-122(211)53-52-119(208)172-62-65-197(11)82-126(215)171-60-55-121(210)169-59-54-120(209)170-61-56-123(212)182-104(41-29-58-174-158(165)166)142(227)190-110(73-96-38-26-19-27-39-96)146(231)196-136-154(239)194-132(92(6)205)152(237)176-79-125(214)184-112(75-100-77-168-88-180-100)144(229)188-108(71-94-34-22-17-23-35-94)140(225)178-81-128(217)199(13)84-130(219)201(15)118(67-90(3)4)150(235)186-106(69-98-46-50-102(207)51-47-98)134(221)156(241)203-64-31-43-116(203)148(233)192-114(138(162)223)86-243-245-160(136,9)10/h16-27,32-39,44-51,76-77,87-92,103-118,131-132,135-136,204-207H,28-31,40-43,52-75,78-86H2,1-15H3,(H2,161,222)(H2,162,223)(H,167,179)(H,168,180)(H,169,210)(H,170,209)(H,171,215)(H,172,208)(H,175,236)(H,176,237)(H,177,224)(H,178,225)(H,181,211)(H,182,212)(H,183,213)(H,184,214)(H,185,234)(H,186,235)(H,187,228)(H,188,229)(H,189,226)(H,190,227)(H,191,232)(H,192,233)(H,193,238)(H,194,239)(H,195,230)(H,196,231)(H4,163,164,173)(H4,165,166,174)/t91-,92-,103+,104+,105+,106+,107+,108+,109+,110+,111+,112+,113+,114+,115+,116+,117+,118+,131+,132+,135-,136-/m1/s1 | PDB
MMDB
KEGG
UniProtKB/SwissProt
B.MOAD
antibodypedia
GoogleScholar
AffyNet
| CHEMBL
PC cid
PC sid
UniChem
Similars
| Article
PubMed
| n/a | n/a | 2.40 | n/a | n/a | n/a | n/a | n/a | n/a |
Syntonix Pharmaceuticals, Inc.
Curated by ChEMBL
| Assay Description
Inhibition of IgG binding to soluble human FcRn after 5 hrs by competition ELISA |
J Med Chem 53: 1587-96 (2010)
Article DOI: 10.1021/jm901128z
BindingDB Entry DOI: 10.7270/Q23R0T1H |
More data for this
Ligand-Target Pair | |
IgG receptor FcRn large subunit p51
(Homo sapiens (Human)) | BDBM50314093
(CHEMBL1090631)Show SMILES CC(C)C[C@@H]1N(C)C(=O)CN(C)C(=O)CNC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](Cc2cnc[nH]2)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](CCCNC(N)=N)NC(=O)CCC(=O)NCCN(C)CC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](Cc2ccccc2)C(=O)N[C@@H]2C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](Cc3cnc[nH]3)C(=O)N[C@@H](Cc3ccccc3)C(=O)NCC(=O)N(C)CC(=O)N(C)[C@@H](CC(C)C)C(=O)N[C@@H](Cc3ccc(O)cc3)C(=O)C(=O)N3CCC[C@H]3C(=O)N[C@@H](CSSC2(C)C)C(N)=O)C(C)(C)SSC[C@H](NC(=O)[C@@H]2CCCN2C(=O)C(=O)[C@@H](Cc2ccc(O)cc2)NC1=O)C(N)=O)[C@@H](C)O |r| Show InChI InChI=1S/C151H210N40O35S4/c1-83(2)60-111-140(219)173-99(62-91-44-48-95(194)49-45-91)124(205)146(225)190-57-30-42-109(190)138(217)179-107(128(152)207)79-227-229-150(7,8)126(144(223)181-122(85(5)192)142(221)163-72-115(198)171-105(68-93-70-158-81-167-93)134(213)175-101(64-87-32-20-16-21-33-87)130(209)165-74-118(201)186(12)77-120(203)188(111)14)183-136(215)103(66-89-36-24-18-25-37-89)177-132(211)97(40-28-54-161-148(154)155)169-114(197)53-52-113(196)160-56-59-185(11)76-117(200)170-98(41-29-55-162-149(156)157)133(212)178-104(67-90-38-26-19-27-39-90)137(216)184-127-145(224)182-123(86(6)193)143(222)164-73-116(199)172-106(69-94-71-159-82-168-94)135(214)176-102(65-88-34-22-17-23-35-88)131(210)166-75-119(202)187(13)78-121(204)189(15)112(61-84(3)4)141(220)174-100(63-92-46-50-96(195)51-47-92)125(206)147(226)191-58-31-43-110(191)139(218)180-108(129(153)208)80-228-230-151(127,9)10/h16-27,32-39,44-51,70-71,81-86,97-112,122-123,126-127,192-195H,28-31,40-43,52-69,72-80H2,1-15H3,(H2,152,207)(H2,153,208)(H,158,167)(H,159,168)(H,160,196)(H,163,221)(H,164,222)(H,165,209)(H,166,210)(H,169,197)(H,170,200)(H,171,198)(H,172,199)(H,173,219)(H,174,220)(H,175,213)(H,176,214)(H,177,211)(H,178,212)(H,179,217)(H,180,218)(H,181,223)(H,182,224)(H,183,215)(H,184,216)(H4,154,155,161)(H4,156,157,162)/t85-,86-,97+,98+,99?,100+,101+,102+,103+,104+,105+,106+,107+,108+,109+,110+,111+,112+,122+,123+,126-,127-/m1/s1 | PDB
MMDB
KEGG
UniProtKB/SwissProt
B.MOAD
antibodypedia
GoogleScholar
AffyNet
| CHEMBL
PC cid
PC sid
UniChem
Similars
| Article
PubMed
| n/a | n/a | 2.60 | n/a | n/a | n/a | n/a | n/a | n/a |
Syntonix Pharmaceuticals, Inc.
Curated by ChEMBL
| Assay Description
Inhibition of IgG binding to soluble human FcRn after 5 hrs by competition ELISA |
J Med Chem 53: 1587-96 (2010)
Article DOI: 10.1021/jm901128z
BindingDB Entry DOI: 10.7270/Q23R0T1H |
More data for this
Ligand-Target Pair | |
IgG receptor FcRn large subunit p51
(Homo sapiens (Human)) | BDBM50314102
(CHEMBL1090640)Show SMILES CC(C)C[C@@H]1N(C)C(=O)CN(C)C(=O)CNC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](Cc2cnc[nH]2)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](CCCNC(N)=N)NC(=O)CN(C)CCNC(=O)CNC(=O)[C@@H]2CSSC(C)(C)[C@H](NC(=O)[C@H](Cc3ccccc3)NC(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](Cc3cnc[nH]3)C(=O)N[C@@H](Cc3ccccc3)C(=O)NCC(=O)N(C)CC(=O)N(C)[C@@H](CC(C)C)C(=O)N[C@@H](Cc3ccc(O)cc3)C(=O)C(=O)N3CCC[C@H]3C(=O)N2)C(C)(C)SSC[C@H](NC(=O)[C@@H]2CCCN2C(=O)C(=O)[C@H](Cc2ccc(O)cc2)NC1=O)C(N)=O)[C@@H](C)O |r| Show InChI InChI=1S/C149H208N40O34S4/c1-82(2)58-110-138(216)171-98(60-90-44-48-94(192)49-45-90)122(202)144(222)188-55-30-42-108(188)136(214)177-106(126(151)204)78-224-226-148(7,8)124(142(220)179-120(84(5)190)140(218)162-71-113(195)169-104(66-92-68-156-80-166-92)132(210)174-100(62-86-32-20-16-21-33-86)128(206)164-73-116(198)184(12)76-118(200)186(110)14)182-135(213)103(65-89-38-26-19-27-39-89)176-131(209)97(41-29-53-160-147(154)155)168-115(197)75-183(11)57-54-158-112(194)70-161-130(208)107-79-225-227-149(9,10)125(181-134(212)102(64-88-36-24-18-25-37-88)173-127(205)96(150)40-28-52-159-146(152)153)143(221)180-121(85(6)191)141(219)163-72-114(196)170-105(67-93-69-157-81-167-93)133(211)175-101(63-87-34-22-17-23-35-87)129(207)165-74-117(199)185(13)77-119(201)187(15)111(59-83(3)4)139(217)172-99(61-91-46-50-95(193)51-47-91)123(203)145(223)189-56-31-43-109(189)137(215)178-107/h16-27,32-39,44-51,68-69,80-85,96-111,120-121,124-125,190-193H,28-31,40-43,52-67,70-79,150H2,1-15H3,(H2,151,204)(H,156,166)(H,157,167)(H,158,194)(H,161,208)(H,162,218)(H,163,219)(H,164,206)(H,165,207)(H,168,197)(H,169,195)(H,170,196)(H,171,216)(H,172,217)(H,173,205)(H,174,210)(H,175,211)(H,176,209)(H,177,214)(H,178,215)(H,179,220)(H,180,221)(H,181,212)(H,182,213)(H4,152,153,159)(H4,154,155,160)/t84-,85-,96+,97+,98+,99+,100+,101+,102+,103+,104+,105+,106+,107+,108+,109+,110+,111+,120+,121+,124-,125-/m1/s1 | PDB
MMDB
KEGG
UniProtKB/SwissProt
B.MOAD
antibodypedia
GoogleScholar
AffyNet
| CHEMBL
PC cid
PC sid
UniChem
Similars
| Article
PubMed
| n/a | n/a | 3.90 | n/a | n/a | n/a | n/a | n/a | n/a |
Syntonix Pharmaceuticals, Inc.
Curated by ChEMBL
| Assay Description
Inhibition of IgG binding to soluble human FcRn after 5 hrs by competition ELISA |
J Med Chem 53: 1587-96 (2010)
Article DOI: 10.1021/jm901128z
BindingDB Entry DOI: 10.7270/Q23R0T1H |
More data for this
Ligand-Target Pair | |
IgG receptor FcRn large subunit p51
(Homo sapiens (Human)) | BDBM50314090
(CHEMBL1090278 | N-[(1S)-1-{[(1S)-1-{[(5S,8S,15S,18...)Show SMILES CC(C)C[C@@H]1N(C)C(=O)CN2CCC[C@H](NC(=O)[C@H](Cc3ccccc3)NC(=O)[C@H](Cc3cnc[nH]3)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](Cc3ccccc3)NC(=O)[C@H](CCCNC(N)=N)NC(=O)CCC(=O)NCCN(C)CC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](Cc3ccccc3)C(=O)N[C@@H]3C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](Cc4cnc[nH]4)C(=O)N[C@@H](Cc4ccccc4)C(=O)N[C@H]4CCCN(CC(=O)N(C)[C@@H](CC(C)C)C(=O)N[C@@H](Cc5ccc(O)cc5)C(=O)C(=O)N5CCC[C@H]5C(=O)N[C@@H](CSSC3(C)C)C(N)=O)C4=O)C(C)(C)SSC[C@H](NC(=O)[C@@H]3CCCN3C(=O)C(=O)[C@H](Cc3ccc(O)cc3)NC1=O)C(N)=O)[C@@H](C)O)C2=O |r| Show InChI InChI=1S/C155H214N40O35S4/c1-85(2)64-115-142(221)177-103(66-93-46-50-97(198)51-47-93)126(207)150(229)194-61-30-44-113(194)140(219)183-111(130(156)209)81-231-233-154(7,8)128(146(225)185-124(87(5)196)144(223)167-76-119(202)173-109(72-95-74-162-83-169-95)136(215)181-105(68-89-32-18-14-19-33-89)134(213)175-101-42-28-59-192(148(101)227)79-122(205)190(115)12)187-138(217)107(70-91-36-22-16-23-37-91)179-132(211)99(40-26-56-165-152(158)159)171-118(201)55-54-117(200)164-58-63-189(11)78-121(204)172-100(41-27-57-166-153(160)161)133(212)180-108(71-92-38-24-17-25-39-92)139(218)188-129-147(226)186-125(88(6)197)145(224)168-77-120(203)174-110(73-96-75-163-84-170-96)137(216)182-106(69-90-34-20-15-21-35-90)135(214)176-102-43-29-60-193(149(102)228)80-123(206)191(13)116(65-86(3)4)143(222)178-104(67-94-48-52-98(199)53-49-94)127(208)151(230)195-62-31-45-114(195)141(220)184-112(131(157)210)82-232-234-155(129,9)10/h14-25,32-39,46-53,74-75,83-88,99-116,124-125,128-129,196-199H,26-31,40-45,54-73,76-82H2,1-13H3,(H2,156,209)(H2,157,210)(H,162,169)(H,163,170)(H,164,200)(H,167,223)(H,168,224)(H,171,201)(H,172,204)(H,173,202)(H,174,203)(H,175,213)(H,176,214)(H,177,221)(H,178,222)(H,179,211)(H,180,212)(H,181,215)(H,182,216)(H,183,219)(H,184,220)(H,185,225)(H,186,226)(H,187,217)(H,188,218)(H4,158,159,165)(H4,160,161,166)/t87-,88-,99+,100+,101+,102+,103+,104+,105+,106+,107+,108+,109+,110+,111+,112+,113+,114+,115+,116+,124+,125+,128-,129-/m1/s1 | PDB
MMDB
KEGG
UniProtKB/SwissProt
B.MOAD
antibodypedia
GoogleScholar
AffyNet
| CHEMBL
PC cid
PC sid
UniChem
Similars
| Article
PubMed
| n/a | n/a | 3.90 | n/a | n/a | n/a | n/a | n/a | n/a |
Syntonix Pharmaceuticals, Inc.
Curated by ChEMBL
| Assay Description
Inhibition of IgG binding to soluble human FcRn after 5 hrs by competition ELISA |
J Med Chem 53: 1587-96 (2010)
Article DOI: 10.1021/jm901128z
BindingDB Entry DOI: 10.7270/Q23R0T1H |
More data for this
Ligand-Target Pair | |
IgG receptor FcRn large subunit p51
(Homo sapiens (Human)) | BDBM50314103
((R,S,S,3R,3'R,8R,8'R,11S,11'S,17S,17'S,20S,20'S,29...)Show SMILES CC(C)C[C@@H]1N(C)C(=O)CN(C)C(=O)CNC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](Cc2cnc[nH]2)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@@H](N)CCCNC(N)=N)C(C)(C)SSC[C@H](NC(=O)[C@@H]2CCCN2C(=O)C(=O)[C@H](Cc2ccc(O)cc2)NC1=O)C(=O)NCC(=O)NCCNCCNC(=O)CNC(=O)[C@@H]1CSSC(C)(C)[C@H](NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](Cc2cnc[nH]2)C(=O)N[C@@H](Cc2ccccc2)C(=O)NCC(=O)N(C)CC(=O)N(C)[C@@H](CC(C)C)C(=O)N[C@@H](Cc2ccc(O)cc2)C(=O)C(=O)N2CCC[C@H]2C(=O)N1)[C@@H](C)O |r| Show InChI InChI=1S/C150H211N41O34S4/c1-83(2)59-111-139(218)174-99(61-91-43-47-95(194)48-44-91)123(204)145(224)190-57-29-41-109(190)137(216)180-107(79-226-228-149(7,8)125(184-135(214)103(65-89-35-23-17-24-36-89)176-127(206)97(151)39-27-51-162-147(153)154)143(222)182-121(85(5)192)141(220)166-73-115(198)172-105(67-93-69-158-81-170-93)133(212)178-101(63-87-31-19-15-20-32-87)129(208)168-75-117(200)186(11)77-119(202)188(111)13)131(210)164-71-113(196)160-55-53-157-54-56-161-114(197)72-165-132(211)108-80-227-229-150(9,10)126(185-136(215)104(66-90-37-25-18-26-38-90)177-128(207)98(152)40-28-52-163-148(155)156)144(223)183-122(86(6)193)142(221)167-74-116(199)173-106(68-94-70-159-82-171-94)134(213)179-102(64-88-33-21-16-22-34-88)130(209)169-76-118(201)187(12)78-120(203)189(14)112(60-84(3)4)140(219)175-100(62-92-45-49-96(195)50-46-92)124(205)146(225)191-58-30-42-110(191)138(217)181-108/h15-26,31-38,43-50,69-70,81-86,97-112,121-122,125-126,157,192-195H,27-30,39-42,51-68,71-80,151-152H2,1-14H3,(H,158,170)(H,159,171)(H,160,196)(H,161,197)(H,164,210)(H,165,211)(H,166,220)(H,167,221)(H,168,208)(H,169,209)(H,172,198)(H,173,199)(H,174,218)(H,175,219)(H,176,206)(H,177,207)(H,178,212)(H,179,213)(H,180,216)(H,181,217)(H,182,222)(H,183,223)(H,184,214)(H,185,215)(H4,153,154,162)(H4,155,156,163)/t85-,86-,97+,98+,99+,100+,101+,102+,103+,104+,105+,106+,107+,108+,109+,110+,111+,112+,121+,122+,125-,126-/m1/s1 | PDB
MMDB
KEGG
UniProtKB/SwissProt
B.MOAD
antibodypedia
GoogleScholar
AffyNet
| CHEMBL
PC cid
PC sid
UniChem
Similars
| Article
PubMed
| n/a | n/a | 4.20 | n/a | n/a | n/a | n/a | n/a | n/a |
Syntonix Pharmaceuticals, Inc.
Curated by ChEMBL
| Assay Description
Inhibition of IgG binding to soluble human FcRn after 5 hrs by competition ELISA |
J Med Chem 53: 1587-96 (2010)
Article DOI: 10.1021/jm901128z
BindingDB Entry DOI: 10.7270/Q23R0T1H |
More data for this
Ligand-Target Pair | |
IgG receptor FcRn large subunit p51
(Homo sapiens (Human)) | BDBM50314100
((S)-N1,N4-bis((S)-1-((S)-1-((3R,8R,11S,17S,20S,29S...)Show SMILES CC(C)C[C@@H]1N(C)C(=O)CN(C)C(=O)CNC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](Cc2cnc[nH]2)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](CCCNC(N)=N)NC(=O)C[C@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](Cc2ccccc2)C(=O)N[C@@H]2C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](Cc3cnc[nH]3)C(=O)N[C@@H](Cc3ccccc3)C(=O)NCC(=O)N(C)CC(=O)N(C)[C@@H](CC(C)C)C(=O)N[C@@H](Cc3ccc(O)cc3)C(=O)C(=O)N3CCC[C@H]3C(=O)N[C@@H](CSSC2(C)C)C(N)=O)C(C)(C)SSC[C@H](NC(=O)[C@@H]2CCCN2C(=O)C(=O)[C@H](Cc2ccc(O)cc2)NC1=O)C(N)=O)[C@@H](C)O |r| Show InChI InChI=1S/C147H202N38O34S4/c1-79(2)56-108-136(212)168-96(59-88-44-48-92(188)49-45-88)119(197)142(218)184-54-30-42-106(184)134(210)174-104(123(148)199)75-220-222-146(8,9)121(140(216)176-117(82(6)186)138(214)158-69-111(191)165-102(65-90-67-154-77-162-90)130(206)170-98(61-84-32-20-16-21-33-84)126(202)160-71-113(193)180(12)73-115(195)182(108)14)178-132(208)100(63-86-36-24-18-25-37-86)172-128(204)94(40-28-52-156-144(150)151)164-110(190)58-81(5)125(201)167-95(41-29-53-157-145(152)153)129(205)173-101(64-87-38-26-19-27-39-87)133(209)179-122-141(217)177-118(83(7)187)139(215)159-70-112(192)166-103(66-91-68-155-78-163-91)131(207)171-99(62-85-34-22-17-23-35-85)127(203)161-72-114(194)181(13)74-116(196)183(15)109(57-80(3)4)137(213)169-97(60-89-46-50-93(189)51-47-89)120(198)143(219)185-55-31-43-107(185)135(211)175-105(124(149)200)76-221-223-147(122,10)11/h16-27,32-39,44-51,67-68,77-83,94-109,117-118,121-122,186-189H,28-31,40-43,52-66,69-76H2,1-15H3,(H2,148,199)(H2,149,200)(H,154,162)(H,155,163)(H,158,214)(H,159,215)(H,160,202)(H,161,203)(H,164,190)(H,165,191)(H,166,192)(H,167,201)(H,168,212)(H,169,213)(H,170,206)(H,171,207)(H,172,204)(H,173,205)(H,174,210)(H,175,211)(H,176,216)(H,177,217)(H,178,208)(H,179,209)(H4,150,151,156)(H4,152,153,157)/t81-,82+,83+,94-,95-,96-,97-,98-,99-,100-,101-,102-,103-,104-,105-,106-,107-,108-,109-,117-,118-,121+,122+/m0/s1 | PDB
MMDB
KEGG
UniProtKB/SwissProt
B.MOAD
antibodypedia
GoogleScholar
AffyNet
| CHEMBL
PC cid
PC sid
UniChem
Similars
| Article
PubMed
| n/a | n/a | 4.60 | n/a | n/a | n/a | n/a | n/a | n/a |
Syntonix Pharmaceuticals, Inc.
Curated by ChEMBL
| Assay Description
Inhibition of IgG binding to soluble human FcRn after 5 hrs by competition ELISA |
J Med Chem 53: 1587-96 (2010)
Article DOI: 10.1021/jm901128z
BindingDB Entry DOI: 10.7270/Q23R0T1H |
More data for this
Ligand-Target Pair | |
IgG receptor FcRn large subunit p51
(Homo sapiens (Human)) | BDBM50314098
(CHEMBL1090636)Show SMILES CC(C)C[C@@H]1N(C)C(=O)CN(C)C(=O)CNC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](Cc2cnc[nH]2)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](CCCNC(N)=N)NC(=O)CN(C)CC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](Cc2ccccc2)C(=O)N[C@@H]2C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](Cc3cnc[nH]3)C(=O)N[C@@H](Cc3ccccc3)C(=O)NCC(=O)N(C)CC(=O)N(C)[C@@H](CC(C)C)C(=O)N[C@@H](Cc3ccc(O)cc3)C(=O)C(=O)N3CCC[C@H]3C(=O)N[C@@H](CSSC2(C)C)C(N)=O)C(C)(C)SSC[C@H](NC(=O)[C@@H]2CCCN2C(=O)C(=O)[C@H](Cc2ccc(O)cc2)NC1=O)C(N)=O)[C@@H](C)O |r| Show InChI InChI=1S/C147H203N39O34S4/c1-80(2)56-108-136(213)168-96(58-88-44-48-92(189)49-45-88)120(199)142(219)185-54-30-42-106(185)134(211)174-104(124(148)201)76-221-223-146(7,8)122(140(217)176-118(82(5)187)138(215)158-68-110(191)166-102(64-90-66-154-78-162-90)130(207)170-98(60-84-32-20-16-21-33-84)126(203)160-70-114(195)181(12)74-116(197)183(108)14)178-132(209)100(62-86-36-24-18-25-37-86)172-128(205)94(40-28-52-156-144(150)151)164-112(193)72-180(11)73-113(194)165-95(41-29-53-157-145(152)153)129(206)173-101(63-87-38-26-19-27-39-87)133(210)179-123-141(218)177-119(83(6)188)139(216)159-69-111(192)167-103(65-91-67-155-79-163-91)131(208)171-99(61-85-34-22-17-23-35-85)127(204)161-71-115(196)182(13)75-117(198)184(15)109(57-81(3)4)137(214)169-97(59-89-46-50-93(190)51-47-89)121(200)143(220)186-55-31-43-107(186)135(212)175-105(125(149)202)77-222-224-147(123,9)10/h16-27,32-39,44-51,66-67,78-83,94-109,118-119,122-123,187-190H,28-31,40-43,52-65,68-77H2,1-15H3,(H2,148,201)(H2,149,202)(H,154,162)(H,155,163)(H,158,215)(H,159,216)(H,160,203)(H,161,204)(H,164,193)(H,165,194)(H,166,191)(H,167,192)(H,168,213)(H,169,214)(H,170,207)(H,171,208)(H,172,205)(H,173,206)(H,174,211)(H,175,212)(H,176,217)(H,177,218)(H,178,209)(H,179,210)(H4,150,151,156)(H4,152,153,157)/t82-,83-,94+,95+,96+,97+,98+,99+,100+,101+,102+,103+,104+,105+,106+,107+,108+,109+,118+,119+,122-,123-/m1/s1 | PDB
MMDB
KEGG
UniProtKB/SwissProt
B.MOAD
antibodypedia
GoogleScholar
AffyNet
| CHEMBL
PC cid
PC sid
UniChem
Similars
| Article
PubMed
| n/a | n/a | 4.70 | n/a | n/a | n/a | n/a | n/a | n/a |
Syntonix Pharmaceuticals, Inc.
Curated by ChEMBL
| Assay Description
Inhibition of IgG binding to soluble human FcRn after 5 hrs by competition ELISA |
J Med Chem 53: 1587-96 (2010)
Article DOI: 10.1021/jm901128z
BindingDB Entry DOI: 10.7270/Q23R0T1H |
More data for this
Ligand-Target Pair | |
IgG receptor FcRn large subunit p51
(Homo sapiens (Human)) | BDBM50314096
(CHEMBL1090634)Show SMILES CC(C)C[C@@H]1N(C)C(=O)CN(C)C(=O)CNC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](Cc2cnc[nH]2)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](CCCNC(N)=N)NC(=O)CCOCCOCCOCCOCCOCCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](Cc2ccccc2)C(=O)N[C@@H]2C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](Cc3cnc[nH]3)C(=O)N[C@@H](Cc3ccccc3)C(=O)NCC(=O)N(C)CC(=O)N(C)[C@@H](CC(C)C)C(=O)N[C@@H](Cc3ccc(O)cc3)C(=O)C(=O)N3CCC[C@H]3C(=O)N[C@@H](CSSC2(C)C)C(N)=O)C(C)(C)SSC[C@H](NC(=O)[C@@H]2CCCN2C(=O)C(=O)[C@H](Cc2ccc(O)cc2)NC1=O)C(N)=O)[C@@H](C)O |r| Show InChI InChI=1S/C156H220N38O39S4/c1-89(2)67-117-145(221)177-105(69-97-43-47-101(197)48-44-97)129(207)151(227)193-55-29-41-115(193)143(219)183-113(133(157)209)85-234-236-155(7,8)131(149(225)185-127(91(5)195)147(223)167-79-121(201)175-111(75-99-77-163-87-171-99)139(215)179-107(71-93-31-19-15-20-32-93)135(211)169-81-123(203)189(11)83-125(205)191(117)13)187-141(217)109(73-95-35-23-17-24-36-95)181-137(213)103(39-27-53-165-153(159)160)173-119(199)51-57-229-59-61-231-63-65-233-66-64-232-62-60-230-58-52-120(200)174-104(40-28-54-166-154(161)162)138(214)182-110(74-96-37-25-18-26-38-96)142(218)188-132-150(226)186-128(92(6)196)148(224)168-80-122(202)176-112(76-100-78-164-88-172-100)140(216)180-108(72-94-33-21-16-22-34-94)136(212)170-82-124(204)190(12)84-126(206)192(14)118(68-90(3)4)146(222)178-106(70-98-45-49-102(198)50-46-98)130(208)152(228)194-56-30-42-116(194)144(220)184-114(134(158)210)86-235-237-156(132,9)10/h15-26,31-38,43-50,77-78,87-92,103-118,127-128,131-132,195-198H,27-30,39-42,51-76,79-86H2,1-14H3,(H2,157,209)(H2,158,210)(H,163,171)(H,164,172)(H,167,223)(H,168,224)(H,169,211)(H,170,212)(H,173,199)(H,174,200)(H,175,201)(H,176,202)(H,177,221)(H,178,222)(H,179,215)(H,180,216)(H,181,213)(H,182,214)(H,183,219)(H,184,220)(H,185,225)(H,186,226)(H,187,217)(H,188,218)(H4,159,160,165)(H4,161,162,166)/t91-,92-,103+,104+,105+,106+,107+,108?,109+,110+,111+,112+,113+,114+,115+,116+,117+,118+,127+,128+,131-,132-/m1/s1 | PDB
MMDB
KEGG
UniProtKB/SwissProt
B.MOAD
antibodypedia
GoogleScholar
AffyNet
| CHEMBL
PC cid
PC sid
UniChem
Similars
| Article
PubMed
| n/a | n/a | 4.80 | n/a | n/a | n/a | n/a | n/a | n/a |
Syntonix Pharmaceuticals, Inc.
Curated by ChEMBL
| Assay Description
Inhibition of IgG binding to soluble human FcRn after 5 hrs by competition ELISA |
J Med Chem 53: 1587-96 (2010)
Article DOI: 10.1021/jm901128z
BindingDB Entry DOI: 10.7270/Q23R0T1H |
More data for this
Ligand-Target Pair | |
IgG receptor FcRn large subunit p51
(Homo sapiens (Human)) | BDBM50314099
(CHEMBL1090637 | N1,N5-bis((S)-1-((S)-1-((3R,8R,11S...)Show SMILES CC(C)C[C@@H]1N(C)C(=O)CN(C)C(=O)CNC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](Cc2cnc[nH]2)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](CCCNC(N)=N)NC(=O)CC(C)(C)CC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](Cc2ccccc2)C(=O)N[C@@H]2C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](Cc3cnc[nH]3)C(=O)N[C@@H](Cc3ccccc3)C(=O)NCC(=O)N(C)CC(=O)N(C)[C@@H](CC(C)C)C(=O)N[C@@H](Cc3ccc(O)cc3)C(=O)C(=O)N3CCC[C@H]3C(=O)N[C@@H](CSSC2(C)C)C(N)=O)C(C)(C)SSC[C@H](NC(=O)[C@@H]2CCCN2C(=O)C(=O)[C@H](Cc2ccc(O)cc2)NC1=O)C(N)=O)[C@@H](C)O |r| Show InChI InChI=1S/C149H206N38O34S4/c1-81(2)57-109-137(214)170-97(59-89-45-49-93(190)50-46-89)121(200)143(220)186-55-31-43-107(186)135(212)176-105(125(150)202)77-222-224-148(9,10)123(141(218)178-119(83(5)188)139(216)160-71-113(194)168-103(65-91-69-156-79-164-91)131(208)172-99(61-85-33-21-17-22-34-85)127(204)162-73-115(196)182(13)75-117(198)184(109)15)180-133(210)101(63-87-37-25-19-26-38-87)174-129(206)95(41-29-53-158-145(152)153)166-111(192)67-147(7,8)68-112(193)167-96(42-30-54-159-146(154)155)130(207)175-102(64-88-39-27-20-28-40-88)134(211)181-124-142(219)179-120(84(6)189)140(217)161-72-114(195)169-104(66-92-70-157-80-165-92)132(209)173-100(62-86-35-23-18-24-36-86)128(205)163-74-116(197)183(14)76-118(199)185(16)110(58-82(3)4)138(215)171-98(60-90-47-51-94(191)52-48-90)122(201)144(221)187-56-32-44-108(187)136(213)177-106(126(151)203)78-223-225-149(124,11)12/h17-28,33-40,45-52,69-70,79-84,95-110,119-120,123-124,188-191H,29-32,41-44,53-68,71-78H2,1-16H3,(H2,150,202)(H2,151,203)(H,156,164)(H,157,165)(H,160,216)(H,161,217)(H,162,204)(H,163,205)(H,166,192)(H,167,193)(H,168,194)(H,169,195)(H,170,214)(H,171,215)(H,172,208)(H,173,209)(H,174,206)(H,175,207)(H,176,212)(H,177,213)(H,178,218)(H,179,219)(H,180,210)(H,181,211)(H4,152,153,158)(H4,154,155,159)/t83-,84-,95+,96+,97+,98+,99+,100+,101+,102+,103+,104+,105+,106+,107+,108+,109+,110+,119+,120+,123-,124-/m1/s1 | PDB
MMDB
KEGG
UniProtKB/SwissProt
B.MOAD
antibodypedia
GoogleScholar
AffyNet
| CHEMBL
PC cid
PC sid
UniChem
Similars
| Article
PubMed
| n/a | n/a | 5 | n/a | n/a | n/a | n/a | n/a | n/a |
Syntonix Pharmaceuticals, Inc.
Curated by ChEMBL
| Assay Description
Inhibition of IgG binding to soluble human FcRn after 5 hrs by competition ELISA |
J Med Chem 53: 1587-96 (2010)
Article DOI: 10.1021/jm901128z
BindingDB Entry DOI: 10.7270/Q23R0T1H |
More data for this
Ligand-Target Pair | |
IgG receptor FcRn large subunit p51
(Homo sapiens (Human)) | BDBM50314097
(CHEMBL1090635 | N1,N1'-(ethane-1,2-diyl)bis(N4-((S...)Show SMILES CC(C)C[C@@H]1N(C)C(=O)CN(C)C(=O)CNC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](Cc2cnc[nH]2)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](CCCNC(N)=N)NC(=O)CCC(=O)N(C)CCN(C)C(=O)CCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](Cc2ccccc2)C(=O)N[C@@H]2C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](Cc3cnc[nH]3)C(=O)N[C@@H](Cc3ccccc3)C(=O)NCC(=O)N(C)CC(=O)N(C)[C@@H](CC(C)C)C(=O)N[C@@H](Cc3ccc(O)cc3)C(=O)C(=O)N3CCC[C@H]3C(=O)N[C@@H](CSSC2(C)C)C(N)=O)C(C)(C)SSC[C@H](NC(=O)[C@@H]2CCCN2C(=O)C(=O)[C@H](Cc2ccc(O)cc2)NC1=O)C(N)=O)[C@@H](C)O |r| Show InChI InChI=1S/C154H214N40O36S4/c1-85(2)63-113-143(223)175-101(65-93-45-49-97(197)50-46-93)127(209)149(229)193-59-31-43-111(193)141(221)181-109(131(155)211)81-231-233-153(7,8)129(147(227)183-125(87(5)195)145(225)165-75-117(201)173-107(71-95-73-161-83-169-95)137(217)177-103(67-89-33-21-17-22-34-89)133(213)167-77-121(205)189(13)79-123(207)191(113)15)185-139(219)105(69-91-37-25-19-26-38-91)179-135(215)99(41-29-57-163-151(157)158)171-115(199)53-55-119(203)187(11)61-62-188(12)120(204)56-54-116(200)172-100(42-30-58-164-152(159)160)136(216)180-106(70-92-39-27-20-28-40-92)140(220)186-130-148(228)184-126(88(6)196)146(226)166-76-118(202)174-108(72-96-74-162-84-170-96)138(218)178-104(68-90-35-23-18-24-36-90)134(214)168-78-122(206)190(14)80-124(208)192(16)114(64-86(3)4)144(224)176-102(66-94-47-51-98(198)52-48-94)128(210)150(230)194-60-32-44-112(194)142(222)182-110(132(156)212)82-232-234-154(130,9)10/h17-28,33-40,45-52,73-74,83-88,99-114,125-126,129-130,195-198H,29-32,41-44,53-72,75-82H2,1-16H3,(H2,155,211)(H2,156,212)(H,161,169)(H,162,170)(H,165,225)(H,166,226)(H,167,213)(H,168,214)(H,171,199)(H,172,200)(H,173,201)(H,174,202)(H,175,223)(H,176,224)(H,177,217)(H,178,218)(H,179,215)(H,180,216)(H,181,221)(H,182,222)(H,183,227)(H,184,228)(H,185,219)(H,186,220)(H4,157,158,163)(H4,159,160,164)/t87-,88-,99+,100+,101+,102+,103+,104+,105+,106+,107+,108+,109+,110+,111+,112+,113+,114+,125+,126+,129-,130-/m1/s1 | PDB
MMDB
KEGG
UniProtKB/SwissProt
B.MOAD
antibodypedia
GoogleScholar
AffyNet
| CHEMBL
PC cid
PC sid
UniChem
Similars
| Article
PubMed
| n/a | n/a | 5.20 | n/a | n/a | n/a | n/a | n/a | n/a |
Syntonix Pharmaceuticals, Inc.
Curated by ChEMBL
| Assay Description
Inhibition of IgG binding to soluble human FcRn after 5 hrs by competition ELISA |
J Med Chem 53: 1587-96 (2010)
Article DOI: 10.1021/jm901128z
BindingDB Entry DOI: 10.7270/Q23R0T1H |
More data for this
Ligand-Target Pair | |
IgG receptor FcRn large subunit p51
(Homo sapiens (Human)) | BDBM50314101
((S)-N1,N5-bis((S)-1-((S)-1-((3R,8R,11S,17S,20S,29S...)Show SMILES CC(C)C[C@@H]1N(C)C(=O)CN(C)C(=O)CNC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](Cc2cnc[nH]2)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](CCCNC(N)=N)NC(=O)CC[C@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](Cc2ccccc2)C(=O)N[C@@H]2C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](Cc3cnc[nH]3)C(=O)N[C@@H](Cc3ccccc3)C(=O)NCC(=O)N(C)CC(=O)N(C)[C@@H](CC(C)C)C(=O)N[C@@H](Cc3ccc(O)cc3)C(=O)C(=O)N3CCC[C@H]3C(=O)N[C@@H](CSSC2(C)C)C(N)=O)C(C)(C)SSC[C@H](NC(=O)[C@@H]2CCCN2C(=O)C(=O)[C@H](Cc2ccc(O)cc2)NC1=O)C(N)=O)[C@@H](C)O |r| Show InChI InChI=1S/C148H204N38O34S4/c1-80(2)58-109-137(213)169-97(60-89-45-49-93(189)50-46-89)120(198)143(219)185-56-30-42-107(185)135(211)175-105(124(149)200)76-221-223-147(8,9)122(141(217)177-118(83(6)187)139(215)159-70-112(192)166-103(66-91-68-155-78-163-91)131(207)171-99(62-85-32-20-16-21-33-85)127(203)161-72-114(194)181(12)74-116(196)183(109)14)179-133(209)101(64-87-36-24-18-25-37-87)173-129(205)95(40-28-54-157-145(151)152)165-111(191)53-44-82(5)126(202)168-96(41-29-55-158-146(153)154)130(206)174-102(65-88-38-26-19-27-39-88)134(210)180-123-142(218)178-119(84(7)188)140(216)160-71-113(193)167-104(67-92-69-156-79-164-92)132(208)172-100(63-86-34-22-17-23-35-86)128(204)162-73-115(195)182(13)75-117(197)184(15)110(59-81(3)4)138(214)170-98(61-90-47-51-94(190)52-48-90)121(199)144(220)186-57-31-43-108(186)136(212)176-106(125(150)201)77-222-224-148(123,10)11/h16-27,32-39,45-52,68-69,78-84,95-110,118-119,122-123,187-190H,28-31,40-44,53-67,70-77H2,1-15H3,(H2,149,200)(H2,150,201)(H,155,163)(H,156,164)(H,159,215)(H,160,216)(H,161,203)(H,162,204)(H,165,191)(H,166,192)(H,167,193)(H,168,202)(H,169,213)(H,170,214)(H,171,207)(H,172,208)(H,173,205)(H,174,206)(H,175,211)(H,176,212)(H,177,217)(H,178,218)(H,179,209)(H,180,210)(H4,151,152,157)(H4,153,154,158)/t82-,83+,84+,95-,96-,97-,98-,99-,100-,101-,102-,103-,104-,105-,106-,107-,108-,109-,110-,118-,119-,122+,123+/m0/s1 | PDB
MMDB
KEGG
UniProtKB/SwissProt
B.MOAD
antibodypedia
GoogleScholar
AffyNet
| CHEMBL
PC cid
PC sid
UniChem
Similars
| Article
PubMed
| n/a | n/a | 5.60 | n/a | n/a | n/a | n/a | n/a | n/a |
Syntonix Pharmaceuticals, Inc.
Curated by ChEMBL
| Assay Description
Inhibition of IgG binding to soluble human FcRn after 5 hrs by competition ELISA |
J Med Chem 53: 1587-96 (2010)
Article DOI: 10.1021/jm901128z
BindingDB Entry DOI: 10.7270/Q23R0T1H |
More data for this
Ligand-Target Pair | |
IgG receptor FcRn large subunit p51
(Homo sapiens (Human)) | BDBM50314091
(CHEMBL1090279 | N-[(1S)-1-{[(1S)-1-{[(5S,8S,15S,18...)Show SMILES CC(C)C[C@@H]1N(C)C(=O)CN2CCC[C@H](NC(=O)[C@H](Cc3ccccc3)NC(=O)[C@H](Cc3cnc[nH]3)NC(=O)CNC(=O)[C@H](C)N(C)C(=O)[C@@H](NC(=O)[C@H](Cc3ccccc3)NC(=O)[C@H](CCCNC(N)=N)NC(=O)CCC(=O)NCCN(C)CC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](Cc3ccccc3)C(=O)N[C@@H]3C(=O)N(C)[C@@H](C)C(=O)NCC(=O)N[C@@H](Cc4cnc[nH]4)C(=O)N[C@@H](Cc4ccccc4)C(=O)N[C@H]4CCCN(CC(=O)N(C)[C@@H](CC(C)C)C(=O)N[C@@H](Cc5ccc(O)cc5)C(=O)C(=O)N5CCC[C@H]5C(=O)N[C@@H](CSSC3(C)C)C(N)=O)C4=O)C(C)(C)SSC[C@H](NC(=O)[C@@H]3CCCN3C(=O)C(=O)[C@H](Cc3ccc(O)cc3)NC1=O)C(N)=O)C2=O |r| Show InChI InChI=1S/C155H214N40O33S4/c1-87(2)66-117-144(221)177-105(68-95-48-52-99(196)53-49-95)126(205)148(225)194-63-32-46-115(194)142(219)183-113(130(156)207)83-229-231-154(7,8)128(150(227)188(12)89(5)132(209)167-78-121(200)173-111(74-97-76-162-85-169-97)138(215)181-107(70-91-34-20-16-21-35-91)136(213)175-103-44-30-61-192(146(103)223)81-124(203)190(117)14)185-140(217)109(72-93-38-24-18-25-39-93)179-134(211)101(42-28-58-165-152(158)159)171-120(199)57-56-119(198)164-60-65-187(11)80-123(202)172-102(43-29-59-166-153(160)161)135(212)180-110(73-94-40-26-19-27-41-94)141(218)186-129-151(228)189(13)90(6)133(210)168-79-122(201)174-112(75-98-77-163-86-170-98)139(216)182-108(71-92-36-22-17-23-37-92)137(214)176-104-45-31-62-193(147(104)224)82-125(204)191(15)118(67-88(3)4)145(222)178-106(69-96-50-54-100(197)55-51-96)127(206)149(226)195-64-33-47-116(195)143(220)184-114(131(157)208)84-230-232-155(129,9)10/h16-27,34-41,48-55,76-77,85-90,101-118,128-129,196-197H,28-33,42-47,56-75,78-84H2,1-15H3,(H2,156,207)(H2,157,208)(H,162,169)(H,163,170)(H,164,198)(H,167,209)(H,168,210)(H,171,199)(H,172,202)(H,173,200)(H,174,201)(H,175,213)(H,176,214)(H,177,221)(H,178,222)(H,179,211)(H,180,212)(H,181,215)(H,182,216)(H,183,219)(H,184,220)(H,185,217)(H,186,218)(H4,158,159,165)(H4,160,161,166)/t89-,90-,101-,102-,103-,104-,105-,106-,107-,108-,109-,110-,111-,112-,113-,114-,115-,116-,117-,118-,128+,129+/m0/s1 | PDB
MMDB
KEGG
UniProtKB/SwissProt
B.MOAD
antibodypedia
GoogleScholar
AffyNet
| CHEMBL
PC cid
PC sid
UniChem
Similars
| Article
PubMed
| n/a | n/a | 18 | n/a | n/a | n/a | n/a | n/a | n/a |
Syntonix Pharmaceuticals, Inc.
Curated by ChEMBL
| Assay Description
Inhibition of IgG binding to soluble human FcRn after 5 hrs by competition ELISA |
J Med Chem 53: 1587-96 (2010)
Article DOI: 10.1021/jm901128z
BindingDB Entry DOI: 10.7270/Q23R0T1H |
More data for this
Ligand-Target Pair | |
IgG receptor FcRn large subunit p51
(Homo sapiens (Human)) | BDBM50314104
(CHEMBL1090969 | N1,N4-bis((S)-1-((S)-1-((3R,8R,11S...)Show SMILES [#6]-[#6](-[#6])-[#6]-[#6@@H]-1-[#7](-[#6])-[#6](=O)-[#6]-[#7](-[#6])-[#6](=O)-[#6]-[#7]-[#6](=O)-[#6@H](-[#6]-c2ccc(cc2)\[#7]=[#6](\[#7])-[#7])-[#7]-[#6](=O)-[#6]-[#7]-[#6](=O)-[#6@@H](-[#7]-[#6](=O)-[#6@@H](-[#7]-[#6](=O)-[#6@H](-[#6]-c2ccccc2)-[#7]-[#6](=O)-[#6@H](-[#6]-[#6]-[#6]-[#7]-[#6](-[#7])=[#7])-[#7]-[#6](=O)-[#6]-[#6]-[#6](=O)-[#7]-[#6@@H](-[#6]-[#6]-[#6]-[#7]-[#6](-[#7])=[#7])-[#6](=O)-[#7]-[#6@@H](-[#6]-c2ccccc2)-[#6](=O)-[#7]-[#6@@H]2-[#6](=O)-[#7]-[#6@@H](-[#6@@H](-[#6])-[#8])-[#6](=O)-[#7]-[#6]-[#6](=O)-[#7]-[#6@@H](-[#6]-c3ccc(cc3)\[#7]=[#6](\[#7])-[#7])-[#6](=O)-[#7]-[#6]-[#6](=O)-[#7](-[#6])-[#6]-[#6](=O)-[#7](-[#6])-[#6@@H](-[#6]-[#6](-[#6])-[#6])-[#6](=O)-[#7]-[#6@@H](-[#6]-c3ccc(-[#8])cc3)-[#6](=O)-[#6](=O)-[#7]-3-[#6]-[#6]-[#6]-[#6@H]-3-[#6](=O)-[#7]-[#6@@H](-[#6]-[#16]-[#16]C2([#6])[#6])-[#6](-[#7])=O)C([#6])([#6])[#16]-[#16]-[#6]-[#6@H](-[#7]-[#6](=O)-[#6@@H]-2-[#6]-[#6]-[#6]-[#7]-2-[#6](=O)-[#6](=O)-[#6@H](-[#6]-c2ccc(-[#8])cc2)-[#7]-[#6]-1=O)-[#6](-[#7])=O)-[#6@@H](-[#6])-[#8] |r| Show InChI InChI=1S/C136H192N38O32S4/c1-71(2)55-97-123(199)159-87(57-79-37-45-83(177)46-38-79)109(187)129(205)173-53-23-31-95(173)121(197)163-93(113(137)189)69-207-209-135(7,8)111(127(203)165-107(73(5)175)125(201)149-63-101(181)157-89(61-77-33-41-81(42-34-77)153-133(143)144)115(191)151-65-103(183)169(11)67-105(185)171(97)13)167-119(195)91(59-75-25-17-15-18-26-75)161-117(193)85(29-21-51-147-131(139)140)155-99(179)49-50-100(180)156-86(30-22-52-148-132(141)142)118(194)162-92(60-76-27-19-16-20-28-76)120(196)168-112-128(204)166-108(74(6)176)126(202)150-64-102(182)158-90(62-78-35-43-82(44-36-78)154-134(145)146)116(192)152-66-104(184)170(12)68-106(186)172(14)98(56-72(3)4)124(200)160-88(58-80-39-47-84(178)48-40-80)110(188)130(206)174-54-24-32-96(174)122(198)164-94(114(138)190)70-208-210-136(112,9)10/h15-20,25-28,33-48,71-74,85-98,107-108,111-112,175-178H,21-24,29-32,49-70H2,1-14H3,(H2,137,189)(H2,138,190)(H,149,201)(H,150,202)(H,151,191)(H,152,192)(H,155,179)(H,156,180)(H,157,181)(H,158,182)(H,159,199)(H,160,200)(H,161,193)(H,162,194)(H,163,197)(H,164,198)(H,165,203)(H,166,204)(H,167,195)(H,168,196)(H4,139,140,147)(H4,141,142,148)(H4,143,144,153)(H4,145,146,154)/t73-,74-,85+,86+,87+,88+,89+,90+,91+,92+,93+,94+,95+,96+,97+,98+,107+,108+,111-,112-/m1/s1 | PDB
MMDB
KEGG
UniProtKB/SwissProt
B.MOAD
antibodypedia
GoogleScholar
AffyNet
| CHEMBL
PC cid
PC sid
UniChem
Similars
| Article
PubMed
| n/a | n/a | 20 | n/a | n/a | n/a | n/a | n/a | n/a |
Syntonix Pharmaceuticals, Inc.
Curated by ChEMBL
| Assay Description
Inhibition of IgG binding to soluble human FcRn after 5 hrs by competition ELISA |
J Med Chem 53: 1587-96 (2010)
Article DOI: 10.1021/jm901128z
BindingDB Entry DOI: 10.7270/Q23R0T1H |
More data for this
Ligand-Target Pair | |
IgG receptor FcRn large subunit p51
(Homo sapiens (Human)) | BDBM50314092
(CHEMBL1090280)Show SMILES CC(C)C[C@@H]1N(C)C(=O)CN(C)C(=O)CNC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](Cc2cnc[nH]2)NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](CC(=O)NCCCC[C@H](NC(=O)[C@@H]2CCCN2C(=O)C(=O)[C@H](Cc2ccc(O)cc2)NC1=O)C(N)=O)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)CCC(=O)NCCN(C)CC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@H]1CC(=O)NCCCC[C@H](NC(=O)[C@@H]2CCCN2C(=O)C(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C(=O)CNC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](Cc2cnc[nH]2)NC(=O)CNC(=O)[C@@H](NC1=O)[C@@H](C)O)C(N)=O)[C@@H](C)O |r| Show InChI InChI=1S/C155H216N42O37/c1-87(2)64-117-148(229)181-105(66-95-46-50-99(200)51-47-95)132(213)152(233)196-61-30-44-115(196)146(227)179-101(134(156)215)40-24-26-56-164-121(204)74-113(144(225)189-130(89(5)198)150(231)169-78-123(206)177-111(72-97-76-162-85-173-97)142(223)183-107(68-91-32-16-12-17-33-91)136(217)171-80-126(209)192(8)83-128(211)194(117)10)187-140(221)109(70-93-36-20-14-21-37-93)185-138(219)103(42-28-58-167-154(158)159)175-120(203)55-54-119(202)166-60-63-191(7)82-125(208)176-104(43-29-59-168-155(160)161)139(220)186-110(71-94-38-22-15-23-39-94)141(222)188-114-75-122(205)165-57-27-25-41-102(135(157)216)180-147(228)116-45-31-62-197(116)153(234)133(214)106(67-96-48-52-100(201)53-49-96)182-149(230)118(65-88(3)4)195(11)129(212)84-193(9)127(210)81-172-137(218)108(69-92-34-18-13-19-35-92)184-143(224)112(73-98-77-163-86-174-98)178-124(207)79-170-151(232)131(90(6)199)190-145(114)226/h12-23,32-39,46-53,76-77,85-90,101-118,130-131,198-201H,24-31,40-45,54-75,78-84H2,1-11H3,(H2,156,215)(H2,157,216)(H,162,173)(H,163,174)(H,164,204)(H,165,205)(H,166,202)(H,169,231)(H,170,232)(H,171,217)(H,172,218)(H,175,203)(H,176,208)(H,177,206)(H,178,207)(H,179,227)(H,180,228)(H,181,229)(H,182,230)(H,183,223)(H,184,224)(H,185,219)(H,186,220)(H,187,221)(H,188,222)(H,189,225)(H,190,226)(H4,158,159,167)(H4,160,161,168)/t89-,90-,101+,102+,103+,104+,105+,106+,107+,108+,109+,110+,111+,112+,113+,114+,115+,116+,117+,118+,130+,131+/m1/s1 | PDB
MMDB
KEGG
UniProtKB/SwissProt
B.MOAD
antibodypedia
GoogleScholar
AffyNet
| CHEMBL
PC cid
PC sid
UniChem
Similars
| Article
PubMed
| n/a | n/a | 50 | n/a | n/a | n/a | n/a | n/a | n/a |
Syntonix Pharmaceuticals, Inc.
Curated by ChEMBL
| Assay Description
Inhibition of IgG binding to soluble human FcRn after 5 hrs by competition ELISA |
J Med Chem 53: 1587-96 (2010)
Article DOI: 10.1021/jm901128z
BindingDB Entry DOI: 10.7270/Q23R0T1H |
More data for this
Ligand-Target Pair | |
IgG receptor FcRn large subunit p51
(Homo sapiens (Human)) | BDBM50270832
(CHEMBL525265)Show SMILES CC(C)C[C@H](N(C)C(=O)CN(C)C(=O)CNC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](Cc1cnc[nH]1)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](N)CCC(N)=O)C(C)(C)S)[C@@H](C)O)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N1CCC[C@H]1C(O)=O |r,wU:90.92,105.110,130.136,73.76,29.37,51.61,4.4,43.45,115.119,84.88,wD:62.72,18.26,47.49,109.113,(31.01,-17.09,;31.01,-18.63,;32.35,-19.39,;29.68,-19.39,;29.68,-20.94,;28.35,-21.7,;28.35,-23.24,;27.01,-20.93,;27.01,-19.39,;25.68,-21.71,;24.35,-20.94,;24.36,-19.4,;23.02,-21.71,;23.02,-23.25,;21.69,-20.94,;20.35,-21.71,;19.02,-20.94,;19.02,-19.4,;17.69,-21.72,;17.69,-23.25,;19.02,-24.03,;20.34,-23.26,;21.68,-24.03,;21.68,-25.56,;20.35,-26.34,;19.02,-25.58,;16.35,-20.95,;15.03,-21.73,;15.03,-23.26,;13.69,-20.96,;13.69,-19.41,;15.03,-18.65,;16.44,-19.27,;17.46,-18.12,;16.69,-16.79,;15.18,-17.11,;12.35,-21.71,;11.01,-20.94,;11.01,-19.4,;9.67,-21.72,;8.34,-20.94,;7.01,-21.71,;7.01,-23.25,;5.67,-20.94,;4.34,-21.71,;3,-20.94,;3,-19.39,;1.67,-21.71,;.34,-20.94,;-.99,-21.73,;-.99,-23.26,;-2.32,-20.95,;-2.32,-19.41,;-.99,-18.64,;.35,-19.42,;1.68,-18.64,;1.68,-17.1,;.34,-16.34,;-.99,-17.11,;-3.66,-21.71,;-5,-20.95,;-5,-19.4,;-6.33,-21.72,;-6.33,-23.26,;-5,-24.03,;-5,-25.57,;-3.66,-26.33,;-3.65,-27.87,;-4.99,-28.64,;-2.32,-28.64,;-7.65,-20.94,;-8.97,-21.74,;-8.97,-23.27,;-10.3,-20.96,;-11.65,-21.71,;-10.3,-19.42,;-8.97,-18.66,;-8.97,-17.11,;-10.3,-16.34,;-7.63,-16.35,;1.67,-23.25,;3.22,-23.26,;.13,-23.24,;1.67,-24.79,;5.67,-19.39,;4.34,-18.63,;7,-18.63,;31.01,-21.71,;31.01,-23.25,;32.35,-20.94,;33.68,-21.71,;35.02,-20.94,;35.02,-19.39,;33.69,-18.63,;33.69,-17.1,;35.02,-16.32,;35.01,-14.77,;36.35,-17.08,;36.36,-18.62,;33.68,-23.25,;32.35,-24.02,;35.02,-24.02,;36.59,-23.49,;37.61,-24.82,;36.66,-26.21,;35.26,-25.52,;34.03,-26.45,;32.62,-25.85,;34.01,-27.99,;32.68,-28.76,;31.35,-27.98,;30.01,-28.74,;32.66,-30.3,;33.99,-31.08,;31.31,-31.04,;31.31,-32.58,;32.63,-33.37,;32.61,-34.9,;31.28,-35.65,;33.95,-35.69,;29.96,-33.34,;28.64,-32.56,;29.95,-34.88,;28.61,-35.63,;28.6,-37.17,;29.92,-37.95,;27.25,-37.93,;26.93,-39.58,;25.26,-39.8,;24.55,-38.27,;25.84,-37.41,;25.66,-35.89,;24.23,-35.3,;26.87,-34.95,)| Show InChI InChI=1S/C86H124N24O22S2/c1-46(2)33-63(80(127)103-59(36-50-24-26-52(112)27-25-50)83(130)110-32-15-22-61(110)79(126)104-60(44-133)78(125)102-58(38-65(89)114)74(121)96-42-68(117)109-31-16-23-62(109)84(131)132)108(7)69(118)43-107(6)67(116)41-95-73(120)55(34-48-17-10-8-11-18-48)100-76(123)57(37-51-39-92-45-97-51)98-66(115)40-94-81(128)70(47(3)111)105-82(129)71(86(4,5)134)106-77(124)56(35-49-19-12-9-13-20-49)101-75(122)54(21-14-30-93-85(90)91)99-72(119)53(87)28-29-64(88)113/h8-13,17-20,24-27,39,45-47,53-63,70-71,111-112,133-134H,14-16,21-23,28-38,40-44,87H2,1-7H3,(H2,88,113)(H2,89,114)(H,92,97)(H,94,128)(H,95,120)(H,96,121)(H,98,115)(H,99,119)(H,100,123)(H,101,122)(H,102,125)(H,103,127)(H,104,126)(H,105,129)(H,106,124)(H,131,132)(H4,90,91,93)/t47-,53+,54+,55+,56+,57+,58+,59+,60+,61+,62+,63+,70+,71-/m1/s1 | PDB
MMDB
KEGG
UniProtKB/SwissProt
B.MOAD
antibodypedia
GoogleScholar
AffyNet
| CHEMBL
KEGG
PC cid
PC sid
UniChem
Similars
| Article
PubMed
| n/a | n/a | 420 | n/a | n/a | n/a | n/a | n/a | n/a |
Syntonix Pharmaceuticals, Inc.
Curated by ChEMBL
| Assay Description
Inhibition of human IgG binding to soluble human FcRn by ELISA |
Bioorg Med Chem 16: 6394-405 (2008)
Article DOI: 10.1016/j.bmc.2008.05.004
BindingDB Entry DOI: 10.7270/Q2QV3M9C |
More data for this
Ligand-Target Pair | |
IgG receptor FcRn large subunit p51
(Homo sapiens (Human)) | BDBM50314078
((5S,8S,15S,18R,23R,26S,32S,35S,38S)-35-benzyl-23-[...)Show SMILES CC(C)C[C@@H]1N(C)C(=O)CN2CCC[C@H](NC(=O)[C@H](Cc3ccccc3)NC(=O)[C@H](Cc3cnc[nH]3)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](Cc3ccccc3)NC(=O)[C@H](CCCNC(N)=N)NC(C)=O)C(C)(C)SSC[C@H](NC(=O)[C@@H]3CCCN3C(=O)C(=O)[C@H](Cc3ccc(O)cc3)NC1=O)C(N)=O)[C@@H](C)O)C2=O |r| Show InChI InChI=1S/C75H103N19O17S2/c1-41(2)31-57-69(107)86-51(32-46-24-26-48(97)27-25-46)61(100)73(111)94-30-16-23-56(94)68(106)89-55(63(76)101)39-112-113-75(5,6)62(91-67(105)53(34-45-19-12-9-13-20-45)87-64(102)49(83-43(4)96)21-14-28-80-74(77)78)71(109)90-60(42(3)95)70(108)81-37-58(98)84-54(35-47-36-79-40-82-47)66(104)88-52(33-44-17-10-8-11-18-44)65(103)85-50-22-15-29-93(72(50)110)38-59(99)92(57)7/h8-13,17-20,24-27,36,40-42,49-57,60,62,95,97H,14-16,21-23,28-35,37-39H2,1-7H3,(H2,76,101)(H,79,82)(H,81,108)(H,83,96)(H,84,98)(H,85,103)(H,86,107)(H,87,102)(H,88,104)(H,89,106)(H,90,109)(H,91,105)(H4,77,78,80)/t42-,49+,50+,51+,52+,53+,54+,55+,56+,57+,60+,62-/m1/s1 | PDB
MMDB
KEGG
UniProtKB/SwissProt
B.MOAD
antibodypedia
GoogleScholar
AffyNet
| CHEMBL
PC cid
PC sid
UniChem
Similars
| Article
PubMed
| n/a | n/a | 430 | n/a | n/a | n/a | n/a | n/a | n/a |
Syntonix Pharmaceuticals, Inc.
Curated by ChEMBL
| Assay Description
Inhibition of IgG binding to soluble human FcRn after 5 hrs by competition ELISA |
J Med Chem 53: 1587-96 (2010)
Article DOI: 10.1021/jm901128z
BindingDB Entry DOI: 10.7270/Q23R0T1H |
More data for this
Ligand-Target Pair | |
IgG receptor FcRn large subunit p51
(Homo sapiens (Human)) | BDBM50314080
((3R,8R,11S,17S,20S,29S,32S,38aS)-17-((1H-imidazol-...)Show SMILES CC(C)C[C@@H]1N(C)C(=O)CN(C)C(=O)CNC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](Cc2cnc[nH]2)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](CCCNC(N)=N)NC(C)=O)C(C)(C)SSC[C@H](NC(=O)[C@@H]2CCCN2C(=O)C(=O)[C@H](Cc2ccc(O)cc2)NC1=O)C(N)=O)[C@@H](C)O |r| Show InChI InChI=1S/C73H101N19O17S2/c1-40(2)29-55-68(106)84-49(30-45-23-25-47(95)26-24-45)60(99)71(109)92-28-16-22-54(92)67(105)87-53(62(74)100)38-110-111-73(5,6)61(89-66(104)51(32-44-19-13-10-14-20-44)86-64(102)48(82-42(4)94)21-15-27-78-72(75)76)70(108)88-59(41(3)93)69(107)79-35-56(96)83-52(33-46-34-77-39-81-46)65(103)85-50(31-43-17-11-9-12-18-43)63(101)80-36-57(97)90(7)37-58(98)91(55)8/h9-14,17-20,23-26,34,39-41,48-55,59,61,93,95H,15-16,21-22,27-33,35-38H2,1-8H3,(H2,74,100)(H,77,81)(H,79,107)(H,80,101)(H,82,94)(H,83,96)(H,84,106)(H,85,103)(H,86,102)(H,87,105)(H,88,108)(H,89,104)(H4,75,76,78)/t41-,48+,49+,50+,51+,52+,53+,54+,55+,59+,61-/m1/s1 | PDB
MMDB
KEGG
UniProtKB/SwissProt
B.MOAD
antibodypedia
GoogleScholar
AffyNet
| CHEMBL
PC cid
PC sid
UniChem
Similars
| Article
PubMed
| n/a | n/a | 520 | n/a | n/a | n/a | n/a | n/a | n/a |
Syntonix Pharmaceuticals, Inc.
Curated by ChEMBL
| Assay Description
Inhibition of IgG binding to soluble human FcRn after 5 hrs by competition ELISA |
J Med Chem 53: 1587-96 (2010)
Article DOI: 10.1021/jm901128z
BindingDB Entry DOI: 10.7270/Q23R0T1H |
More data for this
Ligand-Target Pair | |
IgG receptor FcRn large subunit p51
(Homo sapiens (Human)) | BDBM50270965
((2R)-2-{[(2S)-1-[(2S)-2-[(2S)-2-{2-[(3R)-3-[(2S)-2...)Show SMILES CC(C)C[C@H](N(C)C(=O)CN1CCC[C@@H](NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](Cc2cnc[nH]2)NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@@H](N)CCCN=C(N)N)C(C)(C)S)[C@@H](C)O)C1=O)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CS)C(O)=O |r,wU:102.107,83.86,18.26,62.65,14.14,98.104,wD:4.4,51.61,47.49,43.45,75.79,29.37,(27.77,-6.06,;27.77,-4.53,;29.1,-3.76,;26.45,-3.76,;26.45,-2.22,;25.24,-1.34,;25.35,.19,;23.88,-2.07,;23.83,-3.6,;22.58,-1.25,;21.22,-1.97,;21.17,-3.51,;19.81,-4.23,;18.51,-3.42,;18.56,-1.88,;17.26,-1.07,;15.9,-1.79,;15.91,-3.34,;14.62,-.93,;14.62,.63,;15.95,1.4,;17.28,.62,;18.61,1.39,;18.61,2.93,;17.27,3.7,;15.94,2.93,;13.39,-1.81,;12.04,-1.09,;12.04,.45,;10.76,-1.95,;10.76,-3.5,;12.1,-4.27,;13.56,-3.78,;14.47,-5.02,;13.58,-6.27,;12.11,-5.81,;9.37,-1.07,;8.01,-1.79,;8.02,-3.34,;6.74,-.93,;5.52,-1.81,;4.17,-1.09,;4.17,.45,;2.89,-1.95,;1.68,-1.07,;.34,-1.85,;.35,-3.39,;-1,-1.08,;-2.33,-1.87,;-3.69,-1.14,;-3.69,.41,;-4.98,-2.01,;-4.98,-3.56,;-3.64,-4.35,;-2.3,-3.57,;-.96,-4.35,;-.96,-5.89,;-2.3,-6.66,;-3.64,-5.89,;-6.19,-1.12,;-7.56,-1.84,;-7.55,-3.4,;-8.84,-.97,;-10.06,-1.87,;-8.84,.58,;-7.5,1.35,;-7.5,2.9,;-6.17,3.63,;-6.13,5.17,;-4.77,5.9,;-7.45,5.98,;-1.01,.47,;-2.56,.45,;-1.02,2.02,;.54,.47,;2.89,-3.5,;1.56,-4.27,;4.22,-4.27,;19.91,-1.15,;19.96,.39,;27.71,-1.37,;27.72,.17,;29.07,-2.09,;30.28,-1.21,;30.28,.33,;31.35,1.43,;32.84,1.04,;33.92,2.14,;33.51,3.62,;34.58,4.72,;32.01,4,;30.94,2.91,;31.54,-2.07,;31.55,-3.61,;32.9,-1.35,;33.12,.17,;34.63,.43,;35.35,-.92,;34.29,-2.03,;34.55,-3.55,;33.37,-4.53,;36,-4.08,;37.21,-3.21,;37.21,-1.65,;38.54,-.89,;38.48,-4.06,;39.84,-3.33,;38.49,-5.59,)| Show InChI InChI=1S/C72H102N18O16S2/c1-40(2)30-55(65(100)84-52(33-44-23-25-46(92)26-24-44)69(104)90-29-15-22-54(90)64(99)85-53(38-107)70(105)106)88(6)57(94)37-89-28-14-21-48(68(89)103)81-61(96)49(31-42-16-9-7-10-17-42)83-62(97)51(34-45-35-76-39-79-45)80-56(93)36-78-66(101)58(41(3)91)86-67(102)59(72(4,5)108)87-63(98)50(32-43-18-11-8-12-19-43)82-60(95)47(73)20-13-27-77-71(74)75/h7-12,16-19,23-26,35,39-41,47-55,58-59,91-92,107-108H,13-15,20-22,27-34,36-38,73H2,1-6H3,(H,76,79)(H,78,101)(H,80,93)(H,81,96)(H,82,95)(H,83,97)(H,84,100)(H,85,99)(H,86,102)(H,87,98)(H,105,106)(H4,74,75,77)/t41-,47+,48-,49+,50+,51+,52+,53+,54+,55+,58+,59+/m1/s1 | PDB
MMDB
KEGG
UniProtKB/SwissProt
B.MOAD
antibodypedia
GoogleScholar
AffyNet
| CHEMBL
PC cid
PC sid
UniChem
Similars
| Article
PubMed
| n/a | n/a | 530 | n/a | n/a | n/a | n/a | n/a | n/a |
Syntonix Pharmaceuticals, Inc.
Curated by ChEMBL
| Assay Description
Inhibition of human IgG binding to soluble human FcRn by ELISA |
Bioorg Med Chem 16: 6394-405 (2008)
Article DOI: 10.1016/j.bmc.2008.05.004
BindingDB Entry DOI: 10.7270/Q2QV3M9C |
More data for this
Ligand-Target Pair | |
IgG receptor FcRn large subunit p51
(Homo sapiens (Human)) | BDBM50270987
(CHEMBL443697 | SYN-1327)Show SMILES CC(C)C[C@H](N(C)C(=O)CN(C)C(=O)CNC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](Cc1cnc[nH]1)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](N)CCCN=C(N)N)C(C)(C)S)[C@@H](C)O)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CS)C(O)=O |r,wU:81.83,96.101,29.37,51.61,4.4,43.45,75.79,wD:62.65,18.26,47.49,100.104,(28.79,-21.8,;28.79,-23.34,;30.13,-24.11,;27.46,-24.11,;27.46,-25.65,;26.12,-26.42,;26.13,-27.96,;24.79,-25.65,;24.79,-24.1,;23.46,-26.42,;22.13,-25.65,;22.13,-24.11,;20.8,-26.43,;20.8,-27.96,;19.46,-25.66,;18.13,-26.42,;16.79,-25.66,;16.79,-24.11,;15.46,-26.43,;15.46,-27.97,;16.79,-28.74,;18.12,-27.97,;19.45,-28.74,;19.46,-30.27,;18.13,-31.05,;16.79,-30.29,;14.13,-25.66,;12.8,-26.44,;12.8,-27.98,;11.47,-25.67,;11.47,-24.12,;12.8,-23.36,;14.21,-23.99,;15.24,-22.84,;14.46,-21.51,;12.96,-21.83,;10.12,-26.42,;8.78,-25.66,;8.78,-24.11,;7.45,-26.43,;6.11,-25.65,;4.78,-26.43,;4.78,-27.96,;3.44,-25.65,;2.11,-26.42,;.78,-25.65,;.78,-24.11,;-.55,-26.43,;-1.88,-25.66,;-3.21,-26.44,;-3.21,-27.98,;-4.55,-25.67,;-4.55,-24.12,;-3.21,-23.36,;-1.87,-24.13,;-.54,-23.36,;-.54,-21.81,;-1.89,-21.05,;-3.21,-21.83,;-5.89,-26.43,;-7.22,-25.66,;-7.22,-24.12,;-8.55,-26.43,;-9.88,-25.65,;-8.55,-27.97,;-7.22,-28.74,;-7.22,-30.28,;-5.89,-31.04,;-5.87,-32.58,;-7.22,-33.35,;-4.55,-33.35,;-.55,-27.96,;.99,-27.97,;-2.1,-27.95,;-.55,-29.51,;3.44,-24.11,;2.12,-23.34,;4.78,-23.34,;28.79,-26.42,;28.79,-27.96,;30.13,-25.65,;31.45,-26.42,;32.79,-25.65,;32.79,-24.11,;31.47,-23.35,;31.46,-21.81,;32.79,-21.03,;32.79,-19.49,;34.13,-21.8,;34.14,-23.33,;31.45,-27.96,;30.13,-28.73,;32.79,-28.73,;34.36,-28.21,;35.39,-29.54,;34.44,-30.92,;33.04,-30.24,;31.81,-31.16,;30.39,-30.56,;31.79,-32.7,;30.45,-33.47,;29.13,-32.69,;27.78,-33.45,;30.44,-35.01,;29.1,-35.76,;31.76,-35.8,)| Show InChI InChI=1S/C70H100N18O16S2/c1-39(2)28-53(64(99)82-50(31-43-22-24-45(90)25-23-43)67(102)88-27-15-21-52(88)63(98)83-51(37-105)68(103)104)87(7)56(93)36-86(6)55(92)35-77-60(95)47(29-41-16-10-8-11-17-41)81-61(96)49(32-44-33-74-38-78-44)79-54(91)34-76-65(100)57(40(3)89)84-66(101)58(70(4,5)106)85-62(97)48(30-42-18-12-9-13-19-42)80-59(94)46(71)20-14-26-75-69(72)73/h8-13,16-19,22-25,33,38-40,46-53,57-58,89-90,105-106H,14-15,20-21,26-32,34-37,71H2,1-7H3,(H,74,78)(H,76,100)(H,77,95)(H,79,91)(H,80,94)(H,81,96)(H,82,99)(H,83,98)(H,84,101)(H,85,97)(H,103,104)(H4,72,73,75)/t40-,46+,47+,48+,49+,50+,51+,52+,53+,57+,58-/m1/s1 | PDB
MMDB
KEGG
UniProtKB/SwissProt
B.MOAD
antibodypedia
GoogleScholar
AffyNet
| CHEMBL
PC cid
PC sid
UniChem
Similars
| Article
PubMed
| n/a | n/a | 570 | n/a | n/a | n/a | n/a | n/a | n/a |
Syntonix Pharmaceuticals, Inc.
Curated by ChEMBL
| Assay Description
Inhibition of human IgG binding to soluble human FcRn by ELISA |
Bioorg Med Chem 16: 6394-405 (2008)
Article DOI: 10.1016/j.bmc.2008.05.004
BindingDB Entry DOI: 10.7270/Q2QV3M9C |
More data for this
Ligand-Target Pair | |
IgG receptor FcRn large subunit p51
(Homo sapiens (Human)) | BDBM50314088
(CHEMBL1090276)Show SMILES CC(C)C[C@@H]1N(C)C(=O)CN(C)C(=O)CNC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](Cc2cnc[nH]2)NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](CC(=O)NCCCC[C@H](NC(=O)[C@@H]2CCCN2C(=O)C(=O)[C@H](Cc2ccc(O)cc2)NC1=O)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N1CCC[C@H]1C(N)=O)NC(=O)[C@H](Cc1ccccc1)NC(=O)CSCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@H]1CC(=O)NCCCC[C@H](NC(=O)[C@@H]2CCCN2C(=O)C(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C(=O)CNC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](Cc2cnc[nH]2)NC(=O)CNC(=O)[C@@H](NC1=O)[C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N1CCC[C@H]1C(N)=O)[C@@H](C)O |r| Show InChI InChI=1S/C171H234N46O45S/c1-92(2)64-126-165(257)199-110(66-100-47-51-104(220)52-48-100)145(237)169(261)216-62-30-45-124(216)163(255)197-106(153(245)204-118(74-129(173)223)151(243)188-84-139(233)214-60-28-43-122(214)147(175)239)40-23-25-57-181-131(225)76-120(161(253)208-143(94(5)218)167(259)184-80-133(227)193-116(72-102-78-179-90-190-102)159(251)201-112(68-96-32-15-11-16-33-96)149(241)186-82-137(231)210(7)86-141(235)212(126)9)206-157(249)114(70-98-36-19-13-20-37-98)195-136(230)89-263-88-135(229)192-109(55-56-128(172)222)156(248)196-108(42-27-59-183-171(177)178)155(247)203-115(71-99-38-21-14-22-39-99)158(250)207-121-77-132(226)182-58-26-24-41-107(154(246)205-119(75-130(174)224)152(244)189-85-140(234)215-61-29-44-123(215)148(176)240)198-164(256)125-46-31-63-217(125)170(262)146(238)111(67-101-49-53-105(221)54-50-101)200-166(258)127(65-93(3)4)213(10)142(236)87-211(8)138(232)83-187-150(242)113(69-97-34-17-12-18-35-97)202-160(252)117(73-103-79-180-91-191-103)194-134(228)81-185-168(260)144(95(6)219)209-162(121)254/h11-22,32-39,47-54,78-79,90-95,106-127,143-144,218-221H,23-31,40-46,55-77,80-89H2,1-10H3,(H2,172,222)(H2,173,223)(H2,174,224)(H2,175,239)(H2,176,240)(H,179,190)(H,180,191)(H,181,225)(H,182,226)(H,184,259)(H,185,260)(H,186,241)(H,187,242)(H,188,243)(H,189,244)(H,192,229)(H,193,227)(H,194,228)(H,195,230)(H,196,248)(H,197,255)(H,198,256)(H,199,257)(H,200,258)(H,201,251)(H,202,252)(H,203,247)(H,204,245)(H,205,246)(H,206,249)(H,207,250)(H,208,253)(H,209,254)(H4,177,178,183)/t94-,95-,106+,107+,108+,109+,110+,111+,112+,113+,114+,115+,116+,117+,118+,119+,120+,121+,122+,123+,124+,125+,126+,127+,143+,144+/m1/s1 | PDB
MMDB
KEGG
UniProtKB/SwissProt
B.MOAD
antibodypedia
GoogleScholar
AffyNet
| CHEMBL
PC cid
PC sid
UniChem
Similars
| Article
PubMed
| n/a | n/a | 580 | n/a | n/a | n/a | n/a | n/a | n/a |
Syntonix Pharmaceuticals, Inc.
Curated by ChEMBL
| Assay Description
Inhibition of IgG binding to soluble human FcRn after 5 hrs by competition ELISA |
J Med Chem 53: 1587-96 (2010)
Article DOI: 10.1021/jm901128z
BindingDB Entry DOI: 10.7270/Q23R0T1H |
More data for this
Ligand-Target Pair | |
IgG receptor FcRn large subunit p51
(Homo sapiens (Human)) | BDBM50314084
(CHEMBL1089952)Show SMILES CC(C)C[C@@H]1N(C)C(=O)CN(C)C(=O)CNC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](Cc2cnc[nH]2)NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](CC(=O)NCCCC[C@H](NC(=O)[C@@H]2CCCN2C(=O)C(=O)[C@H](Cc2ccc(O)cc2)NC1=O)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N1CCC[C@H]1C(N)=O)NC(=O)[C@H](Cc1ccccc1)NC(=O)CSCCC(=O)NCCCN(CCCNC(=O)CCSCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@H]1CC(=O)NCCCC[C@H](NC(=O)[C@@H]2CCCN2C(=O)C(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C(=O)CNC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](Cc2cnc[nH]2)NC(=O)CNC(=O)[C@@H](NC1=O)[C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N1CCC[C@H]1C(N)=O)CC(=O)NCC(O)=O)[C@@H](C)O |r| Show InChI InChI=1S/C187H262N50O50S2/c1-104(2)74-138-181(282)218-122(76-112-49-53-116(240)54-50-112)161(262)185(286)236-70-30-47-136(236)179(280)216-118(169(270)223-130(84-141(189)243)167(268)207-94-154(256)234-68-28-45-134(234)163(191)264)42-23-25-61-199-145(247)86-132(177(278)227-159(106(5)238)183(284)203-90-147(249)212-128(82-114-88-195-102-209-114)175(276)220-124(78-108-34-15-11-16-35-108)165(266)205-92-152(254)229(7)98-156(258)231(138)9)225-173(274)126(80-110-38-19-13-20-39-110)214-151(253)101-289-73-60-144(246)198-65-33-67-233(97-149(251)202-96-158(260)261)66-32-64-197-143(245)59-72-288-100-150(252)211-121(57-58-140(188)242)172(273)215-120(44-27-63-201-187(193)194)171(272)222-127(81-111-40-21-14-22-41-111)174(275)226-133-87-146(248)200-62-26-24-43-119(170(271)224-131(85-142(190)244)168(269)208-95-155(257)235-69-29-46-135(235)164(192)265)217-180(281)137-48-31-71-237(137)186(287)162(263)123(77-113-51-55-117(241)56-52-113)219-182(283)139(75-105(3)4)232(10)157(259)99-230(8)153(255)93-206-166(267)125(79-109-36-17-12-18-37-109)221-176(277)129(83-115-89-196-103-210-115)213-148(250)91-204-184(285)160(107(6)239)228-178(133)279/h11-22,34-41,49-56,88-89,102-107,118-139,159-160,238-241H,23-33,42-48,57-87,90-101H2,1-10H3,(H2,188,242)(H2,189,243)(H2,190,244)(H2,191,264)(H2,192,265)(H,195,209)(H,196,210)(H,197,245)(H,198,246)(H,199,247)(H,200,248)(H,202,251)(H,203,284)(H,204,285)(H,205,266)(H,206,267)(H,207,268)(H,208,269)(H,211,252)(H,212,249)(H,213,250)(H,214,253)(H,215,273)(H,216,280)(H,217,281)(H,218,282)(H,219,283)(H,220,276)(H,221,277)(H,222,272)(H,223,270)(H,224,271)(H,225,274)(H,226,275)(H,227,278)(H,228,279)(H,260,261)(H4,193,194,201)/t106-,107-,118+,119+,120+,121+,122+,123+,124+,125+,126+,127+,128+,129+,130+,131+,132+,133+,134+,135+,136+,137+,138+,139+,159+,160+/m1/s1 | PDB
MMDB
KEGG
UniProtKB/SwissProt
B.MOAD
antibodypedia
GoogleScholar
AffyNet
| CHEMBL
PC cid
PC sid
UniChem
Similars
| Article
PubMed
| n/a | n/a | 600 | n/a | n/a | n/a | n/a | n/a | n/a |
Syntonix Pharmaceuticals, Inc.
Curated by ChEMBL
| Assay Description
Inhibition of IgG binding to soluble human FcRn after 5 hrs by competition ELISA |
J Med Chem 53: 1587-96 (2010)
Article DOI: 10.1021/jm901128z
BindingDB Entry DOI: 10.7270/Q23R0T1H |
More data for this
Ligand-Target Pair | |
IgG receptor FcRn large subunit p51
(Homo sapiens (Human)) | BDBM50270966
((2R)-2-{[(2S)-1-[(2S)-2-[(2S)-2-{2-[(3R)-3-[(2S)-2...)Show SMILES CC(C)C[C@H](N(C)C(=O)CN1CCCC[C@@H](NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](Cc2cnc[nH]2)NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@@H](N)CCCN=C(N)N)C(C)(C)S)[C@@H](C)O)C1=O)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CS)C(O)=O |r,wU:103.108,84.87,15.15,63.66,19.27,99.105,wD:4.4,44.46,76.80,30.38,52.62,48.50,(28.01,-21.12,;28.01,-19.59,;29.34,-18.82,;26.69,-18.82,;26.69,-17.29,;25.49,-16.41,;25.47,-14.87,;24.26,-17.34,;24.19,-18.87,;22.84,-16.75,;21.62,-17.68,;21.93,-19.19,;20.95,-20.37,;19.4,-20.34,;18.46,-19.12,;18.84,-17.62,;17.65,-16.64,;16.3,-17.37,;16.31,-18.92,;15.02,-16.5,;15.02,-14.95,;16.35,-14.18,;17.67,-14.96,;19,-14.19,;19.01,-12.65,;17.67,-11.88,;16.34,-12.65,;13.8,-17.39,;12.44,-16.67,;12.45,-15.12,;11.17,-17.53,;11.17,-19.08,;12.5,-19.85,;13.96,-19.36,;14.88,-20.59,;13.99,-21.84,;12.52,-21.38,;9.78,-16.64,;8.42,-17.37,;8.43,-18.91,;7.15,-16.5,;5.94,-17.39,;4.58,-16.67,;4.59,-15.12,;3.3,-17.53,;2.09,-16.64,;.76,-17.42,;.77,-18.97,;-.58,-16.66,;-1.91,-17.44,;-3.27,-16.72,;-3.26,-15.17,;-4.55,-17.58,;-4.55,-19.14,;-3.22,-19.92,;-1.88,-19.14,;-.54,-19.92,;-.54,-21.47,;-1.88,-22.23,;-3.22,-21.47,;-5.77,-16.7,;-7.13,-17.42,;-7.12,-18.97,;-8.41,-16.55,;-9.63,-17.44,;-8.41,-14.99,;-7.07,-14.23,;-7.07,-12.68,;-5.74,-11.96,;-5.7,-10.41,;-4.35,-9.68,;-7.02,-9.61,;-.59,-15.11,;-2.14,-15.13,;-.6,-13.56,;.96,-15.11,;3.3,-19.08,;1.97,-19.85,;4.64,-19.84,;20.24,-16.98,;20.27,-15.44,;27.96,-16.43,;27.96,-14.9,;29.31,-17.16,;30.52,-16.27,;30.52,-14.73,;31.59,-13.64,;33.08,-14.02,;34.16,-12.93,;33.74,-11.45,;34.82,-10.35,;32.25,-11.07,;31.18,-12.16,;31.78,-17.13,;31.79,-18.67,;33.14,-16.41,;33.35,-14.9,;34.87,-14.63,;35.59,-15.99,;34.52,-17.09,;34.78,-18.61,;33.61,-19.59,;36.23,-19.14,;37.44,-18.27,;37.45,-16.72,;38.77,-15.96,;38.71,-19.12,;40.07,-18.39,;38.72,-20.65,)| Show InChI InChI=1S/C73H104N18O16S2/c1-41(2)31-56(66(101)85-53(34-45-24-26-47(93)27-25-45)70(105)91-30-16-23-55(91)65(100)86-54(39-108)71(106)107)89(6)58(95)38-90-29-14-13-22-49(69(90)104)82-62(97)50(32-43-17-9-7-10-18-43)84-63(98)52(35-46-36-77-40-80-46)81-57(94)37-79-67(102)59(42(3)92)87-68(103)60(73(4,5)109)88-64(99)51(33-44-19-11-8-12-20-44)83-61(96)48(74)21-15-28-78-72(75)76/h7-12,17-20,24-27,36,40-42,48-56,59-60,92-93,108-109H,13-16,21-23,28-35,37-39,74H2,1-6H3,(H,77,80)(H,79,102)(H,81,94)(H,82,97)(H,83,96)(H,84,98)(H,85,101)(H,86,100)(H,87,103)(H,88,99)(H,106,107)(H4,75,76,78)/t42-,48+,49-,50+,51+,52+,53+,54+,55+,56+,59+,60+/m1/s1 | PDB
MMDB
KEGG
UniProtKB/SwissProt
B.MOAD
antibodypedia
GoogleScholar
AffyNet
| CHEMBL
PC cid
PC sid
UniChem
Similars
| Article
PubMed
| n/a | n/a | 620 | n/a | n/a | n/a | n/a | n/a | n/a |
Syntonix Pharmaceuticals, Inc.
Curated by ChEMBL
| Assay Description
Inhibition of human IgG binding to soluble human FcRn by ELISA |
Bioorg Med Chem 16: 6394-405 (2008)
Article DOI: 10.1016/j.bmc.2008.05.004
BindingDB Entry DOI: 10.7270/Q2QV3M9C |
More data for this
Ligand-Target Pair | |
IgG receptor FcRn large subunit p51
(Homo sapiens (Human)) | BDBM50270961
((2R)-2-{[(2S)-1-[(2S)-2-[(2S)-2-{2-[(3R)-3-[(2S)-2...)Show SMILES CC(C)C[C@H](NC(=O)CN1CCCC[C@@H](NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](Cc2cnc[nH]2)NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@@H](N)CCCN=C(N)N)C(C)(C)S)[C@@H](C)O)C1=O)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CS)C(O)=O |r,wU:102.107,83.86,14.14,62.65,18.26,98.104,wD:4.4,43.45,75.79,29.37,51.61,47.49,(27.04,-22.59,;27.04,-21.07,;28.37,-20.3,;25.72,-20.3,;25.72,-18.76,;24.52,-17.88,;23.29,-18.81,;23.23,-20.35,;21.87,-18.22,;20.65,-19.15,;20.97,-20.66,;19.98,-21.84,;18.43,-21.82,;17.5,-20.59,;17.87,-19.1,;16.69,-18.11,;15.34,-18.84,;15.34,-20.39,;14.05,-17.98,;14.05,-16.42,;15.38,-15.66,;16.71,-16.43,;18.04,-15.66,;18.04,-14.13,;16.7,-13.36,;15.37,-14.13,;12.83,-18.86,;11.48,-18.14,;11.48,-16.6,;10.2,-19,;10.2,-20.55,;11.54,-21.32,;12.99,-20.83,;13.91,-22.07,;13.02,-23.32,;11.55,-22.86,;8.81,-18.12,;7.46,-18.84,;7.46,-20.38,;6.18,-17.98,;4.97,-18.86,;3.61,-18.14,;3.62,-16.6,;2.34,-19,;1.13,-18.12,;-.21,-18.9,;-.19,-20.44,;-1.54,-18.13,;-2.87,-18.92,;-4.23,-18.19,;-4.23,-16.64,;-5.52,-19.06,;-5.52,-20.61,;-4.18,-21.39,;-2.84,-20.62,;-1.5,-21.39,;-1.5,-22.94,;-2.84,-23.71,;-4.18,-22.94,;-6.73,-18.17,;-8.09,-18.89,;-8.09,-20.45,;-9.38,-18.02,;-10.6,-18.92,;-9.38,-16.47,;-8.04,-15.7,;-8.04,-14.16,;-6.71,-13.43,;-6.66,-11.89,;-5.31,-11.15,;-7.98,-11.08,;-1.56,-16.59,;-3.1,-16.6,;-1.56,-15.04,;-.01,-16.58,;2.34,-20.55,;1.01,-21.32,;3.67,-21.32,;19.28,-18.45,;19.31,-16.91,;26.99,-17.91,;26.99,-16.37,;28.34,-18.63,;29.55,-17.74,;29.55,-16.21,;30.62,-15.11,;32.11,-15.5,;33.19,-14.4,;32.77,-12.92,;33.85,-11.82,;31.28,-12.54,;30.21,-13.64,;30.81,-18.61,;30.82,-20.14,;32.17,-17.89,;32.38,-16.37,;33.9,-16.11,;34.62,-17.46,;33.55,-18.57,;33.81,-20.08,;32.64,-21.07,;35.26,-20.61,;36.47,-19.75,;36.47,-18.19,;37.8,-17.43,;37.74,-20.59,;39.09,-19.86,;37.75,-22.13,)| Show InChI InChI=1S/C72H102N18O16S2/c1-40(2)30-49(61(96)85-53(33-44-23-25-46(92)26-24-44)69(104)90-29-15-22-55(90)65(100)86-54(38-107)70(105)106)81-57(94)37-89-28-13-12-21-48(68(89)103)82-62(97)50(31-42-16-8-6-9-17-42)84-63(98)52(34-45-35-76-39-79-45)80-56(93)36-78-66(101)58(41(3)91)87-67(102)59(72(4,5)108)88-64(99)51(32-43-18-10-7-11-19-43)83-60(95)47(73)20-14-27-77-71(74)75/h6-11,16-19,23-26,35,39-41,47-55,58-59,91-92,107-108H,12-15,20-22,27-34,36-38,73H2,1-5H3,(H,76,79)(H,78,101)(H,80,93)(H,81,94)(H,82,97)(H,83,95)(H,84,98)(H,85,96)(H,86,100)(H,87,102)(H,88,99)(H,105,106)(H4,74,75,77)/t41-,47+,48-,49+,50+,51+,52+,53+,54+,55+,58+,59+/m1/s1 | PDB
MMDB
KEGG
UniProtKB/SwissProt
B.MOAD
antibodypedia
GoogleScholar
AffyNet
| CHEMBL
PC cid
PC sid
UniChem
Similars
| Article
PubMed
| n/a | n/a | 640 | n/a | n/a | n/a | n/a | n/a | n/a |
Syntonix Pharmaceuticals, Inc.
Curated by ChEMBL
| Assay Description
Inhibition of human IgG binding to soluble human FcRn by ELISA |
Bioorg Med Chem 16: 6394-405 (2008)
Article DOI: 10.1016/j.bmc.2008.05.004
BindingDB Entry DOI: 10.7270/Q2QV3M9C |
More data for this
Ligand-Target Pair | |
IgG receptor FcRn large subunit p51
(Homo sapiens (Human)) | BDBM50270959
((2R)-2-{[(2S)-1-[(2S)-2-[(2S)-2-{2-[(3R)-3-[(2S)-2...)Show SMILES CC(C)C[C@H](NC(=O)CN1CCC[C@@H](NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](Cc2cnc[nH]2)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@@H](N)CCCN=C(N)N)C(C)(C)S)[C@@H](C)O)C1=O)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CS)C(O)=O |r,wU:82.85,46.48,17.25,13.13,101.106,wD:4.4,61.64,50.60,42.44,74.78,28.36,97.103,(30.93,-20.12,;30.94,-18.58,;32.28,-17.82,;29.61,-17.81,;29.65,-16.27,;28.34,-15.46,;27.01,-16.23,;27.01,-17.77,;25.67,-15.46,;24.34,-16.23,;24.35,-17.76,;23.01,-18.53,;21.68,-17.76,;21.68,-16.22,;20.35,-15.45,;19.01,-16.22,;19.01,-17.76,;17.68,-15.45,;17.68,-13.91,;19.01,-13.14,;19.01,-11.6,;20.35,-10.83,;21.68,-11.6,;21.68,-13.14,;20.35,-13.91,;16.35,-16.22,;15.01,-15.45,;15.01,-13.91,;13.68,-16.22,;13.68,-17.76,;15.01,-18.53,;16.49,-18.09,;17.35,-19.37,;16.41,-20.59,;14.96,-20.06,;12.35,-15.45,;11.01,-16.22,;11.01,-17.76,;9.68,-15.45,;8.34,-16.22,;7,-15.45,;7,-13.91,;5.67,-16.22,;4.34,-15.45,;3,-16.22,;3,-17.76,;1.67,-15.45,;.34,-16.22,;-1,-15.45,;-1,-13.91,;-2.33,-16.22,;-2.33,-17.76,;-1,-18.53,;.34,-17.76,;1.67,-18.53,;1.67,-20.07,;.34,-20.84,;-1,-20.07,;-3.66,-15.45,;-5.01,-16.22,;-6.34,-15.45,;-5.01,-17.76,;-6.34,-18.53,;-3.66,-18.53,;-3.66,-20.07,;-5.01,-20.84,;-5.01,-22.38,;-6.34,-23.15,;-7.67,-22.38,;-6.34,-24.69,;1.67,-13.91,;1.66,-12.36,;3.21,-13.9,;.13,-13.92,;5.67,-17.76,;4.34,-18.53,;7,-18.53,;23.01,-15.45,;23.02,-13.91,;31.01,-15.53,;31.05,-13.99,;32.32,-16.33,;33.68,-15.6,;33.72,-14.06,;35.08,-13.32,;36.39,-14.13,;37.74,-13.39,;37.78,-11.85,;39.13,-11.12,;36.47,-11.05,;35.12,-11.78,;34.99,-16.4,;36.35,-15.67,;34.96,-17.94,;33.68,-18.82,;34.12,-20.3,;35.66,-20.34,;36.18,-18.89,;37.48,-18.06,;37.48,-16.52,;38.8,-18.84,;40.14,-18.08,;40.16,-16.54,;38.82,-15.76,;41.47,-18.86,;42.81,-18.1,;41.46,-20.4,)| Show InChI InChI=1S/C71H100N18O16S2/c1-39(2)29-48(60(95)84-52(32-43-22-24-45(91)25-23-43)68(103)89-28-14-21-54(89)64(99)85-53(37-106)69(104)105)80-56(93)36-88-27-13-20-47(67(88)102)81-61(96)49(30-41-15-8-6-9-16-41)83-62(97)51(33-44-34-75-38-78-44)79-55(92)35-77-65(100)57(40(3)90)86-66(101)58(71(4,5)107)87-63(98)50(31-42-17-10-7-11-18-42)82-59(94)46(72)19-12-26-76-70(73)74/h6-11,15-18,22-25,34,38-40,46-54,57-58,90-91,106-107H,12-14,19-21,26-33,35-37,72H2,1-5H3,(H,75,78)(H,77,100)(H,79,92)(H,80,93)(H,81,96)(H,82,94)(H,83,97)(H,84,95)(H,85,99)(H,86,101)(H,87,98)(H,104,105)(H4,73,74,76)/t40-,46+,47-,48+,49+,50+,51+,52+,53+,54+,57+,58-/m1/s1 | PDB
MMDB
KEGG
UniProtKB/SwissProt
B.MOAD
antibodypedia
GoogleScholar
AffyNet
| CHEMBL
PC cid
PC sid
UniChem
Similars
| Article
PubMed
| n/a | n/a | 660 | n/a | n/a | n/a | n/a | n/a | n/a |
Syntonix Pharmaceuticals, Inc.
Curated by ChEMBL
| Assay Description
Inhibition of human IgG binding to soluble human FcRn by ELISA |
Bioorg Med Chem 16: 6394-405 (2008)
Article DOI: 10.1016/j.bmc.2008.05.004
BindingDB Entry DOI: 10.7270/Q2QV3M9C |
More data for this
Ligand-Target Pair | |
IgG receptor FcRn large subunit p51
(Homo sapiens (Human)) | BDBM50314087
(CHEMBL1090275)Show SMILES CC(C)C[C@@H]1N(C)C(=O)CN(C)C(=O)CNC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](Cc2cnc[nH]2)NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](CC(=O)NCCCC[C@H](NC(=O)[C@@H]2CCCN2C(=O)C(=O)[C@H](Cc2ccc(O)cc2)NC1=O)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N1CCC[C@H]1C(N)=O)NC(=O)[C@H](Cc1ccccc1)NC(=O)CSCCC(=O)NCCC(=O)NCCC(=O)NCCNCCCN(CCCNC(=O)CCNC(=O)CCNC(=O)CCNC(=O)CCSC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@H]1CC(=O)NCCCC[C@H](NC(=O)[C@@H]2CCCN2C(=O)C(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C(=O)CNC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](Cc2cnc[nH]2)NC(=O)CNC(=O)[C@@H](NC1=O)[C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N1CCC[C@H]1C(N)=O)CC(=O)NCC(O)=O)[C@@H](C)O |r| Show InChI InChI=1S/C203H290N56O55S2/c1-115(2)86-149-196(308)239-133(88-123-49-53-127(262)54-50-123)176(288)200(312)258-82-30-47-147(258)194(306)237-129(184(296)244-141(96-152(205)265)182(294)229-106-169(282)256-80-28-45-145(256)178(207)290)42-23-25-67-215-161(274)98-143(192(304)249-174(117(5)260)198(310)225-102-163(276)233-139(94-125-100-212-113-231-125)190(302)241-135(90-119-34-15-11-16-35-119)180(292)227-104-167(280)251(7)110-171(284)253(149)9)246-188(300)137(92-121-38-19-13-20-39-121)235-166(279)112-315-84-64-159(272)220-74-61-156(269)219-73-63-158(271)222-77-76-211-66-32-78-255(109-165(278)224-108-173(286)287)79-33-70-214-154(267)59-71-217-155(268)60-72-218-157(270)62-75-221-160(273)65-85-316-203(314)248-132(57-58-151(204)264)187(299)236-131(44-27-69-223-202(209)210)186(298)243-138(93-122-40-21-14-22-41-122)189(301)247-144-99-162(275)216-68-26-24-43-130(185(297)245-142(97-153(206)266)183(295)230-107-170(283)257-81-29-46-146(257)179(208)291)238-195(307)148-48-31-83-259(148)201(313)177(289)134(89-124-51-55-128(263)56-52-124)240-197(309)150(87-116(3)4)254(10)172(285)111-252(8)168(281)105-228-181(293)136(91-120-36-17-12-18-37-120)242-191(303)140(95-126-101-213-114-232-126)234-164(277)103-226-199(311)175(118(6)261)250-193(144)305/h11-22,34-41,49-56,100-101,113-118,129-150,174-175,211,260-263H,23-33,42-48,57-99,102-112H2,1-10H3,(H2,204,264)(H2,205,265)(H2,206,266)(H2,207,290)(H2,208,291)(H,212,231)(H,213,232)(H,214,267)(H,215,274)(H,216,275)(H,217,268)(H,218,270)(H,219,269)(H,220,272)(H,221,273)(H,222,271)(H,224,278)(H,225,310)(H,226,311)(H,227,292)(H,228,293)(H,229,294)(H,230,295)(H,233,276)(H,234,277)(H,235,279)(H,236,299)(H,237,306)(H,238,307)(H,239,308)(H,240,309)(H,241,302)(H,242,303)(H,243,298)(H,244,296)(H,245,297)(H,246,300)(H,247,301)(H,248,314)(H,249,304)(H,250,305)(H,286,287)(H4,209,210,223)/t117-,118-,129+,130+,131+,132+,133+,134+,135+,136+,137+,138+,139+,140+,141+,142+,143+,144+,145+,146+,147+,148+,149+,150+,174+,175+/m1/s1 | PDB
MMDB
KEGG
UniProtKB/SwissProt
B.MOAD
antibodypedia
GoogleScholar
AffyNet
| CHEMBL
PC cid
PC sid
UniChem
Similars
| Article
PubMed
| n/a | n/a | 710 | n/a | n/a | n/a | n/a | n/a | n/a |
Syntonix Pharmaceuticals, Inc.
Curated by ChEMBL
| Assay Description
Inhibition of IgG binding to soluble human FcRn after 5 hrs by competition ELISA |
J Med Chem 53: 1587-96 (2010)
Article DOI: 10.1021/jm901128z
BindingDB Entry DOI: 10.7270/Q23R0T1H |
More data for this
Ligand-Target Pair | |
IgG receptor FcRn large subunit p51
(Homo sapiens (Human)) | BDBM50270827
(CHEMBL505899)Show SMILES CC(C)C[C@H](NC(=O)CN(C)C(=O)CNC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](Cc1cnc[nH]1)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](N)CCC(N)=O)C(C)(C)S)[C@@H](C)O)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N1CCC[C@H]1C(O)=O |r,wU:89.91,104.109,129.135,72.75,28.36,50.60,4.4,42.44,114.118,83.87,wD:61.71,17.25,46.48,108.112,(32.33,1.5,;32.33,-.04,;33.66,-.81,;31,-.81,;31,-2.35,;29.66,-3.12,;28.33,-2.35,;28.33,-.8,;27,-3.12,;25.67,-2.35,;25.67,-.81,;24.34,-3.13,;24.34,-4.67,;23,-2.36,;21.67,-3.13,;20.33,-2.36,;20.33,-.81,;19,-3.13,;19,-4.67,;20.33,-5.44,;21.66,-4.67,;22.99,-5.44,;23,-6.98,;21.67,-7.75,;20.33,-6.99,;17.67,-2.36,;16.34,-3.14,;16.34,-4.68,;15.01,-2.37,;15.01,-.82,;16.34,-.06,;17.75,-.69,;18.78,.46,;18,1.79,;16.49,1.47,;13.66,-3.12,;12.32,-2.36,;12.32,-.81,;10.98,-3.13,;9.65,-2.36,;8.32,-3.13,;8.32,-4.66,;6.98,-2.35,;5.65,-3.12,;4.32,-2.35,;4.32,-.81,;2.99,-3.13,;1.65,-2.36,;.33,-3.14,;.33,-4.68,;-1.01,-2.37,;-1.01,-.82,;.33,-.06,;1.67,-.83,;3,-.06,;2.99,1.49,;1.65,2.25,;.33,1.47,;-2.35,-3.13,;-3.68,-2.36,;-3.68,-.82,;-5.01,-3.13,;-5.01,-4.67,;-3.68,-5.44,;-3.68,-6.98,;-2.35,-7.74,;-2.34,-9.28,;-3.68,-10.05,;-1.01,-10.05,;-6.34,-2.35,;-7.65,-3.15,;-7.65,-4.69,;-8.98,-2.38,;-10.33,-3.12,;-8.98,-.83,;-7.65,-.07,;-7.65,1.48,;-8.99,2.24,;-6.32,2.24,;2.99,-4.66,;4.53,-4.67,;1.44,-4.65,;2.99,-6.21,;6.98,-.81,;5.65,-.04,;8.32,-.04,;32.33,-3.13,;32.33,-4.66,;33.66,-2.35,;34.99,-3.13,;36.33,-2.35,;36.33,-.81,;35,-.05,;35,1.49,;36.33,2.27,;36.33,3.81,;37.67,1.5,;37.68,-.03,;34.99,-4.66,;33.66,-5.43,;36.33,-5.43,;37.9,-4.91,;38.93,-6.24,;37.98,-7.62,;36.57,-6.94,;35.35,-7.87,;33.93,-7.26,;35.33,-9.41,;33.99,-10.18,;32.67,-9.39,;31.32,-10.15,;33.98,-11.71,;35.3,-12.5,;32.63,-12.46,;32.62,-14,;33.94,-14.78,;33.93,-16.32,;32.59,-17.06,;35.26,-17.1,;31.28,-14.75,;29.95,-13.97,;31.26,-16.29,;29.92,-17.04,;29.91,-18.58,;31.24,-19.37,;28.57,-19.34,;28.24,-21,;26.58,-21.21,;25.87,-19.69,;27.15,-18.83,;26.97,-17.3,;25.54,-16.71,;28.18,-16.36,)| Show InChI InChI=1S/C85H122N24O22S2/c1-45(2)32-54(75(122)103-59(35-49-23-25-51(111)26-24-49)82(129)109-31-14-21-61(109)79(126)104-60(43-132)78(125)102-58(37-64(88)113)73(120)95-41-68(117)108-30-15-22-62(108)83(130)131)98-66(115)42-107(6)67(116)40-94-72(119)55(33-47-16-9-7-10-17-47)100-76(123)57(36-50-38-91-44-96-50)97-65(114)39-93-80(127)69(46(3)110)105-81(128)70(85(4,5)133)106-77(124)56(34-48-18-11-8-12-19-48)101-74(121)53(20-13-29-92-84(89)90)99-71(118)52(86)27-28-63(87)112/h7-12,16-19,23-26,38,44-46,52-62,69-70,110-111,132-133H,13-15,20-22,27-37,39-43,86H2,1-6H3,(H2,87,112)(H2,88,113)(H,91,96)(H,93,127)(H,94,119)(H,95,120)(H,97,114)(H,98,115)(H,99,118)(H,100,123)(H,101,121)(H,102,125)(H,103,122)(H,104,126)(H,105,128)(H,106,124)(H,130,131)(H4,89,90,92)/t46-,52+,53+,54+,55+,56+,57+,58+,59+,60+,61+,62+,69+,70-/m1/s1 | PDB
MMDB
KEGG
UniProtKB/SwissProt
B.MOAD
antibodypedia
GoogleScholar
AffyNet
| CHEMBL
KEGG
PC cid
PC sid
UniChem
Similars
| Article
PubMed
| n/a | n/a | 900 | n/a | n/a | n/a | n/a | n/a | n/a |
Syntonix Pharmaceuticals, Inc.
Curated by ChEMBL
| Assay Description
Inhibition of human IgG binding to soluble human FcRn by ELISA |
Bioorg Med Chem 16: 6394-405 (2008)
Article DOI: 10.1016/j.bmc.2008.05.004
BindingDB Entry DOI: 10.7270/Q2QV3M9C |
More data for this
Ligand-Target Pair | |
IgG receptor FcRn large subunit p51
(Homo sapiens (Human)) | BDBM50270912
((2S)-1-{2-[(2S)-2-[(2S)-2-{[(2S)-1-[(2S)-2-[(2S)-2...)Show SMILES CC(C)C[C@H](NC(=O)CNC(=O)CNC(=O)[C@H](Cc1ccccc1C)NC(=O)[C@H](Cc1cnc[nH]1)NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](N)CCC(N)=O)C(C)(C)S)[C@@H](C)O)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N1CCC[C@H]1C(=O)N[C@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N1CCC[C@H]1C(O)=O |r,wU:50.60,46.48,42.44,83.87,28.36,4.4,89.91,104.109,108.112,114.118,129.135,72.75,wD:61.71,16.25,(35.58,-.23,;35.58,-1.75,;36.93,-2.53,;34.25,-2.53,;34.25,-4.05,;32.92,-4.82,;31.59,-4.04,;31.59,-2.52,;30.26,-4.8,;28.92,-4.02,;27.6,-4.79,;27.6,-6.34,;26.26,-4.02,;24.94,-4.78,;23.6,-3.99,;23.6,-2.47,;22.28,-4.76,;22.28,-6.31,;23.03,-7.63,;24.55,-7.64,;25.3,-8.95,;24.53,-10.28,;23.02,-10.26,;22.26,-8.94,;20.72,-8.94,;20.94,-3.99,;19.62,-4.75,;19.62,-6.29,;18.28,-3.97,;18.28,-2.45,;19.62,-1.67,;21.02,-2.31,;22.06,-1.19,;21.3,.15,;19.79,-.16,;16.96,-4.74,;15.62,-3.96,;15.62,-2.43,;14.29,-4.72,;12.96,-3.95,;11.63,-4.73,;11.63,-6.25,;10.29,-3.95,;8.98,-4.72,;7.64,-3.94,;7.65,-2.37,;6.3,-4.7,;4.96,-3.92,;3.62,-4.7,;3.62,-6.24,;2.29,-3.92,;2.29,-2.38,;3.62,-1.6,;4.98,-2.38,;6.31,-1.61,;6.31,-.07,;4.98,.7,;3.63,-.07,;.94,-4.7,;-.39,-3.92,;-.39,-2.38,;-1.74,-4.7,;-1.74,-6.24,;-.39,-7.01,;-.39,-8.58,;.94,-9.35,;.94,-10.89,;-.39,-11.66,;2.29,-11.66,;-3.09,-3.92,;-4.42,-4.7,;-4.42,-6.24,;-5.77,-3.92,;-7.12,-4.7,;-5.77,-2.38,;-4.42,-1.6,;-4.42,-.06,;-5.77,.71,;-3.09,.71,;6.31,-6.25,;7.84,-6.27,;4.76,-6.23,;6.3,-7.78,;10.29,-2.4,;8.97,-1.64,;11.64,-1.63,;35.58,-4.82,;35.58,-6.38,;36.91,-4.06,;38.25,-4.84,;39.57,-4.08,;39.57,-2.56,;38.26,-1.78,;38.26,-.25,;39.6,.51,;39.6,2.05,;40.93,-.26,;40.91,-1.79,;38.25,-6.39,;36.91,-7.17,;39.57,-7.15,;41.14,-6.61,;42.16,-7.94,;41.22,-9.32,;39.83,-8.64,;38.6,-9.57,;37.22,-8.89,;38.71,-11.1,;37.44,-11.97,;36.05,-11.28,;34.78,-12.15,;37.54,-13.49,;38.92,-14.17,;36.26,-14.36,;36.37,-15.88,;37.75,-16.56,;37.86,-18.09,;36.59,-18.95,;39.25,-18.76,;35.1,-16.75,;33.72,-16.07,;35.21,-18.28,;33.93,-19.14,;34.04,-20.67,;35.42,-21.34,;32.77,-21.53,;32.58,-23.2,;30.94,-23.54,;30.11,-22.09,;31.32,-21.13,;31.02,-19.62,;29.56,-19.13,;32.17,-18.61,)| Show InChI InChI=1S/C85H122N24O22S2/c1-44(2)31-54(75(122)104-59(33-48-22-24-51(111)25-23-48)82(129)109-30-13-20-61(109)79(126)105-60(42-132)78(125)103-58(36-64(88)113)73(120)96-41-68(117)108-29-14-21-62(108)83(130)131)98-66(115)39-93-65(114)38-94-72(119)56(34-49-18-11-10-15-45(49)3)102-76(123)57(35-50-37-91-43-97-50)99-67(116)40-95-80(127)69(46(4)110)106-81(128)70(85(5,6)133)107-77(124)55(32-47-16-8-7-9-17-47)101-74(121)53(19-12-28-92-84(89)90)100-71(118)52(86)26-27-63(87)112/h7-11,15-18,22-25,37,43-44,46,52-62,69-70,110-111,132-133H,12-14,19-21,26-36,38-42,86H2,1-6H3,(H2,87,112)(H2,88,113)(H,91,97)(H,93,114)(H,94,119)(H,95,127)(H,96,120)(H,98,115)(H,99,116)(H,100,118)(H,101,121)(H,102,123)(H,103,125)(H,104,122)(H,105,126)(H,106,128)(H,107,124)(H,130,131)(H4,89,90,92)/t46-,52+,53+,54+,55+,56+,57+,58+,59+,60-,61+,62+,69+,70+/m1/s1 | PDB
MMDB
KEGG
UniProtKB/SwissProt
B.MOAD
antibodypedia
GoogleScholar
AffyNet
| CHEMBL
PC cid
PC sid
UniChem
Similars
| Article
PubMed
| n/a | n/a | 1.00E+3 | n/a | n/a | n/a | n/a | n/a | n/a |
Syntonix Pharmaceuticals, Inc.
Curated by ChEMBL
| Assay Description
Inhibition of human IgG binding to soluble human FcRn by ELISA |
Bioorg Med Chem 16: 6394-405 (2008)
Article DOI: 10.1016/j.bmc.2008.05.004
BindingDB Entry DOI: 10.7270/Q2QV3M9C |
More data for this
Ligand-Target Pair | |
IgG receptor FcRn large subunit p51
(Homo sapiens (Human)) | BDBM50314081
((3R,8R,11S,17S,26S,29S,35aS)-8-((S)-2-((S)-2-aceta...)Show SMILES [#6]-[#6](-[#6])-[#6]-[#6@@H]-1-[#7](-[#6])-[#6](=O)-[#6]-[#7](-[#6])-[#6](=O)-[#6]-[#7]-[#6](=O)-[#6@H](-[#6]-c2ccc(cc2)\[#7]=[#6](\[#7])-[#7])-[#7]-[#6](=O)-[#6]-[#7]-[#6](=O)-[#6@@H](-[#7]-[#6](=O)-[#6@@H](-[#7]-[#6](=O)-[#6@H](-[#6]-c2ccccc2)-[#7]-[#6](=O)-[#6@H](-[#6]-[#6]-[#6]-[#7]-[#6](-[#7])=[#7])-[#7]-[#6](-[#6])=O)C([#6])([#6])[#16]-[#16]-[#6]-[#6@H](-[#7]-[#6](=O)-[#6@@H]-2-[#6]-[#6]-[#6]-[#7]-2-[#6](=O)-[#6](=O)-[#6@H](-[#6]-c2ccc(-[#8])cc2)-[#7]-[#6]-1=O)-[#6](-[#7])=O)-[#6@@H](-[#6])-[#8] |r| Show InChI InChI=1S/C68H97N19O16S2/c1-36(2)28-50-62(100)80-45(29-41-20-24-43(90)25-21-41)55(94)65(103)87-27-13-17-49(87)61(99)82-48(57(69)95)35-104-105-68(5,6)56(84-60(98)47(30-39-14-10-9-11-15-39)81-59(97)44(77-38(4)89)16-12-26-74-66(70)71)64(102)83-54(37(3)88)63(101)75-32-51(91)79-46(31-40-18-22-42(23-19-40)78-67(72)73)58(96)76-33-52(92)85(7)34-53(93)86(50)8/h9-11,14-15,18-25,36-37,44-50,54,56,88,90H,12-13,16-17,26-35H2,1-8H3,(H2,69,95)(H,75,101)(H,76,96)(H,77,89)(H,79,91)(H,80,100)(H,81,97)(H,82,99)(H,83,102)(H,84,98)(H4,70,71,74)(H4,72,73,78)/t37-,44+,45+,46+,47+,48+,49+,50+,54+,56-/m1/s1 | PDB
MMDB
KEGG
UniProtKB/SwissProt
B.MOAD
antibodypedia
GoogleScholar
AffyNet
| CHEMBL
PC cid
PC sid
UniChem
Similars
| Article
PubMed
| n/a | n/a | 1.00E+3 | n/a | n/a | n/a | n/a | n/a | n/a |
Syntonix Pharmaceuticals, Inc.
Curated by ChEMBL
| Assay Description
Inhibition of IgG binding to soluble human FcRn after 5 hrs by competition ELISA |
J Med Chem 53: 1587-96 (2010)
Article DOI: 10.1021/jm901128z
BindingDB Entry DOI: 10.7270/Q23R0T1H |
More data for this
Ligand-Target Pair | |
IgG receptor FcRn large subunit p51
(Homo sapiens (Human)) | BDBM50270831
((2R)-2-{[(2S)-1-[(2S)-2-[(2S)-2-(2-{2-[(2S)-2-[(2S...)Show SMILES CC(C)C[C@H](NC(=O)CN(C)C(=O)CNC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](Cc1cnc[nH]1)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](N)CCCN=C(N)N)C(C)(C)S)[C@@H](C)O)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CS)C(O)=O |r,wU:80.82,95.100,28.36,50.60,42.44,4.4,74.78,wD:61.64,17.25,46.48,99.103,(29.75,3.77,;29.75,2.23,;31.09,1.45,;28.41,1.45,;28.41,-.09,;27.08,-.86,;25.75,-.09,;25.75,1.45,;24.42,-.86,;23.08,-.1,;23.09,1.44,;21.75,-.87,;21.75,-2.41,;20.42,-.1,;19.08,-.87,;17.75,-.1,;17.75,1.44,;16.42,-.87,;16.42,-2.41,;17.75,-3.18,;19.08,-2.41,;20.41,-3.18,;20.42,-4.72,;19.09,-5.49,;17.75,-4.73,;15.09,-.1,;13.76,-.88,;13.76,-2.42,;12.42,-.11,;12.42,1.44,;13.76,2.2,;15.17,1.58,;16.19,2.73,;15.42,4.06,;13.91,3.73,;11.08,-.86,;9.74,-.09,;9.74,1.45,;8.41,-.87,;7.08,-.08,;5.75,-.87,;5.75,-2.41,;4.42,-.1,;3.08,-.87,;1.75,-.1,;1.75,1.45,;.42,-.87,;-.91,-.1,;-2.24,-.88,;-2.24,-2.42,;-3.58,-.11,;-3.58,1.44,;-2.24,2.2,;-.9,1.43,;.43,2.2,;.43,3.75,;-.92,4.51,;-2.24,3.73,;-4.92,-.86,;-6.26,-.1,;-6.26,1.44,;-7.59,-.88,;-8.94,-.08,;-7.59,-2.41,;-6.26,-3.18,;-6.26,-4.72,;-4.92,-5.49,;-4.92,-7.03,;-6.27,-7.77,;-3.6,-7.79,;.42,-2.41,;1.97,-2.41,;-1.12,-2.4,;.42,-3.95,;4.42,1.45,;3.09,2.21,;5.75,2.21,;29.74,-.86,;29.74,-2.4,;31.08,-.09,;32.41,-.86,;33.74,-.09,;33.74,1.45,;32.42,2.22,;32.41,3.75,;33.75,4.53,;33.75,6.07,;35.08,3.77,;35.09,2.23,;32.41,-2.4,;31.08,-3.17,;33.74,-3.17,;35.32,-2.64,;36.34,-3.98,;35.39,-5.36,;33.99,-4.67,;32.76,-5.6,;31.35,-5,;32.74,-7.14,;31.41,-7.9,;30.08,-7.12,;28.74,-7.88,;31.39,-9.44,;30.04,-10.2,;32.71,-10.23,)| Show InChI InChI=1S/C69H98N18O16S2/c1-38(2)27-46(60(95)82-50(30-42-21-23-44(89)24-22-42)66(101)87-26-14-20-52(87)63(98)83-51(36-104)67(102)103)79-54(91)35-86(6)55(92)34-76-59(94)47(28-40-15-9-7-10-16-40)81-61(96)49(31-43-32-73-37-77-43)78-53(90)33-75-64(99)56(39(3)88)84-65(100)57(69(4,5)105)85-62(97)48(29-41-17-11-8-12-18-41)80-58(93)45(70)19-13-25-74-68(71)72/h7-12,15-18,21-24,32,37-39,45-52,56-57,88-89,104-105H,13-14,19-20,25-31,33-36,70H2,1-6H3,(H,73,77)(H,75,99)(H,76,94)(H,78,90)(H,79,91)(H,80,93)(H,81,96)(H,82,95)(H,83,98)(H,84,100)(H,85,97)(H,102,103)(H4,71,72,74)/t39-,45+,46+,47+,48+,49+,50+,51+,52+,56+,57-/m1/s1 | PDB
MMDB
KEGG
UniProtKB/SwissProt
B.MOAD
antibodypedia
GoogleScholar
AffyNet
| CHEMBL
PC cid
PC sid
UniChem
Similars
| Article
PubMed
| n/a | n/a | 1.00E+3 | n/a | n/a | n/a | n/a | n/a | n/a |
Syntonix Pharmaceuticals, Inc.
Curated by ChEMBL
| Assay Description
Inhibition of human IgG binding to soluble human FcRn by ELISA |
Bioorg Med Chem 16: 6394-405 (2008)
Article DOI: 10.1016/j.bmc.2008.05.004
BindingDB Entry DOI: 10.7270/Q2QV3M9C |
More data for this
Ligand-Target Pair | |
IgG receptor FcRn large subunit p51
(Homo sapiens (Human)) | BDBM50314086
(CHEMBL1090274)Show SMILES CC(C)C[C@@H]1N(C)C(=O)CN(C)C(=O)CNC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](Cc2cnc[nH]2)NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](CC(=O)NCCCC[C@H](NC(=O)[C@@H]2CCCN2C(=O)C(=O)[C@H](Cc2ccc(O)cc2)NC1=O)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N1CCC[C@H]1C(N)=O)NC(=O)[C@H](Cc1ccccc1)NC(=O)CSCCC(=O)NCCC(=O)NCCC(=O)NCCCN(CCCNC(=O)CCNC(=O)CCSCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@H]1CC(=O)NCCCC[C@H](NC(=O)[C@@H]2CCCN2C(=O)C(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C(=O)CNC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](Cc2cnc[nH]2)NC(=O)CNC(=O)[C@@H](NC1=O)[C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N1CCC[C@H]1C(N)=O)CC(=O)NCC(O)=O)[C@@H](C)O |r| Show InChI InChI=1S/C196H277N53O53S2/c1-110(2)80-144-190(297)230-128(82-118-49-53-122(252)54-50-118)170(277)194(301)248-76-30-47-142(248)188(295)228-124(178(285)235-136(90-147(198)255)176(283)219-100-163(271)246-74-28-45-140(246)172(200)279)42-23-25-64-208-154(262)92-138(186(293)239-168(112(5)250)192(299)215-96-156(264)224-134(88-120-94-204-108-221-120)184(291)232-130(84-114-34-15-11-16-35-114)174(281)217-98-161(269)241(7)104-165(273)243(144)9)237-182(289)132(86-116-38-19-13-20-39-116)226-160(268)107-304-79-63-153(261)212-71-61-151(259)210-69-59-149(257)206-67-32-72-245(103-158(266)214-102-167(275)276)73-33-68-207-150(258)60-70-211-152(260)62-78-303-106-159(267)223-127(57-58-146(197)254)181(288)227-126(44-27-66-213-196(202)203)180(287)234-133(87-117-40-21-14-22-41-117)183(290)238-139-93-155(263)209-65-26-24-43-125(179(286)236-137(91-148(199)256)177(284)220-101-164(272)247-75-29-46-141(247)173(201)280)229-189(296)143-48-31-77-249(143)195(302)171(278)129(83-119-51-55-123(253)56-52-119)231-191(298)145(81-111(3)4)244(10)166(274)105-242(8)162(270)99-218-175(282)131(85-115-36-17-12-18-37-115)233-185(292)135(89-121-95-205-109-222-121)225-157(265)97-216-193(300)169(113(6)251)240-187(139)294/h11-22,34-41,49-56,94-95,108-113,124-145,168-169,250-253H,23-33,42-48,57-93,96-107H2,1-10H3,(H2,197,254)(H2,198,255)(H2,199,256)(H2,200,279)(H2,201,280)(H,204,221)(H,205,222)(H,206,257)(H,207,258)(H,208,262)(H,209,263)(H,210,259)(H,211,260)(H,212,261)(H,214,266)(H,215,299)(H,216,300)(H,217,281)(H,218,282)(H,219,283)(H,220,284)(H,223,267)(H,224,264)(H,225,265)(H,226,268)(H,227,288)(H,228,295)(H,229,296)(H,230,297)(H,231,298)(H,232,291)(H,233,292)(H,234,287)(H,235,285)(H,236,286)(H,237,289)(H,238,290)(H,239,293)(H,240,294)(H,275,276)(H4,202,203,213)/t112-,113-,124+,125+,126+,127+,128+,129+,130+,131+,132+,133+,134+,135+,136+,137+,138+,139+,140+,141+,142+,143+,144+,145+,168+,169+/m1/s1 | PDB
MMDB
KEGG
UniProtKB/SwissProt
B.MOAD
antibodypedia
GoogleScholar
AffyNet
| CHEMBL
PC cid
PC sid
UniChem
Similars
| Article
PubMed
| n/a | n/a | 1.10E+3 | n/a | n/a | n/a | n/a | n/a | n/a |
Syntonix Pharmaceuticals, Inc.
Curated by ChEMBL
| Assay Description
Inhibition of IgG binding to soluble human FcRn after 5 hrs by competition ELISA |
J Med Chem 53: 1587-96 (2010)
Article DOI: 10.1021/jm901128z
BindingDB Entry DOI: 10.7270/Q23R0T1H |
More data for this
Ligand-Target Pair | |
IgG receptor FcRn large subunit p51
(Homo sapiens (Human)) | BDBM50314079
((5S,8S,15S,18R,23R,26S,32S,35S,38S)-35-benzyl-23-[...)Show SMILES CC(C)C[C@@H]1N(C)C(=O)CN2CCC[C@H](NC(=O)[C@H](Cc3ccccc3)NC(=O)[C@H](Cc3cnc[nH]3)NC(=O)CNC(=O)[C@H](C)N(C)C(=O)[C@@H](NC(=O)[C@H](Cc3ccccc3)NC(=O)[C@H](CCCNC(N)=N)NC(C)=O)C(C)(C)SSC[C@H](NC(=O)[C@@H]3CCCN3C(=O)C(=O)[C@H](Cc3ccc(O)cc3)NC1=O)C(N)=O)C2=O |r| Show InChI InChI=1S/C75H103N19O16S2/c1-42(2)32-58-70(107)86-52(33-47-25-27-49(96)28-26-47)61(99)72(109)94-31-17-24-57(94)69(106)89-56(63(76)100)40-111-112-75(5,6)62(90-68(105)54(35-46-20-13-10-14-21-46)87-65(102)50(83-44(4)95)22-15-29-80-74(77)78)73(110)91(7)43(3)64(101)81-38-59(97)84-55(36-48-37-79-41-82-48)67(104)88-53(34-45-18-11-9-12-19-45)66(103)85-51-23-16-30-93(71(51)108)39-60(98)92(58)8/h9-14,18-21,25-28,37,41-43,50-58,62,96H,15-17,22-24,29-36,38-40H2,1-8H3,(H2,76,100)(H,79,82)(H,81,101)(H,83,95)(H,84,97)(H,85,103)(H,86,107)(H,87,102)(H,88,104)(H,89,106)(H,90,105)(H4,77,78,80)/t43-,50-,51-,52-,53-,54-,55-,56-,57-,58-,62+/m0/s1 | PDB
MMDB
KEGG
UniProtKB/SwissProt
B.MOAD
antibodypedia
GoogleScholar
AffyNet
| CHEMBL
PC cid
PC sid
UniChem
Similars
| Article
PubMed
| n/a | n/a | 1.10E+3 | n/a | n/a | n/a | n/a | n/a | n/a |
Syntonix Pharmaceuticals, Inc.
Curated by ChEMBL
| Assay Description
Inhibition of IgG binding to soluble human FcRn after 5 hrs by competition ELISA |
J Med Chem 53: 1587-96 (2010)
Article DOI: 10.1021/jm901128z
BindingDB Entry DOI: 10.7270/Q23R0T1H |
More data for this
Ligand-Target Pair | |
IgG receptor FcRn large subunit p51
(Homo sapiens (Human)) | BDBM50270941
((2R)-2-{[(2S)-1-[(2S)-2-[(2S)-2-(2-{2-[(2S)-2-[(2S...)Show SMILES [#6]-[#6](-[#6])-[#6]-[#6@H](-[#7](-[#6])-[#6](=O)-[#6]-[#7](-[#6])-[#6](=O)-[#6]-[#7]-[#6](=O)-[#6@H](-[#6]-c1ccccc1)-[#7]-[#6](=O)-[#6@H](-[#6]-c1cccnc1)-[#7]-[#6](=O)-[#6]-[#7]-[#6](=O)-[#6@@H](-[#7]-[#6](=O)-[#6@@H](-[#7]-[#6](=O)-[#6@H](-[#6]-c1ccccc1)-[#7]-[#6](=O)-[#6@@H](-[#7])-[#6]-[#6]-[#6]\[#7]=[#6](/[#7])-[#7])C([#6])([#6])[#16])-[#6@@H](-[#6])-[#8])-[#6](=O)-[#7]-[#6@@H](-[#6]-c1ccc(-[#8])cc1)-[#6](=O)-[#7]-1-[#6]-[#6]-[#6]-[#6@H]-1-[#6](=O)-[#7]-[#6@@H](-[#6]-[#16])-[#6](-[#8])=O |r| Show InChI InChI=1S/C72H101N17O16S2/c1-41(2)31-55(66(100)83-52(34-45-24-26-47(91)27-25-45)69(103)89-30-16-23-54(89)65(99)84-53(40-106)70(104)105)88(7)58(94)39-87(6)57(93)38-79-62(96)49(32-43-17-10-8-11-18-43)82-63(97)50(35-46-21-14-28-76-36-46)80-56(92)37-78-67(101)59(42(3)90)85-68(102)60(72(4,5)107)86-64(98)51(33-44-19-12-9-13-20-44)81-61(95)48(73)22-15-29-77-71(74)75/h8-14,17-21,24-28,36,41-42,48-55,59-60,90-91,106-107H,15-16,22-23,29-35,37-40,73H2,1-7H3,(H,78,101)(H,79,96)(H,80,92)(H,81,95)(H,82,97)(H,83,100)(H,84,99)(H,85,102)(H,86,98)(H,104,105)(H4,74,75,77)/t42-,48+,49+,50+,51+,52+,53+,54+,55+,59+,60-/m1/s1 | PDB
MMDB
KEGG
UniProtKB/SwissProt
B.MOAD
antibodypedia
GoogleScholar
AffyNet
| CHEMBL
PC cid
PC sid
UniChem
Similars
| Article
PubMed
| n/a | n/a | 1.20E+3 | n/a | n/a | n/a | n/a | n/a | n/a |
Syntonix Pharmaceuticals, Inc.
Curated by ChEMBL
| Assay Description
Inhibition of human IgG binding to soluble human FcRn by ELISA |
Bioorg Med Chem 16: 6394-405 (2008)
Article DOI: 10.1016/j.bmc.2008.05.004
BindingDB Entry DOI: 10.7270/Q2QV3M9C |
More data for this
Ligand-Target Pair | |
IgG receptor FcRn large subunit p51
(Homo sapiens (Human)) | BDBM50270891
(CHEMBL506623)Show SMILES CC(C)C[C@H](N(C)C(=O)CNC(=O)[C@@H](Cc1ccccc1)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](Cc1cnc[nH]1)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](N)CCC(N)=O)C(C)(C)S)[C@@H](C)O)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N1CCC[C@H]1C(O)=O |r,wU:79.83,57.68,49.52,90.95,35.44,4.4,96.99,111.117,121.126,136.143,wD:68.79,53.56,24.33,115.120,13.21,(34.57,1.35,;34.57,-.19,;35.91,-.96,;33.24,-.96,;33.24,-2.5,;31.91,-3.27,;31.91,-4.81,;30.57,-2.5,;30.57,-.96,;29.24,-3.27,;27.9,-2.5,;26.57,-3.27,;26.57,-4.81,;25.23,-2.5,;25.24,-.96,;26.57,-.2,;27.9,-.98,;29.23,-.21,;29.24,1.33,;27.9,2.1,;26.57,1.33,;23.9,-3.26,;22.57,-2.5,;22.57,-.96,;21.24,-3.27,;21.24,-4.81,;22.57,-5.58,;23.89,-4.81,;25.23,-5.58,;25.23,-7.11,;23.9,-7.89,;22.57,-7.13,;19.9,-2.5,;18.57,-3.27,;18.57,-4.81,;17.24,-2.5,;17.24,-.96,;18.57,-.19,;19.99,-.82,;21,.33,;20.23,1.66,;18.73,1.33,;15.9,-3.27,;14.56,-2.5,;14.56,-.96,;13.24,-3.27,;11.9,-2.5,;10.56,-3.27,;10.56,-4.81,;9.24,-2.5,;7.9,-3.27,;6.56,-2.5,;6.56,-.96,;5.23,-3.27,;3.9,-2.5,;2.56,-3.27,;2.56,-4.81,;1.23,-2.5,;1.23,-.96,;2.56,-.19,;3.91,-.96,;5.23,-.19,;5.22,1.35,;3.89,2.11,;2.56,1.33,;-.1,-3.27,;-1.44,-2.5,;-1.44,-.96,;-2.77,-3.27,;-2.77,-4.81,;-1.44,-5.58,;-1.44,-7.12,;-.1,-7.89,;-.1,-9.43,;-1.44,-10.2,;1.23,-10.2,;-4.1,-2.5,;-5.44,-3.27,;-5.44,-4.81,;-6.77,-2.5,;-8.11,-3.27,;-6.77,-.96,;-5.44,-.19,;-5.44,1.35,;-6.77,2.12,;-4.1,2.12,;5.23,-4.81,;6.77,-4.81,;3.69,-4.81,;5.23,-6.35,;9.24,-.96,;7.9,-.19,;10.56,-.19,;34.57,-3.27,;34.57,-4.81,;35.91,-2.5,;37.24,-3.27,;38.57,-2.5,;38.57,-.96,;37.26,-.19,;37.25,1.34,;38.57,2.12,;38.57,3.66,;39.91,1.35,;39.91,-.18,;37.24,-4.81,;35.91,-5.58,;38.57,-5.58,;40.14,-5.05,;41.16,-6.38,;40.21,-7.76,;38.82,-7.08,;37.59,-8.01,;36.17,-7.41,;37.78,-9.53,;36.55,-10.46,;35.13,-9.86,;33.9,-10.78,;36.73,-11.99,;38.14,-12.59,;35.5,-12.92,;35.69,-14.44,;37.1,-15.04,;37.29,-16.57,;36.06,-17.5,;38.71,-17.18,;34.45,-15.37,;33.04,-14.76,;34.64,-16.9,;33.41,-17.83,;33.59,-19.35,;35.01,-19.95,;32.37,-20.28,;32.26,-21.95,;30.64,-22.38,;29.73,-20.97,;30.89,-19.95,;30.52,-18.46,;29.03,-18.06,;31.61,-17.37,)| Show InChI InChI=1S/C92H128N24O22S2/c1-50(2)37-69(86(133)110-65(41-55-28-30-57(118)31-29-55)89(136)116-36-17-26-67(116)85(132)111-66(48-139)84(131)109-64(43-71(95)120)79(126)102-47-74(123)115-35-18-27-68(115)90(137)138)114(6)73(122)46-101-78(125)60(38-52-19-10-7-11-20-52)106-81(128)61(39-53-21-12-8-13-22-53)108-82(129)63(42-56-44-98-49-103-56)104-72(121)45-100-87(134)75(51(3)117)112-88(135)76(92(4,5)140)113-83(130)62(40-54-23-14-9-15-24-54)107-80(127)59(25-16-34-99-91(96)97)105-77(124)58(93)32-33-70(94)119/h7-15,19-24,28-31,44,49-51,58-69,75-76,117-118,139-140H,16-18,25-27,32-43,45-48,93H2,1-6H3,(H2,94,119)(H2,95,120)(H,98,103)(H,100,134)(H,101,125)(H,102,126)(H,104,121)(H,105,124)(H,106,128)(H,107,127)(H,108,129)(H,109,131)(H,110,133)(H,111,132)(H,112,135)(H,113,130)(H,137,138)(H4,96,97,99)/t51-,58+,59+,60-,61+,62+,63+,64+,65+,66+,67+,68+,69+,75+,76-/m1/s1 | PDB
MMDB
KEGG
UniProtKB/SwissProt
B.MOAD
antibodypedia
GoogleScholar
AffyNet
| CHEMBL
KEGG
PC cid
PC sid
UniChem
Similars
| Article
PubMed
| n/a | n/a | 1.30E+3 | n/a | n/a | n/a | n/a | n/a | n/a |
Syntonix Pharmaceuticals, Inc.
Curated by ChEMBL
| Assay Description
Inhibition of human IgG binding to soluble human FcRn by ELISA |
Bioorg Med Chem 16: 6394-405 (2008)
Article DOI: 10.1016/j.bmc.2008.05.004
BindingDB Entry DOI: 10.7270/Q2QV3M9C |
More data for this
Ligand-Target Pair | |
IgG receptor FcRn large subunit p51
(Homo sapiens (Human)) | BDBM50270942
((2R)-2-{[(2S)-1-[(2S)-2-[(2S)-2-(2-{2-[(2S)-2-[(2S...)Show SMILES [#6]-[#6](-[#6])-[#6]-[#6@H](-[#7](-[#6])-[#6](=O)-[#6]-[#7](-[#6])-[#6](=O)-[#6]-[#7]-[#6](=O)-[#6@H](-[#6]-c1ccccc1)-[#7]-[#6](=O)-[#6@H](-[#6]-c1ccncc1)-[#7]-[#6](=O)-[#6]-[#7]-[#6](=O)-[#6@@H](-[#7]-[#6](=O)-[#6@@H](-[#7]-[#6](=O)-[#6@H](-[#6]-c1ccccc1)-[#7]-[#6](=O)-[#6@@H](-[#7])-[#6]-[#6]-[#6]\[#7]=[#6](/[#7])-[#7])C([#6])([#6])[#16])-[#6@@H](-[#6])-[#8])-[#6](=O)-[#7]-[#6@@H](-[#6]-c1ccc(-[#8])cc1)-[#6](=O)-[#7]-1-[#6]-[#6]-[#6]-[#6@H]-1-[#6](=O)-[#7]-[#6@@H](-[#6]-[#16])-[#6](-[#8])=O |r| Show InChI InChI=1S/C72H101N17O16S2/c1-41(2)32-55(66(100)83-52(36-45-22-24-47(91)25-23-45)69(103)89-31-15-21-54(89)65(99)84-53(40-106)70(104)105)88(7)58(94)39-87(6)57(93)38-79-62(96)49(33-43-16-10-8-11-17-43)82-63(97)50(35-46-26-29-76-30-27-46)80-56(92)37-78-67(101)59(42(3)90)85-68(102)60(72(4,5)107)86-64(98)51(34-44-18-12-9-13-19-44)81-61(95)48(73)20-14-28-77-71(74)75/h8-13,16-19,22-27,29-30,41-42,48-55,59-60,90-91,106-107H,14-15,20-21,28,31-40,73H2,1-7H3,(H,78,101)(H,79,96)(H,80,92)(H,81,95)(H,82,97)(H,83,100)(H,84,99)(H,85,102)(H,86,98)(H,104,105)(H4,74,75,77)/t42-,48+,49+,50+,51+,52+,53+,54+,55+,59+,60-/m1/s1 | PDB
MMDB
KEGG
UniProtKB/SwissProt
B.MOAD
antibodypedia
GoogleScholar
AffyNet
| CHEMBL
PC cid
PC sid
UniChem
Similars
| Article
PubMed
| n/a | n/a | 1.30E+3 | n/a | n/a | n/a | n/a | n/a | n/a |
Syntonix Pharmaceuticals, Inc.
Curated by ChEMBL
| Assay Description
Inhibition of human IgG binding to soluble human FcRn by ELISA |
Bioorg Med Chem 16: 6394-405 (2008)
Article DOI: 10.1016/j.bmc.2008.05.004
BindingDB Entry DOI: 10.7270/Q2QV3M9C |
More data for this
Ligand-Target Pair | |
IgG receptor FcRn large subunit p51
(Homo sapiens (Human)) | BDBM50270838
(CHEMBL508564)Show SMILES CC(C)C[C@H](NC(=O)[C@H]1CCCN1C(=O)CNC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](Cc1cnc[nH]1)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](N)CCC(N)=O)C(C)(C)S)[C@@H](C)O)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N1CCC[C@H]1C(O)=O |r,wU:74.78,52.63,44.47,85.90,30.39,4.4,91.94,106.112,116.121,131.138,wD:63.74,48.51,19.28,8.7,110.115,(33.24,1.45,;32.47,.11,;33.25,-1.22,;30.94,.1,;30.18,-1.24,;28.63,-1.24,;27.85,.09,;28.62,1.43,;26.32,.08,;25.28,1.22,;23.87,.59,;24.05,-.95,;25.56,-1.26,;26.33,-2.59,;27.87,-2.58,;25.57,-3.93,;24.24,-4.7,;22.9,-3.93,;22.9,-2.39,;21.57,-4.7,;21.57,-6.24,;22.9,-7.01,;24.22,-6.24,;25.56,-7.01,;25.56,-8.54,;24.24,-9.32,;22.9,-8.56,;20.24,-3.93,;18.9,-4.7,;18.9,-6.24,;17.57,-3.93,;17.57,-2.39,;18.9,-1.62,;20.32,-2.25,;21.34,-1.1,;20.56,.23,;19.06,-.1,;16.24,-4.7,;14.9,-3.93,;14.9,-2.39,;13.57,-4.7,;12.23,-3.93,;10.9,-4.7,;10.9,-6.24,;9.57,-3.93,;8.23,-4.7,;6.9,-3.93,;6.9,-2.39,;5.57,-4.7,;4.23,-3.93,;2.9,-4.7,;2.9,-6.24,;1.57,-3.93,;1.57,-2.39,;2.9,-1.62,;4.24,-2.39,;5.56,-1.62,;5.56,-.09,;4.23,.68,;2.9,-.1,;.23,-4.7,;-1.11,-3.93,;-1.11,-2.39,;-2.43,-4.7,;-2.43,-6.24,;-1.11,-7.01,;-1.11,-8.55,;.23,-9.32,;.23,-10.86,;-1.11,-11.63,;1.57,-11.63,;-3.77,-3.93,;-5.11,-4.7,;-5.11,-6.24,;-6.43,-3.93,;-7.77,-4.7,;-6.43,-2.39,;-5.11,-1.62,;-5.11,-.08,;-6.43,.69,;-3.77,.69,;5.57,-6.24,;7.11,-6.24,;4.03,-6.24,;5.57,-7.78,;9.57,-2.39,;8.23,-1.62,;10.9,-1.62,;30.95,-2.56,;30.18,-3.9,;32.49,-2.56,;33.27,-3.89,;34.8,-3.88,;35.56,-2.54,;34.8,-1.23,;35.55,.11,;37.09,.13,;37.85,1.46,;37.86,-1.2,;37.11,-2.54,;32.51,-5.23,;30.96,-5.23,;33.28,-6.55,;34.9,-6.87,;35.13,-8.54,;33.62,-9.26,;32.75,-7.98,;31.2,-7.99,;30.43,-6.65,;30.44,-9.32,;28.9,-9.32,;28.13,-7.99,;28.9,-6.66,;28.13,-10.66,;28.9,-11.99,;26.59,-10.66,;25.83,-11.99,;26.6,-13.33,;25.83,-14.66,;24.29,-14.66,;26.6,-16,;24.28,-12,;23.51,-10.66,;23.52,-13.33,;21.98,-13.34,;21.21,-14.67,;21.98,-16,;19.67,-14.67,;18.58,-15.95,;17.03,-15.32,;17.15,-13.65,;18.69,-13.53,;19.28,-12.11,;18.33,-10.9,;20.81,-11.89,)| Show InChI InChI=1S/C87H124N24O22S2/c1-46(2)34-55(76(123)105-60(37-50-24-26-52(113)27-25-50)84(131)111-33-14-22-63(111)81(128)106-61(44-134)79(126)103-59(39-66(90)115)74(121)97-43-69(118)110-32-15-23-64(110)85(132)133)104-80(127)62-21-13-31-109(62)68(117)42-96-73(120)56(35-48-16-8-6-9-17-48)101-77(124)58(38-51-40-93-45-98-51)99-67(116)41-95-82(129)70(47(3)112)107-83(130)71(87(4,5)135)108-78(125)57(36-49-18-10-7-11-19-49)102-75(122)54(20-12-30-94-86(91)92)100-72(119)53(88)28-29-65(89)114/h6-11,16-19,24-27,40,45-47,53-64,70-71,112-113,134-135H,12-15,20-23,28-39,41-44,88H2,1-5H3,(H2,89,114)(H2,90,115)(H,93,98)(H,95,129)(H,96,120)(H,97,121)(H,99,116)(H,100,119)(H,101,124)(H,102,122)(H,103,126)(H,104,127)(H,105,123)(H,106,128)(H,107,130)(H,108,125)(H,132,133)(H4,91,92,94)/t47-,53+,54+,55+,56+,57+,58+,59+,60+,61+,62-,63+,64+,70+,71-/m1/s1 | PDB
MMDB
KEGG
UniProtKB/SwissProt
B.MOAD
antibodypedia
GoogleScholar
AffyNet
| CHEMBL
KEGG
PC cid
PC sid
UniChem
Similars
| Article
PubMed
| n/a | n/a | 1.40E+3 | n/a | n/a | n/a | n/a | n/a | n/a |
Syntonix Pharmaceuticals, Inc.
Curated by ChEMBL
| Assay Description
Inhibition of human IgG binding to soluble human FcRn by ELISA |
Bioorg Med Chem 16: 6394-405 (2008)
Article DOI: 10.1016/j.bmc.2008.05.004
BindingDB Entry DOI: 10.7270/Q2QV3M9C |
More data for this
Ligand-Target Pair | |
IgG receptor FcRn large subunit p51
(Homo sapiens (Human)) | BDBM50270828
(CHEMBL525614)Show SMILES CC(C)C[C@H](N(C)C(=O)CNC(=O)CNC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](Cc1cnc[nH]1)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](N)CCC(N)=O)C(C)(C)S)[C@@H](C)O)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N1CCC[C@H]1C(O)=O |r,wU:89.91,104.109,129.135,72.75,28.36,50.60,4.4,42.44,114.118,83.87,wD:61.71,17.25,46.48,108.112,(34.37,-30.34,;34.37,-31.88,;35.7,-32.64,;33.04,-32.64,;33.04,-34.19,;31.7,-34.95,;31.71,-36.49,;30.37,-34.18,;30.37,-32.64,;29.04,-34.96,;27.71,-34.19,;26.38,-34.97,;26.38,-36.5,;25.04,-34.19,;23.71,-34.96,;22.37,-34.19,;22.37,-32.65,;21.04,-34.97,;21.04,-36.5,;22.37,-37.28,;23.7,-36.51,;25.03,-37.28,;25.04,-38.81,;23.71,-39.59,;22.37,-38.83,;19.71,-34.2,;18.38,-34.98,;18.38,-36.51,;17.05,-34.21,;17.05,-32.66,;18.38,-31.9,;19.79,-32.52,;20.82,-31.37,;20.04,-30.04,;18.53,-30.37,;15.7,-34.96,;14.36,-34.19,;14.36,-32.65,;13.03,-34.97,;11.69,-34.19,;10.36,-34.96,;10.36,-36.5,;9.02,-34.19,;7.69,-34.96,;6.36,-34.19,;6.36,-32.65,;5.03,-34.96,;3.69,-34.19,;2.37,-34.98,;2.37,-36.51,;1.03,-34.2,;1.03,-32.66,;2.37,-31.89,;3.71,-32.67,;5.04,-31.89,;5.03,-30.35,;3.69,-29.59,;2.37,-30.36,;-.31,-34.97,;-1.64,-34.2,;-1.64,-32.65,;-2.97,-34.97,;-2.97,-36.51,;-1.64,-37.28,;-1.64,-38.82,;-.31,-39.58,;-.3,-41.12,;-1.64,-41.89,;1.03,-41.89,;-4.3,-34.19,;-5.61,-34.99,;-5.61,-36.52,;-6.94,-34.21,;-8.3,-34.96,;-6.94,-32.67,;-5.61,-31.91,;-5.61,-30.36,;-6.94,-29.59,;-4.27,-29.6,;5.03,-36.5,;6.57,-36.51,;3.48,-36.49,;5.03,-38.04,;9.02,-32.65,;7.69,-31.88,;10.36,-31.88,;34.37,-34.96,;34.37,-36.5,;35.7,-34.19,;37.03,-34.96,;38.37,-34.19,;38.37,-32.64,;37.04,-31.88,;37.04,-30.35,;38.37,-29.57,;38.37,-28.02,;39.7,-30.33,;39.72,-31.87,;37.03,-36.5,;35.7,-37.27,;38.37,-37.27,;39.94,-36.74,;40.97,-38.07,;40.02,-39.46,;38.61,-38.77,;37.39,-39.7,;35.97,-39.1,;37.37,-41.24,;36.03,-42.01,;34.71,-41.23,;33.36,-41.99,;36.01,-43.55,;37.34,-44.33,;34.67,-44.29,;34.66,-45.83,;35.98,-46.62,;35.97,-48.15,;34.63,-48.9,;37.3,-48.94,;33.32,-46.59,;31.99,-45.81,;33.3,-48.13,;31.96,-48.88,;31.95,-50.42,;33.28,-51.2,;30.61,-51.18,;30.28,-52.83,;28.62,-53.05,;27.91,-51.52,;29.19,-50.66,;29.01,-49.14,;27.58,-48.55,;30.22,-48.2,)| Show InChI InChI=1S/C85H122N24O22S2/c1-45(2)32-62(79(126)103-58(35-49-23-25-51(111)26-24-49)82(129)109-31-14-21-60(109)78(125)104-59(43-132)77(124)102-57(37-64(88)113)73(120)96-42-68(117)108-30-15-22-61(108)83(130)131)107(6)67(116)41-93-65(114)39-94-72(119)54(33-47-16-9-7-10-17-47)100-75(122)56(36-50-38-91-44-97-50)98-66(115)40-95-80(127)69(46(3)110)105-81(128)70(85(4,5)133)106-76(123)55(34-48-18-11-8-12-19-48)101-74(121)53(20-13-29-92-84(89)90)99-71(118)52(86)27-28-63(87)112/h7-12,16-19,23-26,38,44-46,52-62,69-70,110-111,132-133H,13-15,20-22,27-37,39-43,86H2,1-6H3,(H2,87,112)(H2,88,113)(H,91,97)(H,93,114)(H,94,119)(H,95,127)(H,96,120)(H,98,115)(H,99,118)(H,100,122)(H,101,121)(H,102,124)(H,103,126)(H,104,125)(H,105,128)(H,106,123)(H,130,131)(H4,89,90,92)/t46-,52+,53+,54+,55+,56+,57+,58+,59+,60+,61+,62+,69+,70-/m1/s1 | PDB
MMDB
KEGG
UniProtKB/SwissProt
B.MOAD
antibodypedia
GoogleScholar
AffyNet
| CHEMBL
KEGG
PC cid
PC sid
UniChem
Similars
| Article
PubMed
| n/a | n/a | 1.60E+3 | n/a | n/a | n/a | n/a | n/a | n/a |
Syntonix Pharmaceuticals, Inc.
Curated by ChEMBL
| Assay Description
Inhibition of human IgG binding to soluble human FcRn by ELISA |
Bioorg Med Chem 16: 6394-405 (2008)
Article DOI: 10.1016/j.bmc.2008.05.004
BindingDB Entry DOI: 10.7270/Q2QV3M9C |
More data for this
Ligand-Target Pair | |
IgG receptor FcRn large subunit p51
(Homo sapiens (Human)) | BDBM50270937
((2R)-2-{[(2S)-1-[(2S)-2-[(2S)-2-(2-{2-[(2S)-2-[(2S...)Show SMILES [#6]-[#6](-[#6])-[#6]-[#6@H](-[#7](-[#6])-[#6](=O)-[#6]-[#7](-[#6])-[#6](=O)-[#6]-[#7]-[#6](=O)-[#6@H](-[#6]-c1ccccc1)-[#7]-[#6](=O)-[#6@H](-[#6]-c1cscn1)-[#7]-[#6](=O)-[#6]-[#7]-[#6](=O)-[#6@@H](-[#7]-[#6](=O)-[#6@@H](-[#7]-[#6](=O)-[#6@H](-[#6]-c1ccccc1)-[#7]-[#6](=O)-[#6@@H](-[#7])-[#6]-[#6]-[#6]\[#7]=[#6](/[#7])-[#7])C([#6])([#6])[#16])-[#6@@H](-[#6])-[#8])-[#6](=O)-[#7]-[#6@@H](-[#6]-c1ccc(-[#8])cc1)-[#6](=O)-[#7]-1-[#6]-[#6]-[#6]-[#6@H]-1-[#6](=O)-[#7]-[#6@@H](-[#6]-[#16])-[#6](-[#8])=O |r| Show InChI InChI=1S/C70H99N17O16S3/c1-39(2)28-53(64(98)81-50(31-43-22-24-45(89)25-23-43)67(101)87-27-15-21-52(87)63(97)82-51(36-104)68(102)103)86(7)56(92)35-85(6)55(91)34-76-60(94)47(29-41-16-10-8-11-17-41)80-61(95)49(32-44-37-106-38-77-44)78-54(90)33-75-65(99)57(40(3)88)83-66(100)58(70(4,5)105)84-62(96)48(30-42-18-12-9-13-19-42)79-59(93)46(71)20-14-26-74-69(72)73/h8-13,16-19,22-25,37-40,46-53,57-58,88-89,104-105H,14-15,20-21,26-36,71H2,1-7H3,(H,75,99)(H,76,94)(H,78,90)(H,79,93)(H,80,95)(H,81,98)(H,82,97)(H,83,100)(H,84,96)(H,102,103)(H4,72,73,74)/t40-,46+,47+,48+,49+,50+,51+,52+,53+,57+,58-/m1/s1 | PDB
MMDB
KEGG
UniProtKB/SwissProt
B.MOAD
antibodypedia
GoogleScholar
AffyNet
| CHEMBL
PC cid
PC sid
UniChem
Similars
| Article
PubMed
| n/a | n/a | 1.60E+3 | n/a | n/a | n/a | n/a | n/a | n/a |
Syntonix Pharmaceuticals, Inc.
Curated by ChEMBL
| Assay Description
Inhibition of human IgG binding to soluble human FcRn by ELISA |
Bioorg Med Chem 16: 6394-405 (2008)
Article DOI: 10.1016/j.bmc.2008.05.004
BindingDB Entry DOI: 10.7270/Q2QV3M9C |
More data for this
Ligand-Target Pair | |
IgG receptor FcRn large subunit p51
(Homo sapiens (Human)) | BDBM50270947
((2R)-2-{[(2S)-1-[(2S)-2-[(2S)-2-(2-{2-[(2S)-2-[(2S...)Show SMILES [#6]-[#6](-[#6])-[#6]-[#6@H](-[#7](-[#6])-[#6](=O)-[#6]-[#7](-[#6])-[#6](=O)-[#6]-[#7]-[#6](=O)-[#6@H](-[#6]-c1ccccc1)-[#7]-[#6](=O)-[#6@H](-[#6]-c1ccc(cc1)\[#7]=[#6](\[#7])-[#7])-[#7]-[#6](=O)-[#6]-[#7]-[#6](=O)-[#6@@H](-[#7]-[#6](=O)-[#6@@H](-[#7]-[#6](=O)-[#6@H](-[#6]-c1ccccc1)-[#7]-[#6](=O)-[#6@@H](-[#7])-[#6]-[#6]-[#6]\[#7]=[#6](/[#7])-[#7])C([#6])([#6])[#16])-[#6@@H](-[#6])-[#8])-[#6](=O)-[#7]-[#6@@H](-[#6]-c1ccc(-[#8])cc1)-[#6](=O)-[#7]-1-[#6]-[#6]-[#6]-[#6@H]-1-[#6](=O)-[#7]-[#6@@H](-[#6]-[#16])-[#6](-[#8])=O |r| Show InChI InChI=1S/C74H105N19O16S2/c1-41(2)32-56(67(104)87-53(36-46-24-28-48(95)29-25-46)70(107)93-31-15-21-55(93)66(103)88-54(40-110)71(108)109)92(7)59(98)39-91(6)58(97)38-82-63(100)50(33-43-16-10-8-11-17-43)86-64(101)51(35-45-22-26-47(27-23-45)83-73(78)79)84-57(96)37-81-68(105)60(42(3)94)89-69(106)61(74(4,5)111)90-65(102)52(34-44-18-12-9-13-19-44)85-62(99)49(75)20-14-30-80-72(76)77/h8-13,16-19,22-29,41-42,49-56,60-61,94-95,110-111H,14-15,20-21,30-40,75H2,1-7H3,(H,81,105)(H,82,100)(H,84,96)(H,85,99)(H,86,101)(H,87,104)(H,88,103)(H,89,106)(H,90,102)(H,108,109)(H4,76,77,80)(H4,78,79,83)/t42-,49+,50+,51+,52+,53+,54+,55+,56+,60+,61-/m1/s1 | PDB
MMDB
KEGG
UniProtKB/SwissProt
B.MOAD
antibodypedia
GoogleScholar
AffyNet
| CHEMBL
PC cid
PC sid
UniChem
Similars
| Article
PubMed
| n/a | n/a | 1.70E+3 | n/a | n/a | n/a | n/a | n/a | n/a |
Syntonix Pharmaceuticals, Inc.
Curated by ChEMBL
| Assay Description
Inhibition of human IgG binding to soluble human FcRn by ELISA |
Bioorg Med Chem 16: 6394-405 (2008)
Article DOI: 10.1016/j.bmc.2008.05.004
BindingDB Entry DOI: 10.7270/Q2QV3M9C |
More data for this
Ligand-Target Pair | |
IgG receptor FcRn large subunit p51
(Homo sapiens (Human)) | BDBM50270820
((2R)-2-{[(2S)-1-[(2S)-2-[(2S)-2-(2-{2-[(2S)-2-[(2S...)Show SMILES CC(C)C[C@H](NC(=O)CNC(=O)CNC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](Cc1cnc[nH]1)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](N)Cc1ccccc1)C(C)(C)S)[C@@H](C)O)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CS)C(O)=O |r| Show InChI InChI=1S/C62H84N14O15S2/c1-34(2)23-42(55(84)72-45(26-38-18-20-40(78)21-19-38)60(89)76-22-12-17-47(76)57(86)73-46(32-92)61(90)91)69-49(80)30-65-48(79)29-66-54(83)43(25-37-15-10-7-11-16-37)71-56(85)44(27-39-28-64-33-68-39)70-50(81)31-67-58(87)51(35(3)77)74-59(88)52(62(4,5)93)75-53(82)41(63)24-36-13-8-6-9-14-36/h6-11,13-16,18-21,28,33-35,41-47,51-52,77-78,92-93H,12,17,22-27,29-32,63H2,1-5H3,(H,64,68)(H,65,79)(H,66,83)(H,67,87)(H,69,80)(H,70,81)(H,71,85)(H,72,84)(H,73,86)(H,74,88)(H,75,82)(H,90,91)/t35-,41+,42+,43+,44+,45+,46+,47+,51+,52-/m1/s1 | PDB
MMDB
KEGG
UniProtKB/SwissProt
B.MOAD
antibodypedia
GoogleScholar
AffyNet
| CHEMBL
PC cid
PC sid
UniChem
Similars
| Article
PubMed
| n/a | n/a | 1.70E+3 | n/a | n/a | n/a | n/a | n/a | n/a |
Syntonix Pharmaceuticals, Inc.
Curated by ChEMBL
| Assay Description
Inhibition of human IgG binding to soluble human FcRn by ELISA |
Bioorg Med Chem 16: 6394-405 (2008)
Article DOI: 10.1016/j.bmc.2008.05.004
BindingDB Entry DOI: 10.7270/Q2QV3M9C |
More data for this
Ligand-Target Pair | |
IgG receptor FcRn large subunit p51
(Homo sapiens (Human)) | BDBM50270914
((2S)-1-{2-[(2S)-2-[(2S)-2-{[(2S)-1-[(2S)-2-[(2S)-2...)Show SMILES CC(C)C[C@H](NC(=O)CNC(=O)CNC(=O)[C@H](Cc1ccc(C)cc1)NC(=O)[C@H](Cc1cnc[nH]1)NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](N)CCC(N)=O)C(C)(C)S)[C@@H](C)O)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N1CCC[C@H]1C(=O)N[C@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N1CCC[C@H]1C(O)=O |r,wU:50.60,46.48,42.44,83.87,28.36,4.4,89.91,104.109,108.112,114.118,129.135,72.75,wD:61.71,16.25,(30.17,1.34,;30.17,-.18,;31.52,-.96,;28.84,-.96,;28.84,-2.48,;27.51,-3.25,;26.18,-2.47,;26.18,-.95,;24.85,-3.24,;23.51,-2.45,;22.19,-3.22,;22.19,-4.77,;20.85,-2.45,;19.53,-3.21,;18.19,-2.43,;18.19,-.91,;16.87,-3.19,;16.87,-4.74,;17.63,-6.06,;19.14,-6.07,;19.9,-7.38,;19.13,-8.71,;19.89,-10.05,;17.61,-8.7,;16.85,-7.38,;15.53,-2.42,;14.21,-3.18,;14.21,-4.73,;12.87,-2.4,;12.87,-.88,;14.21,-.11,;15.62,-.75,;16.65,.38,;15.89,1.72,;14.39,1.4,;11.55,-3.17,;10.21,-2.4,;10.21,-.87,;8.89,-3.15,;7.55,-2.39,;6.22,-3.16,;6.22,-4.68,;4.88,-2.38,;3.57,-3.15,;2.24,-2.37,;2.24,-.8,;.89,-3.13,;-.45,-2.36,;-1.78,-3.13,;-1.78,-4.67,;-3.11,-2.36,;-3.11,-.81,;-1.78,-.03,;-.43,-.82,;.9,-.04,;.9,1.5,;-.43,2.26,;-1.78,1.5,;-4.46,-3.13,;-5.79,-2.36,;-5.79,-.81,;-7.14,-3.13,;-7.14,-4.67,;-5.79,-5.45,;-5.79,-7.01,;-4.46,-7.79,;-4.46,-9.32,;-5.79,-10.09,;-3.11,-10.09,;-8.5,-2.36,;-9.83,-3.13,;-9.83,-4.67,;-11.17,-2.36,;-12.54,-3.13,;-11.17,-.81,;-9.83,-.03,;-9.83,1.51,;-11.17,2.27,;-8.5,2.27,;.9,-4.68,;2.44,-4.7,;-.65,-4.66,;.89,-6.21,;4.88,-.84,;3.57,-.08,;6.23,-.07,;30.17,-3.26,;30.17,-4.81,;31.5,-2.5,;32.84,-3.27,;34.16,-2.51,;34.16,-.99,;32.85,-.21,;32.85,1.32,;34.19,2.08,;34.19,3.62,;35.52,1.31,;35.51,-.22,;32.84,-4.82,;31.5,-5.6,;34.16,-5.58,;35.73,-5.04,;36.75,-6.37,;35.81,-7.75,;34.42,-7.07,;33.19,-8,;31.81,-7.33,;33.3,-9.53,;32.03,-10.4,;30.64,-9.72,;29.37,-10.58,;32.13,-11.92,;33.51,-12.6,;30.86,-12.79,;30.97,-14.31,;32.34,-14.99,;32.45,-16.52,;31.18,-17.38,;33.84,-17.19,;29.69,-15.18,;28.31,-14.5,;29.8,-16.71,;28.52,-17.57,;28.63,-19.1,;30.02,-19.77,;27.36,-19.96,;27.17,-21.63,;25.53,-21.97,;24.7,-20.52,;25.91,-19.56,;25.61,-18.05,;24.16,-17.56,;26.76,-17.04,)| Show InChI InChI=1S/C85H122N24O22S2/c1-44(2)31-54(75(122)104-59(34-49-22-24-51(111)25-23-49)82(129)109-30-11-16-61(109)79(126)105-60(42-132)78(125)103-58(36-64(88)113)73(120)96-41-68(117)108-29-12-17-62(108)83(130)131)98-66(115)39-93-65(114)38-94-72(119)55(33-48-20-18-45(3)19-21-48)101-76(123)57(35-50-37-91-43-97-50)99-67(116)40-95-80(127)69(46(4)110)106-81(128)70(85(5,6)133)107-77(124)56(32-47-13-8-7-9-14-47)102-74(121)53(15-10-28-92-84(89)90)100-71(118)52(86)26-27-63(87)112/h7-9,13-14,18-25,37,43-44,46,52-62,69-70,110-111,132-133H,10-12,15-17,26-36,38-42,86H2,1-6H3,(H2,87,112)(H2,88,113)(H,91,97)(H,93,114)(H,94,119)(H,95,127)(H,96,120)(H,98,115)(H,99,116)(H,100,118)(H,101,123)(H,102,121)(H,103,125)(H,104,122)(H,105,126)(H,106,128)(H,107,124)(H,130,131)(H4,89,90,92)/t46-,52+,53+,54+,55+,56+,57+,58+,59+,60-,61+,62+,69+,70+/m1/s1 | PDB
MMDB
KEGG
UniProtKB/SwissProt
B.MOAD
antibodypedia
GoogleScholar
AffyNet
| CHEMBL
PC cid
PC sid
UniChem
Similars
| Article
PubMed
| n/a | n/a | 1.70E+3 | n/a | n/a | n/a | n/a | n/a | n/a |
Syntonix Pharmaceuticals, Inc.
Curated by ChEMBL
| Assay Description
Inhibition of human IgG binding to soluble human FcRn by ELISA |
Bioorg Med Chem 16: 6394-405 (2008)
Article DOI: 10.1016/j.bmc.2008.05.004
BindingDB Entry DOI: 10.7270/Q2QV3M9C |
More data for this
Ligand-Target Pair | |
IgG receptor FcRn large subunit p51
(Homo sapiens (Human)) | BDBM50270896
(CHEMBL525636)Show SMILES CC(C)C[C@H](NC(=O)CN(C)C(=O)[C@@H](C)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](Cc1cnc[nH]1)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](N)CCC(N)=O)C(C)(C)S)[C@@H](C)O)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N1CCC[C@H]1C(O)=O |r,wU:73.76,51.61,43.45,84.88,29.37,90.92,105.110,115.119,130.136,4.4,wD:62.72,47.49,18.26,109.113,13.13,(35.06,-25.73,;35.05,-27.27,;36.38,-28.04,;33.72,-28.03,;33.71,-29.57,;32.38,-30.33,;31.04,-29.56,;31.04,-28.02,;29.71,-30.33,;28.38,-29.56,;28.38,-28.02,;27.04,-30.33,;27.04,-31.87,;25.71,-29.57,;25.71,-28.03,;24.38,-30.33,;23.04,-29.56,;23.04,-28.02,;21.71,-30.33,;21.71,-31.87,;23.04,-32.64,;24.36,-31.88,;25.7,-32.64,;25.7,-34.18,;24.38,-34.96,;23.04,-34.19,;20.38,-29.56,;19.04,-30.33,;19.04,-31.87,;17.71,-29.56,;17.71,-28.02,;19.04,-27.25,;20.46,-27.88,;21.48,-26.73,;20.7,-25.41,;19.2,-25.74,;16.38,-30.33,;15.04,-29.56,;15.04,-28.02,;13.71,-30.33,;12.37,-29.56,;11.04,-30.33,;11.04,-31.87,;9.71,-29.56,;8.37,-30.33,;7.04,-29.56,;7.04,-28.02,;5.71,-30.33,;4.37,-29.56,;3.04,-30.33,;3.04,-31.87,;1.71,-29.56,;1.71,-28.02,;3.04,-27.25,;4.38,-28.02,;5.7,-27.25,;5.7,-25.72,;4.37,-24.96,;3.04,-25.73,;.37,-30.33,;-.97,-29.56,;-.97,-28.02,;-2.29,-30.33,;-2.29,-31.87,;-.97,-32.64,;-.97,-34.18,;.37,-34.95,;.37,-36.49,;-.97,-37.26,;1.71,-37.26,;-3.63,-29.56,;-4.97,-30.33,;-4.97,-31.87,;-6.29,-29.56,;-7.63,-30.33,;-6.29,-28.02,;-4.97,-27.25,;-4.97,-25.71,;-6.29,-24.94,;-3.63,-24.94,;5.71,-31.87,;7.25,-31.87,;4.17,-31.87,;5.71,-33.41,;9.71,-28.02,;8.37,-27.25,;11.04,-27.25,;35.04,-30.33,;35.04,-31.87,;36.38,-29.56,;37.72,-30.33,;39.05,-29.56,;39.05,-28.02,;37.73,-27.26,;37.72,-25.73,;39.05,-24.95,;39.05,-23.41,;40.38,-25.71,;40.39,-27.25,;37.72,-31.87,;36.38,-32.64,;39.05,-32.64,;40.61,-32.11,;41.64,-33.45,;40.69,-34.83,;39.3,-34.15,;38.06,-35.08,;36.65,-34.47,;38.25,-36.6,;37.02,-37.53,;35.61,-36.92,;34.37,-37.85,;37.2,-39.06,;38.62,-39.66,;35.97,-39.98,;36.16,-41.51,;37.58,-42.11,;37.77,-43.64,;36.53,-44.57,;39.18,-44.25,;34.93,-42.43,;33.51,-41.83,;35.12,-43.97,;33.89,-44.89,;34.07,-46.42,;35.48,-47.02,;32.84,-47.34,;32.73,-49.02,;31.12,-49.45,;30.21,-48.04,;31.37,-47.02,;30.99,-45.53,;29.5,-45.12,;32.08,-44.44,)| Show InChI InChI=1S/C86H124N24O22S2/c1-45(2)33-55(75(122)104-60(36-50-24-26-52(112)27-25-50)83(130)110-32-15-22-62(110)79(126)105-61(43-133)78(125)103-59(38-65(89)114)72(119)95-41-68(117)109-31-16-23-63(109)84(131)132)99-67(116)42-108(7)82(129)46(3)97-74(121)56(34-48-17-10-8-11-18-48)102-76(123)58(37-51-39-92-44-96-51)98-66(115)40-94-80(127)69(47(4)111)106-81(128)70(86(5,6)134)107-77(124)57(35-49-19-12-9-13-20-49)101-73(120)54(21-14-30-93-85(90)91)100-71(118)53(87)28-29-64(88)113/h8-13,17-20,24-27,39,44-47,53-63,69-70,111-112,133-134H,14-16,21-23,28-38,40-43,87H2,1-7H3,(H2,88,113)(H2,89,114)(H,92,96)(H,94,127)(H,95,119)(H,97,121)(H,98,115)(H,99,116)(H,100,118)(H,101,120)(H,102,123)(H,103,125)(H,104,122)(H,105,126)(H,106,128)(H,107,124)(H,131,132)(H4,90,91,93)/t46-,47-,53+,54+,55+,56+,57+,58+,59+,60+,61+,62+,63+,69+,70-/m1/s1 | PDB
MMDB
KEGG
UniProtKB/SwissProt
B.MOAD
antibodypedia
GoogleScholar
AffyNet
| CHEMBL
KEGG
PC cid
PC sid
UniChem
Similars
| Article
PubMed
| n/a | n/a | 1.70E+3 | n/a | n/a | n/a | n/a | n/a | n/a |
Syntonix Pharmaceuticals, Inc.
Curated by ChEMBL
| Assay Description
Inhibition of human IgG binding to soluble human FcRn by ELISA |
Bioorg Med Chem 16: 6394-405 (2008)
Article DOI: 10.1016/j.bmc.2008.05.004
BindingDB Entry DOI: 10.7270/Q2QV3M9C |
More data for this
Ligand-Target Pair | |
IgG receptor FcRn large subunit p51
(Homo sapiens (Human)) | BDBM50270897
((2S)-1-{2-[(2S)-2-[(2S)-2-{[(2S)-1-[(2S)-2-[(2S)-2...)Show SMILES CC(C)C[C@H](NC(=O)CNC(=O)CNC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](Cc1cnc[nH]1)NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](CCCN=C(N)N)NC(=O)[C@@H](N)CCC(N)=O)C(C)(C)S)[C@@H](C)O)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N1CCC[C@H]1C(=O)N[C@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N1CCC[C@H]1C(O)=O |r,wU:103.108,41.43,4.4,88.90,82.86,71.74,27.35,60.70,49.59,45.47,wD:128.134,113.117,107.111,16.24,(30.78,-30.7,;30.78,-32.21,;32.11,-32.99,;29.44,-32.99,;29.44,-34.51,;28.11,-35.29,;26.78,-34.52,;26.78,-33.01,;25.46,-35.28,;24.12,-34.52,;22.79,-35.29,;22.79,-36.83,;21.45,-34.51,;20.12,-35.29,;18.79,-34.51,;18.79,-32.98,;17.48,-35.27,;17.48,-36.81,;18.79,-37.57,;20.12,-36.83,;21.45,-37.6,;21.44,-39.13,;20.11,-39.89,;18.79,-39.12,;16.14,-34.5,;14.82,-35.28,;14.82,-36.83,;13.48,-34.5,;13.48,-32.98,;14.82,-32.21,;16.23,-32.85,;17.25,-31.72,;16.5,-30.39,;14.98,-30.68,;12.16,-35.29,;10.81,-34.54,;10.81,-33,;9.49,-35.29,;8.17,-34.51,;6.83,-35.27,;6.83,-36.79,;5.49,-34.49,;4.16,-35.27,;2.81,-34.53,;2.81,-32.99,;1.47,-35.3,;.14,-34.52,;-1.19,-35.29,;-1.19,-36.84,;-2.53,-34.52,;-2.53,-32.98,;-1.19,-32.21,;.15,-32.98,;1.48,-32.21,;1.48,-30.66,;.15,-29.9,;-1.2,-30.66,;-3.87,-35.28,;-5.21,-34.53,;-5.21,-32.99,;-6.55,-35.3,;-6.55,-36.85,;-5.21,-37.62,;-5.21,-39.17,;-3.87,-39.93,;-3.89,-41.47,;-5.19,-42.25,;-2.52,-42.23,;-7.88,-34.52,;-9.21,-35.29,;-9.21,-36.85,;-10.55,-34.52,;-11.88,-35.28,;-10.55,-32.98,;-9.21,-32.21,;-9.21,-30.66,;-10.54,-29.88,;-7.89,-29.89,;1.48,-36.84,;3.02,-36.85,;-.06,-36.84,;1.46,-38.37,;5.49,-32.95,;4.19,-32.19,;6.87,-32.17,;30.78,-35.28,;30.78,-36.83,;32.12,-34.53,;33.47,-35.27,;34.78,-34.51,;34.78,-33,;33.47,-32.22,;33.47,-30.68,;34.81,-29.94,;34.81,-28.42,;36.13,-30.71,;36.12,-32.23,;33.47,-36.83,;32.12,-37.61,;34.78,-37.59,;36.35,-37.04,;37.37,-38.38,;36.43,-39.76,;35.03,-39.08,;33.8,-40,;32.44,-39.33,;33.96,-41.53,;35.32,-42.26,;36.62,-41.43,;37.96,-42.18,;35.36,-43.79,;34.07,-44.59,;36.7,-44.56,;36.79,-46.1,;35.51,-46.9,;35.56,-48.45,;36.91,-49.19,;34.27,-49.25,;38.16,-46.83,;39.46,-46.02,;38.21,-48.36,;39.56,-49.11,;39.61,-50.62,;38.33,-51.43,;40.97,-51.35,;41.34,-52.96,;43,-53.12,;43.66,-51.6,;42.36,-50.79,;42.5,-49.27,;43.85,-48.55,;41.21,-48.45,)| Show InChI InChI=1S/C84H120N24O22S2/c1-44(2)31-53(74(121)103-58(34-48-22-24-50(110)25-23-48)81(128)108-30-13-20-60(108)78(125)104-59(42-131)77(124)102-57(36-63(87)112)72(119)95-41-67(116)107-29-14-21-61(107)82(129)130)97-65(114)39-92-64(113)38-93-71(118)54(32-46-15-8-6-9-16-46)100-75(122)56(35-49-37-90-43-96-49)98-66(115)40-94-79(126)68(45(3)109)105-80(127)69(84(4,5)132)106-76(123)55(33-47-17-10-7-11-18-47)101-73(120)52(19-12-28-91-83(88)89)99-70(117)51(85)26-27-62(86)111/h6-11,15-18,22-25,37,43-45,51-61,68-69,109-110,131-132H,12-14,19-21,26-36,38-42,85H2,1-5H3,(H2,86,111)(H2,87,112)(H,90,96)(H,92,113)(H,93,118)(H,94,126)(H,95,119)(H,97,114)(H,98,115)(H,99,117)(H,100,122)(H,101,120)(H,102,124)(H,103,121)(H,104,125)(H,105,127)(H,106,123)(H,129,130)(H4,88,89,91)/t45-,51+,52-,53+,54+,55+,56+,57+,58+,59-,60+,61+,68+,69+/m1/s1 | PDB
MMDB
KEGG
UniProtKB/SwissProt
B.MOAD
antibodypedia
GoogleScholar
AffyNet
| CHEMBL
PC cid
PC sid
UniChem
Similars
| Article
PubMed
| n/a | n/a | 1.70E+3 | n/a | n/a | n/a | n/a | n/a | n/a |
Syntonix Pharmaceuticals, Inc.
Curated by ChEMBL
| Assay Description
Inhibition of human IgG binding to soluble human FcRn by ELISA |
Bioorg Med Chem 16: 6394-405 (2008)
Article DOI: 10.1016/j.bmc.2008.05.004
BindingDB Entry DOI: 10.7270/Q2QV3M9C |
More data for this
Ligand-Target Pair | |
IgG receptor FcRn large subunit p51
(Homo sapiens (Human)) | BDBM50314083
((3S,11S,14S,20S,23R,32S,35S,41aS)-20-((1H-imidazol...)Show SMILES CC(C)C[C@@H]1N(C)C(=O)CN(C)C(=O)CNC(=O)[C@@H](Cc2ccccc2)NC(=O)[C@H](Cc2cnc[nH]2)NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](CC(=O)NCCCC[C@H](NC(=O)[C@@H]2CCCN2C(=O)C(=O)[C@H](Cc2ccc(O)cc2)NC1=O)C(N)=O)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CCCNC(N)=N)NC(C)=O)[C@@H](C)O |r| Show InChI InChI=1S/C75H104N20O18/c1-42(2)31-58-72(111)88-52(32-47-24-26-49(98)27-25-47)64(103)74(113)95-30-16-23-57(95)71(110)87-50(65(76)104)21-13-14-28-80-59(99)36-56(91-68(107)54(34-46-19-11-8-12-20-46)90-67(106)51(85-44(4)97)22-15-29-81-75(77)78)70(109)92-63(43(3)96)73(112)82-38-60(100)86-55(35-48-37-79-41-84-48)69(108)89-53(33-45-17-9-7-10-18-45)66(105)83-39-61(101)93(5)40-62(102)94(58)6/h7-12,17-20,24-27,37,41-43,50-58,63,96,98H,13-16,21-23,28-36,38-40H2,1-6H3,(H2,76,104)(H,79,84)(H,80,99)(H,82,112)(H,83,105)(H,85,97)(H,86,100)(H,87,110)(H,88,111)(H,89,108)(H,90,106)(H,91,107)(H,92,109)(H4,77,78,81)/t43-,50+,51+,52+,53?,54+,55+,56+,57+,58+,63+/m1/s1 | PDB
MMDB
KEGG
UniProtKB/SwissProt
B.MOAD
antibodypedia
GoogleScholar
AffyNet
| CHEMBL
PC cid
PC sid
UniChem
Similars
| Article
PubMed
| n/a | n/a | 1.90E+3 | n/a | n/a | n/a | n/a | n/a | n/a |
Syntonix Pharmaceuticals, Inc.
Curated by ChEMBL
| Assay Description
Inhibition of IgG binding to soluble human FcRn after 5 hrs by competition ELISA |
J Med Chem 53: 1587-96 (2010)
Article DOI: 10.1021/jm901128z
BindingDB Entry DOI: 10.7270/Q23R0T1H |
More data for this
Ligand-Target Pair | |
IgG receptor FcRn large subunit p51
(Homo sapiens (Human)) | BDBM50270815
((2S)-1-{2-[(2S)-2-[(2R)-2-{[(2S)-1-[(2S)-2-[(2S)-2...)Show SMILES CC(C)C[C@H](NC(=O)CNC(=O)CNC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](Cc1cnc[nH]1)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](N)CCC(N)=O)C(C)(C)S)[C@@H](C)O)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N1CCC[C@H]1C(O)=O |r,wU:88.90,103.108,128.134,71.74,27.35,49.59,4.4,41.43,113.117,82.86,wD:60.70,16.24,45.47,107.111,(34.1,-23.52,;34.1,-25.07,;35.44,-25.83,;32.77,-25.83,;32.77,-27.38,;31.43,-28.14,;30.1,-27.37,;30.1,-25.83,;28.77,-28.14,;27.44,-27.37,;26.11,-28.15,;26.11,-29.69,;24.77,-27.38,;23.44,-28.15,;22.1,-27.38,;22.1,-25.84,;20.77,-28.15,;20.77,-29.69,;22.1,-30.46,;23.43,-29.69,;24.76,-30.46,;24.77,-32,;23.44,-32.77,;22.1,-32.01,;19.44,-27.38,;18.11,-28.17,;18.11,-29.7,;16.78,-27.39,;16.78,-25.85,;18.11,-25.08,;19.52,-25.71,;20.55,-24.56,;19.77,-23.23,;18.27,-23.55,;15.43,-28.14,;14.09,-27.38,;14.09,-25.84,;12.76,-28.15,;11.43,-27.38,;10.09,-28.15,;10.09,-29.69,;8.75,-27.38,;7.42,-28.15,;6.09,-27.38,;6.09,-25.83,;4.76,-28.15,;3.43,-27.38,;2.1,-28.16,;2.1,-29.7,;.76,-27.39,;.76,-25.85,;2.1,-25.08,;3.44,-25.86,;4.77,-25.08,;4.77,-23.54,;3.42,-22.78,;2.1,-23.55,;-.58,-28.15,;-1.91,-27.39,;-1.91,-25.84,;-3.24,-28.16,;-3.24,-29.69,;-1.91,-30.47,;-1.91,-32,;-.57,-32.77,;-.56,-34.31,;-1.91,-35.08,;.76,-35.08,;-4.56,-27.37,;-5.88,-28.17,;-5.88,-29.71,;-7.21,-27.4,;-8.57,-28.15,;-7.21,-25.86,;-5.88,-25.09,;-5.88,-23.55,;-7.21,-22.78,;-4.54,-22.78,;4.76,-29.69,;6.31,-29.69,;3.22,-29.68,;4.76,-31.23,;8.75,-25.83,;7.43,-25.07,;10.09,-25.06,;34.1,-28.15,;34.1,-29.69,;35.44,-27.38,;36.76,-28.15,;38.1,-27.38,;38.1,-25.83,;36.78,-25.07,;36.77,-23.53,;38.1,-22.76,;38.1,-21.21,;39.44,-23.52,;39.45,-25.06,;36.76,-29.69,;35.44,-30.46,;38.1,-30.46,;39.67,-29.93,;40.7,-31.26,;39.75,-32.64,;38.35,-31.96,;37.12,-32.89,;35.7,-32.28,;37.3,-34.42,;36.08,-35.36,;34.66,-34.75,;33.43,-35.68,;36.26,-36.88,;37.67,-37.49,;35.02,-37.8,;35.21,-39.32,;36.63,-39.93,;36.81,-41.46,;35.58,-42.37,;38.23,-42.06,;33.98,-40.24,;32.56,-39.65,;34.16,-41.77,;32.93,-42.7,;33.12,-44.22,;34.54,-44.83,;31.89,-45.15,;31.78,-46.83,;30.16,-47.26,;29.25,-45.84,;30.42,-44.82,;30.04,-43.33,;28.55,-42.93,;31.12,-42.24,)| Show InChI InChI=1S/C84H120N24O22S2/c1-44(2)31-53(74(121)103-58(34-48-22-24-50(110)25-23-48)81(128)108-30-13-20-60(108)78(125)104-59(42-131)77(124)102-57(36-63(87)112)72(119)95-41-67(116)107-29-14-21-61(107)82(129)130)97-65(114)39-92-64(113)38-93-71(118)54(32-46-15-8-6-9-16-46)100-75(122)56(35-49-37-90-43-96-49)98-66(115)40-94-79(126)68(45(3)109)105-80(127)69(84(4,5)132)106-76(123)55(33-47-17-10-7-11-18-47)101-73(120)52(19-12-28-91-83(88)89)99-70(117)51(85)26-27-62(86)111/h6-11,15-18,22-25,37,43-45,51-61,68-69,109-110,131-132H,12-14,19-21,26-36,38-42,85H2,1-5H3,(H2,86,111)(H2,87,112)(H,90,96)(H,92,113)(H,93,118)(H,94,126)(H,95,119)(H,97,114)(H,98,115)(H,99,117)(H,100,122)(H,101,120)(H,102,124)(H,103,121)(H,104,125)(H,105,127)(H,106,123)(H,129,130)(H4,88,89,91)/t45-,51+,52+,53+,54+,55+,56+,57+,58+,59+,60+,61+,68+,69-/m1/s1 | PDB
MMDB
KEGG
UniProtKB/SwissProt
B.MOAD
antibodypedia
GoogleScholar
AffyNet
| CHEMBL
KEGG
PC cid
PC sid
UniChem
Similars
| Article
PubMed
| n/a | n/a | 2.00E+3 | n/a | n/a | n/a | n/a | n/a | n/a |
Syntonix Pharmaceuticals, Inc.
Curated by ChEMBL
| Assay Description
Inhibition of human IgG binding to soluble human FcRn by ELISA |
Bioorg Med Chem 16: 6394-405 (2008)
Article DOI: 10.1016/j.bmc.2008.05.004
BindingDB Entry DOI: 10.7270/Q2QV3M9C |
More data for this
Ligand-Target Pair | |
IgG receptor FcRn large subunit p51
(Homo sapiens (Human)) | BDBM50270821
((2R)-2-{[(2S)-1-[(2S)-2-[(2S)-2-(2-{2-[(2S)-2-[(2S...)Show SMILES CC(C)C[C@H](NC(=O)CNC(=O)CNC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](Cc1cnc[nH]1)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](N)CCCN=C(N)N)C(C)(C)S)[C@@H](C)O)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CS)C(O)=O |r,wU:79.81,94.99,27.35,49.59,41.43,4.4,73.77,wD:60.63,16.24,45.47,98.102,(30.11,-18.61,;30.11,-20.15,;31.45,-20.92,;28.79,-20.92,;28.79,-22.47,;27.46,-23.23,;26.12,-22.47,;26.12,-20.92,;24.79,-23.23,;23.45,-22.47,;22.12,-23.24,;22.12,-24.78,;20.78,-22.47,;19.45,-23.25,;18.12,-22.47,;18.12,-20.93,;16.79,-23.24,;16.79,-24.78,;18.12,-25.55,;19.43,-24.78,;20.77,-25.55,;20.78,-27.09,;19.44,-27.86,;18.12,-27.1,;15.45,-22.48,;14.11,-23.24,;14.11,-24.78,;12.77,-22.47,;12.77,-20.93,;14.11,-20.16,;15.52,-20.79,;16.55,-19.64,;15.77,-18.31,;14.26,-18.63,;11.43,-23.23,;10.1,-22.47,;10.1,-20.92,;8.77,-23.24,;7.44,-22.46,;6.1,-23.23,;6.1,-24.77,;4.77,-22.46,;3.43,-23.23,;2.1,-22.46,;2.1,-20.92,;.77,-23.23,;-.57,-22.46,;-1.9,-23.24,;-1.9,-24.77,;-3.24,-22.47,;-3.24,-20.92,;-1.9,-20.16,;-.57,-20.94,;.76,-20.16,;.76,-18.61,;-.58,-17.85,;-1.9,-18.63,;-4.58,-23.23,;-5.93,-22.48,;-5.93,-20.94,;-7.26,-23.25,;-8.58,-22.46,;-7.26,-24.79,;-5.93,-25.56,;-5.93,-27.1,;-4.58,-27.85,;-4.6,-29.39,;-5.92,-30.14,;-3.27,-30.17,;.77,-24.77,;2.31,-24.77,;-.78,-24.76,;.77,-26.31,;4.77,-20.92,;3.44,-20.15,;6.1,-20.15,;30.11,-23.23,;30.11,-24.77,;31.45,-22.47,;32.78,-23.23,;34.12,-22.47,;34.12,-20.92,;32.79,-20.16,;32.79,-18.62,;34.12,-17.85,;34.12,-16.31,;35.45,-18.61,;35.47,-20.14,;32.78,-24.77,;31.45,-25.55,;34.12,-25.55,;35.69,-25.01,;36.72,-26.35,;35.76,-27.73,;34.36,-27.05,;33.03,-27.82,;31.7,-27.06,;33.03,-29.36,;31.7,-30.14,;30.38,-29.37,;29.04,-30.15,;31.7,-31.68,;30.37,-32.45,;33.04,-32.44,)| Show InChI InChI=1S/C68H96N18O16S2/c1-37(2)26-45(59(94)82-49(29-41-20-22-43(88)23-21-41)65(100)86-25-13-19-51(86)62(97)83-50(35-103)66(101)102)78-53(90)33-74-52(89)32-75-58(93)46(27-39-14-8-6-9-15-39)81-60(95)48(30-42-31-72-36-77-42)79-54(91)34-76-63(98)55(38(3)87)84-64(99)56(68(4,5)104)85-61(96)47(28-40-16-10-7-11-17-40)80-57(92)44(69)18-12-24-73-67(70)71/h6-11,14-17,20-23,31,36-38,44-51,55-56,87-88,103-104H,12-13,18-19,24-30,32-35,69H2,1-5H3,(H,72,77)(H,74,89)(H,75,93)(H,76,98)(H,78,90)(H,79,91)(H,80,92)(H,81,95)(H,82,94)(H,83,97)(H,84,99)(H,85,96)(H,101,102)(H4,70,71,73)/t38-,44+,45+,46+,47+,48+,49+,50+,51+,55+,56-/m1/s1 | PDB
MMDB
KEGG
UniProtKB/SwissProt
B.MOAD
antibodypedia
GoogleScholar
AffyNet
| CHEMBL
PC cid
PC sid
UniChem
Similars
| Article
PubMed
| n/a | n/a | 2.00E+3 | n/a | n/a | n/a | n/a | n/a | n/a |
Syntonix Pharmaceuticals, Inc.
Curated by ChEMBL
| Assay Description
Inhibition of human IgG binding to soluble human FcRn by ELISA |
Bioorg Med Chem 16: 6394-405 (2008)
Article DOI: 10.1016/j.bmc.2008.05.004
BindingDB Entry DOI: 10.7270/Q2QV3M9C |
More data for this
Ligand-Target Pair | |
IgG receptor FcRn large subunit p51
(Homo sapiens (Human)) | BDBM50270818
((2S)-1-{2-[(2S)-2-[(2S)-2-{[(2S)-1-[(2S)-2-[(2S)-2...)Show SMILES CC(C)C[C@H](NC(=O)CNC(=O)CNC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](Cc1cnc[nH]1)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](N)CCC(N)=O)C(C)(C)S)[C@@H](C)O)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCS)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N1CCC[C@H]1C(O)=O |r,wU:88.90,103.108,129.135,71.74,27.35,49.59,4.4,41.43,114.118,82.86,wD:60.70,16.24,45.47,107.111,(33,3.42,;33,1.87,;34.34,1.11,;31.67,1.11,;31.67,-.44,;30.33,-1.2,;29,-.43,;29,1.11,;27.67,-1.2,;26.34,-.43,;25.01,-1.21,;25.01,-2.75,;23.67,-.44,;22.34,-1.21,;21,-.44,;21,1.1,;19.68,-1.21,;19.68,-2.75,;21,-3.52,;22.33,-2.75,;23.67,-3.52,;23.67,-5.06,;22.34,-5.83,;21,-5.07,;18.34,-.44,;17.02,-1.23,;17.02,-2.76,;15.68,-.45,;15.68,1.09,;17.02,1.85,;18.43,1.23,;19.45,2.38,;18.67,3.71,;17.17,3.39,;14.33,-1.2,;13,-.44,;13,1.1,;11.66,-1.21,;10.33,-.44,;8.99,-1.21,;8.99,-2.75,;7.66,-.44,;6.32,-1.21,;4.99,-.44,;4.99,1.11,;3.66,-1.21,;2.33,-.44,;1,-1.22,;1,-2.76,;-.34,-.45,;-.34,1.09,;1,1.86,;2.34,1.08,;3.67,1.86,;3.67,3.4,;2.32,4.16,;1,3.39,;-1.67,-1.21,;-3.01,-.45,;-3.01,1.1,;-4.34,-1.22,;-4.34,-2.76,;-3.01,-3.53,;-3.01,-5.06,;-1.67,-5.83,;-1.66,-7.37,;-3.01,-8.14,;-.34,-8.14,;-5.66,-.43,;-6.98,-1.23,;-6.98,-2.77,;-8.31,-.46,;-9.66,-1.21,;-8.31,1.08,;-6.98,1.85,;-6.98,3.39,;-8.31,4.16,;-5.64,4.16,;3.66,-2.75,;5.21,-2.75,;2.12,-2.74,;3.66,-4.29,;7.66,1.11,;6.33,1.87,;8.99,1.88,;33,-1.21,;33,-2.75,;34.34,-.44,;35.67,-1.21,;37,-.44,;37,1.11,;35.68,1.87,;35.67,3.41,;37,4.18,;37,5.73,;38.34,3.42,;38.35,1.88,;35.67,-2.75,;34.34,-3.52,;37,-3.52,;38.57,-2.99,;39.6,-4.32,;38.65,-5.7,;37.25,-5.02,;36.02,-5.95,;34.6,-5.34,;36.2,-7.48,;34.98,-8.42,;33.56,-7.81,;32.33,-8.74,;30.9,-8.13,;35.16,-9.94,;36.58,-10.55,;33.92,-10.86,;34.11,-12.38,;35.53,-12.99,;35.71,-14.52,;34.48,-15.43,;37.13,-15.12,;32.88,-13.3,;31.46,-12.71,;33.06,-14.83,;31.83,-15.76,;32.02,-17.28,;33.44,-17.89,;30.79,-18.21,;30.68,-19.89,;29.06,-20.32,;28.15,-18.9,;29.32,-17.88,;28.94,-16.39,;27.45,-15.99,;30.02,-15.3,)| Show InChI InChI=1S/C85H122N24O22S2/c1-45(2)33-55(76(123)105-60(36-49-22-24-51(111)25-23-49)82(129)109-31-13-20-61(109)79(126)101-54(28-32-132)75(122)104-59(38-64(88)113)73(120)96-43-68(117)108-30-14-21-62(108)83(130)131)98-66(115)41-93-65(114)40-94-72(119)56(34-47-15-8-6-9-16-47)102-77(124)58(37-50-39-91-44-97-50)99-67(116)42-95-80(127)69(46(3)110)106-81(128)70(85(4,5)133)107-78(125)57(35-48-17-10-7-11-18-48)103-74(121)53(19-12-29-92-84(89)90)100-71(118)52(86)26-27-63(87)112/h6-11,15-18,22-25,39,44-46,52-62,69-70,110-111,132-133H,12-14,19-21,26-38,40-43,86H2,1-5H3,(H2,87,112)(H2,88,113)(H,91,97)(H,93,114)(H,94,119)(H,95,127)(H,96,120)(H,98,115)(H,99,116)(H,100,118)(H,101,126)(H,102,124)(H,103,121)(H,104,122)(H,105,123)(H,106,128)(H,107,125)(H,130,131)(H4,89,90,92)/t46-,52+,53+,54+,55+,56+,57+,58+,59+,60+,61+,62+,69+,70-/m1/s1 | PDB
MMDB
KEGG
UniProtKB/SwissProt
B.MOAD
antibodypedia
GoogleScholar
AffyNet
| CHEMBL
PC cid
PC sid
UniChem
Similars
| Article
PubMed
| n/a | n/a | 2.00E+3 | n/a | n/a | n/a | n/a | n/a | n/a |
Syntonix Pharmaceuticals, Inc.
Curated by ChEMBL
| Assay Description
Inhibition of human IgG binding to soluble human FcRn by ELISA |
Bioorg Med Chem 16: 6394-405 (2008)
Article DOI: 10.1016/j.bmc.2008.05.004
BindingDB Entry DOI: 10.7270/Q2QV3M9C |
More data for this
Ligand-Target Pair | |
IgG receptor FcRn large subunit p51
(Homo sapiens (Human)) | BDBM50270817
(CHEMBL524659)Show SMILES CC(C)C[C@H](NC(=O)CNC(=O)CNC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](Cc1cnc[nH]1)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](N)CCC(N)=O)C(C)(C)S)[C@@H](C)O)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N1CCC[C@H]1C(=O)N[C@H](C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N1CCC[C@H]1C(O)=O)C(C)(C)S |r,wU:88.90,103.108,126.132,71.74,27.35,49.59,4.4,41.43,111.115,82.86,wD:60.70,16.24,45.47,107.111,(33.06,-30.98,;33.06,-32.53,;34.4,-33.29,;31.73,-33.29,;31.73,-34.83,;30.39,-35.6,;29.06,-34.83,;29.06,-33.28,;27.73,-35.6,;26.4,-34.83,;25.07,-35.61,;25.07,-37.15,;23.73,-34.84,;22.4,-35.61,;21.06,-34.84,;21.06,-33.29,;19.73,-35.61,;19.73,-37.15,;21.06,-37.92,;22.39,-37.15,;23.72,-37.92,;23.73,-39.46,;22.4,-40.23,;21.06,-39.47,;18.4,-34.84,;17.07,-35.62,;17.07,-37.16,;15.74,-34.85,;15.74,-33.31,;17.07,-32.54,;18.48,-33.17,;19.51,-32.02,;18.73,-30.69,;17.23,-31.01,;14.39,-35.6,;13.05,-34.84,;13.05,-33.29,;11.72,-35.61,;10.39,-34.84,;9.05,-35.61,;9.05,-37.14,;7.72,-34.83,;6.38,-35.61,;5.05,-34.83,;5.05,-33.29,;3.72,-35.61,;2.39,-34.84,;1.06,-35.62,;1.06,-37.16,;-.28,-34.85,;-.28,-33.3,;1.06,-32.54,;2.4,-33.31,;3.73,-32.54,;3.73,-30.99,;2.38,-30.23,;1.06,-31.01,;-1.62,-35.61,;-2.95,-34.84,;-2.95,-33.3,;-4.28,-35.62,;-4.28,-37.15,;-2.95,-37.92,;-2.95,-39.46,;-1.61,-40.22,;-1.6,-41.76,;-2.95,-42.53,;-.28,-42.53,;-5.6,-34.83,;-6.92,-35.63,;-6.92,-37.17,;-8.25,-34.86,;-9.6,-35.6,;-8.25,-33.31,;-6.92,-32.55,;-6.92,-31.01,;-8.25,-30.24,;-5.58,-30.24,;3.72,-37.14,;5.27,-37.15,;2.18,-37.13,;3.72,-38.69,;7.72,-33.29,;6.39,-32.53,;9.05,-32.52,;33.06,-35.61,;33.06,-37.14,;34.4,-34.83,;35.72,-35.61,;37.06,-34.83,;37.06,-33.29,;35.73,-32.53,;35.73,-30.99,;37.06,-30.22,;37.06,-28.67,;38.4,-30.98,;38.41,-32.51,;35.72,-37.14,;34.4,-37.92,;37.06,-37.92,;38.63,-37.39,;39.66,-38.72,;38.71,-40.1,;37.31,-39.42,;36.08,-40.35,;34.66,-39.74,;36.26,-41.88,;35.04,-42.81,;35.22,-44.34,;36.63,-44.94,;33.98,-45.25,;34.17,-46.78,;35.59,-47.39,;35.77,-48.91,;34.54,-49.82,;37.19,-49.52,;32.94,-47.7,;31.52,-47.1,;33.12,-49.23,;31.89,-50.15,;32.08,-51.68,;33.5,-52.28,;30.85,-52.61,;30.74,-54.29,;29.12,-54.72,;28.21,-53.3,;29.38,-52.28,;29,-50.79,;27.51,-50.39,;30.08,-49.7,;33.62,-42.21,;34.13,-40.75,;33.13,-43.67,;32.12,-41.8,)| Show InChI InChI=1S/C86H124N24O22S2/c1-45(2)33-54(75(123)105-59(36-49-24-26-51(112)27-25-49)82(130)110-32-15-22-60(110)78(126)108-69(85(4,5)133)80(128)104-58(38-63(89)114)73(121)97-43-67(118)109-31-16-23-61(109)83(131)132)99-65(116)41-94-64(115)40-95-72(120)55(34-47-17-10-8-11-18-47)102-76(124)57(37-50-39-92-44-98-50)100-66(117)42-96-79(127)68(46(3)111)106-81(129)70(86(6,7)134)107-77(125)56(35-48-19-12-9-13-20-48)103-74(122)53(21-14-30-93-84(90)91)101-71(119)52(87)28-29-62(88)113/h8-13,17-20,24-27,39,44-46,52-61,68-70,111-112,133-134H,14-16,21-23,28-38,40-43,87H2,1-7H3,(H2,88,113)(H2,89,114)(H,92,98)(H,94,115)(H,95,120)(H,96,127)(H,97,121)(H,99,116)(H,100,117)(H,101,119)(H,102,124)(H,103,122)(H,104,128)(H,105,123)(H,106,129)(H,107,125)(H,108,126)(H,131,132)(H4,90,91,93)/t46-,52+,53+,54+,55+,56+,57+,58+,59+,60+,61+,68+,69-,70-/m1/s1 | PDB
MMDB
KEGG
UniProtKB/SwissProt
B.MOAD
antibodypedia
GoogleScholar
AffyNet
| CHEMBL
PC cid
PC sid
UniChem
Similars
| Article
PubMed
| n/a | n/a | 2.00E+3 | n/a | n/a | n/a | n/a | n/a | n/a |
Syntonix Pharmaceuticals, Inc.
Curated by ChEMBL
| Assay Description
Inhibition of human IgG binding to soluble human FcRn by ELISA |
Bioorg Med Chem 16: 6394-405 (2008)
Article DOI: 10.1016/j.bmc.2008.05.004
BindingDB Entry DOI: 10.7270/Q2QV3M9C |
More data for this
Ligand-Target Pair | |
IgG receptor FcRn large subunit p51
(Homo sapiens (Human)) | BDBM50270884
(CHEMBL506263)Show SMILES CC(C)C[C@H](NC(=O)[C@@H](C)NC(=O)CNC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](Cc1cnc[nH]1)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](N)CCC(N)=O)C(C)(C)S)[C@@H](C)O)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N1CCC[C@H]1C(O)=O |r,wU:72.75,50.60,42.44,83.87,28.36,4.4,89.91,104.109,114.118,129.135,8.8,wD:61.71,46.48,17.25,108.112,(36.55,-26.48,;36.55,-28.02,;37.88,-28.79,;35.22,-28.79,;35.22,-30.33,;33.88,-31.1,;32.54,-30.33,;32.54,-28.79,;31.22,-31.1,;31.22,-32.64,;29.88,-30.33,;28.54,-31.1,;28.54,-32.64,;27.21,-30.33,;25.88,-31.09,;24.54,-30.33,;24.54,-28.79,;23.21,-31.1,;23.21,-32.64,;24.54,-33.41,;25.86,-32.64,;27.2,-33.41,;27.2,-34.94,;25.88,-35.72,;24.54,-34.95,;21.88,-30.33,;20.54,-31.1,;20.54,-32.64,;19.21,-30.33,;19.21,-28.79,;20.54,-28.02,;21.96,-28.64,;22.98,-27.5,;22.2,-26.17,;20.7,-26.5,;17.88,-31.1,;16.54,-30.33,;16.54,-28.79,;15.21,-31.1,;13.88,-30.33,;12.54,-31.1,;12.54,-32.64,;11.21,-30.33,;9.87,-31.1,;8.54,-30.33,;8.54,-28.79,;7.21,-31.1,;5.87,-30.33,;4.54,-31.1,;4.54,-32.64,;3.21,-30.33,;3.21,-28.79,;4.54,-28.02,;5.89,-28.79,;7.2,-28.02,;7.2,-26.48,;5.87,-25.72,;4.54,-26.5,;1.87,-31.1,;.54,-30.33,;.54,-28.79,;-.79,-31.1,;-.79,-32.64,;.54,-33.41,;.54,-34.95,;1.87,-35.72,;1.87,-37.26,;.54,-38.03,;3.21,-38.03,;-2.13,-30.33,;-3.47,-31.1,;-3.47,-32.64,;-4.79,-30.33,;-6.13,-31.1,;-4.79,-28.79,;-3.47,-28.02,;-3.47,-26.48,;-4.79,-25.71,;-2.13,-25.71,;7.21,-32.64,;8.75,-32.64,;5.67,-32.64,;7.21,-34.18,;11.21,-28.79,;9.87,-28.02,;12.54,-28.02,;36.55,-31.1,;36.55,-32.64,;37.88,-30.33,;39.22,-31.1,;40.55,-30.33,;40.55,-28.79,;39.23,-28.02,;39.22,-26.49,;40.55,-25.71,;40.55,-24.17,;41.88,-26.48,;41.89,-28.01,;39.22,-32.64,;37.88,-33.41,;40.55,-33.41,;42.11,-32.88,;43.14,-34.21,;42.19,-35.59,;40.8,-34.91,;39.56,-35.84,;38.15,-35.23,;39.75,-37.36,;38.52,-38.29,;37.11,-37.69,;35.87,-38.61,;38.7,-39.82,;40.12,-40.42,;37.48,-40.75,;37.66,-42.27,;39.08,-42.87,;39.27,-44.4,;38.03,-45.33,;40.68,-45.01,;36.43,-43.2,;35.01,-42.59,;36.62,-44.73,;35.39,-45.65,;35.57,-47.18,;36.98,-47.78,;34.34,-48.11,;34.23,-49.78,;32.62,-50.21,;31.71,-48.8,;32.87,-47.78,;32.49,-46.29,;31,-45.89,;33.58,-45.2,)| Show InChI InChI=1S/C85H122N24O22S2/c1-44(2)32-54(75(122)104-59(35-49-23-25-51(111)26-24-49)82(129)109-31-14-21-61(109)79(126)105-60(42-132)78(125)103-58(37-64(88)113)73(120)95-41-67(116)108-30-15-22-62(108)83(130)131)100-70(117)45(3)97-65(114)39-93-72(119)55(33-47-16-9-7-10-17-47)101-76(123)57(36-50-38-91-43-96-50)98-66(115)40-94-80(127)68(46(4)110)106-81(128)69(85(5,6)133)107-77(124)56(34-48-18-11-8-12-19-48)102-74(121)53(20-13-29-92-84(89)90)99-71(118)52(86)27-28-63(87)112/h7-12,16-19,23-26,38,43-46,52-62,68-69,110-111,132-133H,13-15,20-22,27-37,39-42,86H2,1-6H3,(H2,87,112)(H2,88,113)(H,91,96)(H,93,119)(H,94,127)(H,95,120)(H,97,114)(H,98,115)(H,99,118)(H,100,117)(H,101,123)(H,102,121)(H,103,125)(H,104,122)(H,105,126)(H,106,128)(H,107,124)(H,130,131)(H4,89,90,92)/t45-,46-,52+,53+,54+,55+,56+,57+,58+,59+,60+,61+,62+,68+,69-/m1/s1 | PDB
MMDB
KEGG
UniProtKB/SwissProt
B.MOAD
antibodypedia
GoogleScholar
AffyNet
| CHEMBL
KEGG
PC cid
PC sid
UniChem
Similars
| Article
PubMed
| n/a | n/a | 2.00E+3 | n/a | n/a | n/a | n/a | n/a | n/a |
Syntonix Pharmaceuticals, Inc.
Curated by ChEMBL
| Assay Description
Inhibition of human IgG binding to soluble human FcRn by ELISA |
Bioorg Med Chem 16: 6394-405 (2008)
Article DOI: 10.1016/j.bmc.2008.05.004
BindingDB Entry DOI: 10.7270/Q2QV3M9C |
More data for this
Ligand-Target Pair | |
Search and Browse
